Secondary Logo

Journal Logo

Current World Literature

Current Opinion in Gastroenterology: November 2010 - Volume 26 - Issue 6 - p 656–675
doi: 10.1097/MOG.0b013e328340a7b4
Current World Literature: Bibliography
Free

This bibliography is compiled by clinicians from the journals listed at the end of this publication. It is based on literature entered into our database between 1 July 2009 and 30 June 2010 (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

• Papers considered by the reviewers to be of special interest

•• Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline

Immunology

Paneth cells and innate mucosal immunity

Review: (pp. 547–553)

Berglund M, Thomas JA, Fredin MF, Melgar S, et al. Gender dependent importance of IRAK-1 in dextran sulfate sodium induced colitis. Cell Immunol 2009; 259:27–32.

Chakraborty K, Maity PC, Sil AK, Takeda Y, et al. cAMP Stringently Regulates Human Cathelicidin Antimicrobial Peptide Expression in the Mucosal Epithelial Cells by Activating cAMP-response Element-binding Protein, AP-1, and Inducible cAMP Early Repressor. J Biol Chem 2009; 284:21810–21827.

Dave SH, Tilstra JS, Matsuoka K, Li FL, et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009; 86:633–643.

de Leeuw E, Rajabi M, Zou GZ, Pazgier M, et al. Selective arginines are important for the antibacterial activity and host cell interaction of human alpha-defensin 5. FEBS Lett 2009; 583:2507–2512.

Dema B, Fernandez-Arquero M, Maluenda C, Polanco I, et al. Lack of association of NKX2-3, IRGM, and ATG16L1 inflammatory bowel disease susceptibility variants with celiac disease. Hum Immunol 2009; 70:946–949.

• Di L, Srivastava S, Zhdanova O, et al. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A 2010; 107:1541–1546.[49]

Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity [Review]. J Leukoc Biol 2010; 87:79–92.

Fahlen-Yrlid L, Gustafsson T, Westlund J, Holmberg A, et al. CD11c(high) Dendritic Cells Are Essential for Activation of CD4(+) T Cells and Generation of Specific Antibodies following Mucosal Immunization. J Immunol 2009; 183:5032–5041.

Fischer S, Schlosser E, Mueller M, Csaba N, et al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Targeting 2009; 17:652–661.

Hu GK, Zhou R, Liu J, Gong AY, et al. MicroRNA-98 and let-7 Confer Cholangiocyte Expression of Cytokine-Inducible Src Homology 2-Containing Protein in Response to Microbial Challenge. J Immunol 2009; 183:1617–1624.

Isakov D, Dzutsev A, Belyakov IM, Berzofsky JA. Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCR alpha beta(+) CD8 alpha beta(+) T cells in the small intestinal mucosa. Mucosal Immunol 2009; 2:450–461.

Jakab C, Rusvai M, Galfi P, Szabo Z, et al. Expression of claudin-1,-3,-4,-5 and-7 proteins in low grade colorectal carcinoma of canines. Histol Histopathol 2010; 25:55–62.

Liu YJ, Mao EQ, Ouyang B, Chen J, et al. Effect of biliary tract external drainage on cytokine expression and histomorphology of intestine, liver, and lung in rats with hemorrhagic shock. Crit Care Med 2009; 37:2800–2806.

Nijnik A, Madera L, Ma SH, Waldbrook M, et al. Synthetic Cationic Peptide IDR-1002 Provides Protection against Bacterial Infections through Chemokine Induction and Enhanced Leukocyte Recruitment. J Immunol 2010; 184:2539–2550.

•• Ootani A, Li X, Sangiorgi E, et al. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat Med 2009; 15:701–706.[17]

• Park SW, Zhen G, Verhaeghe C, et al. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci U S A 2009; 106:6950–6955.[52]

Pickert G, Neufert C, Leppkes M, Zheng Y, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206:1465–1472.

•• Salzman NH, Hung K, Haribhai D, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11:76–83.[29]

•• Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459:262–265.[18]

Shang LM, Thirunarayanan N, Viejo-Borbolla A, Martin AP, et al. Expression of the Chemokine Binding Protein M3 Promotes Marked Changes in the Accumulation of Specific Leukocytes Subsets Within the Intestine. Gastroenterology 2009; 137:1006–1018.

• Simms LA, Doecke JD, Roberts RL, et al. KCNN4 gene variant is associated with Ileal Crohn's disease in the Australian and New Zealand population. Am J Gastroenterol. [Epub ahead of print][50]

Treede I, Braun A, Jeliaskova P, Giese T, et al. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells - art. no. 53. BMC Gastroenterology 2009:53.

Wehkamp J, Stange EF, Fellermann K. Defensin-immunology in inflammatory bowel disease. Gastroenterol Clin Biol 2009; 33:S137–S144.

Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 2009; 16:1445–1459.

• Wolfs TG, Derikx JP, Hodin CM, et al. Localization of the lipopolysaccharide recognition complex in the human healthy and inflamed premature and adult gut. Inflamm Bowel Dis 2010; 16:68–75[53]

• Zhao F, Edwards R, Dizon D, et al. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2−/− mice. Dev Biol 2010; 338:270–279.[09]

Back to Top | Article Outline

Update on mucosal immunoglobulin A in gastrointestinal disease

Review: (pp. 554–563)

Amin M, Jaafari MR, Tafaghodi M. Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloid Surf B-Biointerfaces 2009; 74:225–229, 2009 Nov 1.

Anand P, Nair HB, Sung BK, Kunnumakkara AB, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010; 79:330–338.

• Beaugerie L, Sokol H. Appendicitis, not appendectomy, is protective against ulcerative colitis, both in the general population and first-degree relatives of patients with IBD. Inflamm Bowel Dis 2010; 16:356–357.[66]

Betancourt T, Byrne JD, Sunaryo N, Crowder SW, et al. PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J Biomed Mater Res Part A 2009; 91A:263–276.

Borselli C, Ungaro F, Oliviero O, d'Angelo I, et al. Bioactivation of collagen matrices through sustained VEGF release from PLGA microspheres. J Biomed Mater Res Part A 2010; 92A:94–102.

•• Brandtzaeg P. Food allergy: separating the science from the mythology. Nat Rev Gastroenterol Hepatol 2010; 7:380–400.[100]

• Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009; 70:505–515.[02]

• Brandtzaeg P. Functions of mucosa-associated lymphoid tissue in antibody formation. Immunol Invest 2010; 39:303–355.[05]

Cai CF, Mao SR, Germershaus O, Schaper A, et al. Influence of morphology and drug distribution on the release process of FITC-dextran-loaded microspheres prepared with different types of PLGA. J Microencapsul 2009; 26:334–345.

Corrigan OI, Li X. Quantifying drug release from PLGA nanoparticulates. Eur J Pharm Sci 2009; 37:477–485.

•• Corthésy B. Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces. Future Microbiol 2010; 5:817–829.[03]

Courant T, Roullin VG, Cadiou C, De lavoie F, et al. Development and physicochemical characterization of copper complexes-loaded PLGA nanoparticles. Int J Pharm 2009; 379:226–234.

Ellis MJ, Forsey R, Chaudhuri JB. Post-culture treatment protocols for PLGA membrane scaffolds. Biotechnol Lett 2010; 32:215–222.

• Feng T, Wang L, Schoeb TR, et al. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med 2010; 207:1321–1332.[37]

• Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009; 31:677–689.[40]

Gacic B, Todorovic L, Kokovic V, Danilovic V, et al. The closure of oroantral communications with resorbable PLGA-coated beta-TCP root analogs, hemostatic gauze, or buccal flaps: A prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:844–850.

Gao ZH, Tang Y, Chen JQ, Bai R, et al. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres. Peptides 2009; 30:1874–1881.

Hayakawa T, Mochizuki C, Hara H, Yang F, et al. In vivo evaluation of composites of PLGA and apatite with two different levels of crystallinity. J Mater Sci-Mater Med 2010; 21:251–258.

Holgado MA, Cozar-Bernal MJ, Salas S, Arias JL, et al. Protein-loaded PLGA microparticles engineered by flow focusing: Physicochemical characterization and protein detection by reversed-phase HPLC. Int J Pharm 2009; 380:147–154.

Holzer M, Vogel V, Mantele W, Schwartz D, et al. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm 2009; 72:428–437.

• Ivanov II, Littman DR. Segmented filamentous bacteria take the stage. Mucosal Immunol 2010; 3:209–212.[41]

• Janzi M, Kull I, Sjöberg R, et al. Selective IgA deficiency in early life: association to infections and allergic diseases during childhood. Clin Immunol 2009; 133:78–85.[30]

Kanazawa T, Takashima Y, Murakoshi M, Nakai Y, et al. Enhancement of gene transfection into human dendritic cells using cationic PLGA nanospheres with a synthesized nuclear localization signal. Int J Pharm 2009; 379:187–195.

•• Karlsson MR, Johansen FE, Kahu H, et al. Hypersensitivity and oral tolerance in the absence of a secretory immune system. Allergy 2010; 65:561–570.[29]

Kempe S, Metz H, Pereira PGC, Mader K. Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy. Eur J Pharm Biopharm 2010; 74:102–108.

Klose D, Siepmann F, Willart JF, Descamps M, et al. Drug release from PLGA-based microparticles: Effects of the “microparticle:bulk fluid” ratio. Int J Pharm 2010; 383:123–131.

Kovacs JR, Tidball J, Ross A, Jia L, et al. Characterization of Nickel-Decorated PLGA Particles Anchored with a His-tagged Polycation. J Biomater Sci-Polym Ed 2009; 20.

Laquintana V, Denora N, Musacchio T, Lasorsa M, et al. Peripheral Benzodiazepine Receptor ligand-PLGA polymer conjugates potentially useful as delivery systems of apoptotic agents. J Controlled Release 2009; 137:185–195.

Liao S, Wang W, Yokoyama A, Zhu YH, et al. In Vitro and In Vivo Behaviors of the Three-layered Nano-carbonated Hydroxyapatite/Collagen/PLGA Composite. Journal of Bioactive and Compatible Polymers 2010; 25:154–168.

•• Ménard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol 2010; 3:247–259.[90]

• Mantis NJ, Forbes SJ. Secretory IgA: arresting microbial pathogens at epithelial borders. Immunol Invest 2010; 39:383–406.[04]

• Mazumdar K, Alvarez X, Borda JT, et al. Visualization of transepithelial passage of the immunogenic 33-residue peptide from alpha-2 gliadin in gluten-sensitive macaques. PLoS One 2010; 5:e10228.[91]

Mochizuki C, Sasaki Y, Hara H, Sato M, et al. Crystallinity Control of Apatite Through Ca-EDTA Complexes and Porous Composites With PLGA. J Biomed Mater Res Part B 2009; 90B:290–301.

Morais WA, Costa MP, Paixao ADO, Maciel MAM, et al. Encapsulation and release characteristics of DCTN/PLGA microspheres. J Microencapsul 2009; 26:529–534.

Nafee N, Schneider M, Schaefer UF, Lehr CM. Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm 2009; 381:130–139.

• Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136:65–80.[35]

Nie HM, Khew ST, Lee LY, Poh KL, et al. Lysine-based peptide-functionalized PLGA foams for controlled DNA delivery. J Controlled Release 2009; 138:64–70.

• Obata T, Goto Y, Kunisawa J, et al. Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci U S A 2010; 107:7419–7424.[42]

Ohyanagi K, Shintani K, Koga K. Preparation of PLGA Microspheres Encapsulating Highly Concentrated Glycyrrhizin and the Bile Elimination of Glycyrrhizin after Subcutaneous Administration in Rats [Japanese]. Yakugaku Zasshi-J Pharm Soc Jpn 2010; 130:103–111.

Perron JK, Naguib HE, Daka J, Chawla A, et al. A Study on the Effect of Degradation Media on the Physical and Mechanical Properties of Porous PLGA 85/15 Scaffolds. J Biomed Mater Res Part B 2009; 91B:876–886.

•• Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59–65.[62]

• Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9:313–323.[38]

Sani SN, Das NG, Das SK. Effect of microfluidization parameters on the physical properties of PEG-PLGA nanoparticles prepared using high pressure microfluidization. J Microencapsul 2009; 26:556–561.

Scillitani G, Liquori GE, Mastrodonato M, Ferri D. Histochemical and immunohistochemical characterization of exocrine cells in the foregut of the red-eared slider turtle, Trachemys scripta (Emydidae). Arch Histol Cytol 2008; 71:279–290.

•• Slack E, Hapfelmeier S, Stecher B, et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009; 325:617–620.[58]

Sophocleous AM, Zhang Y, Schwendeman SP. A new class of inhibitors of peptide sorption and acylation in PLGA. J Controlled Release 2009; 137:179–184.

Tahara K, Sakai T, Yamamoto H, Takeuchi H, et al. Improved cellular uptake of chitosan-modi fled PLGA nanospheres by A549 cells. Int J Pharm 2009; 382:198–204.

Tan HY, Widjaja E, Boey F, Loo SCJ. Spectroscopy Techniques for Analyzing the Hydrolysis of PLGA and PLLA. J Biomed Mater Res Part B 2009; 91B:433–440.

Thomas C, Gupta V, Ahsan F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 2009; 379:41–50.

Treede I, Braun A, Jeliaskova P, Giese T, et al. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells - art. no. 53. BMC Gastroenterology 2009:53.

Wu LL, Li H, Li S, Li XR, et al. Composite fibrous membranes of PLGA and chitosan prepared by coelectrospinning and coaxial electrospinning. J Biomed Mater Res Part A 2010; 92A:563–574.

Xie SY, Wang SL, Zhu LY, Wang FH, et al. The effect of glycolic acid monomer ratio on the emulsifying activity of PLGA in preparation of protein-loaded SLN. Colloid Surf B-Biointerfaces 2009; 74:358–361, 2009 Nov 1.

Xu JS, Huang JW, Qin RG, Hinkle GH, et al. Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging. Biomaterials 2010; 31:1716–1722.

Yang LL, Cui F, Shi K, Cun DM, et al. Design of high payload PLGA nanoparticles containing melittin/sodium dodecyl sulfate complex by the hydrophobic ion-pairing technique. Drug Dev Ind Pharm 2009; 35:959–968.

Zhang Y, Sophocleous AM, Schwendeman SP. Inhibition of Peptide Acylation in PLGA Microspheres with Water-soluble Divalent Cationic Salts. Pharm Res 2009; 26:1986–1994.

Back to Top | Article Outline

The role of mucosal immunity and host genetics in defining intestinal commensal bacteria

Review: (pp. 564–571)

Benson A, Pifer R, Behrendt CL, Hooper LV, et al. Gut Commensal Bacteria Direct a Protective Immune Response against Toxoplasma gondii. Cell Host Microbe 2009; 6:187–196.

Bogunovic M, Ginhoux F, Helft J, Shang LM, et al. Origin of the Lamina Propria Dendritic Cell Network. Immunity 2009; 31:513–525.

Brandtzaeg P. Mucosal Immunity: Induction, Dissemination, and Effector Functions [Review]. Scand J Immunol 2009; 70:505–515.

Brandtzaeg P. The Mucosal Immune System and Its Integration with the Mammary Glands. J Pediatr 2010; 156:S8–S15.

Buchon N, Broderick NA, Chakrabarti S, Lemaitre B. Invasive and indigenous microbiota impact intestinal stem cell activity through multiple pathways in Drosophila. Genes Dev 2009; 23:2333–2344.

• Carvalho FA, Barnich N, Sivignon A, et al. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009; 206:2179–2189.[33]

Corthesy B. Secretory immunoglobulin A: well beyond immune exclusion at mucosal surfaces [Review]. Immunopharmacol Immunotoxicol 2009; 31:174–179.

Crispe IN. The Liver as a Lymphoid Organ [Review]. Annu Rev Immunol 2009:147–163.

Deretic V, Levine B. Autophagy, Immunity, and Microbial Adaptations [Review]. Cell Host Microbe 2009; 5:527–549.

Dogi CA, Weill F, Perdigon G. Immune response of non-pathogenic Gram(+) and Gram(-) bacteria in inductive sites of the intestinal mucosa Study of the pathway of signaling involved. Immunobiology 2010; 215:60–69.

Duerkop BA, Vaishnava S, Hooper LV. Immune Responses to the Microbiota at the Intestinal Mucosal Surface [Review]. Immunity 2009; 31:368–376.

Enck P, Zimmermann K, Rusch K, Schwiertz A, et al. The Effects of Ageing on the Colonic Bacterial Microflora in Adults. Z Gastroenterol 2009; 47:653–658.

Fan J, Xie Y, Li XD, Guo GH, et al. The influence of Peyer's patch apoptosis on intestinal mucosal immunity in burned mice. Burns 2009; 35:687–694.

• Frank DN, Robertson CE, Hamm CM, et al. Clinical phenotype and genetic factors are associated with shifts in mucosal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (in press).[56]

Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58:929–939.

Hartman AL, Lough DM, Barupal DK, Fiehn O, et al. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci USA 2009; 106:17187–17192.

Hussey S, Travassos LH, Jones NL. Autophagy as an emerging dimension to adaptive and innate immunity [Review]. Semin Immunol 2009; 21:233–241.

Ilan Y. Oral tolerance: Can we make it work? [Review]. Hum Immunol 2009; 70:768–776.

•• Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139:485–498.[38]

Jiang HQ, Patel PH, Kohlmaier A, Grenley MO, et al. Cytokine/Jak/Stat Signaling Mediates Regeneration and Homeostasis in the Drosophila Midgut. Cell 2009; 137:1343–1355.

Kaetzel CS. ICMI 2009: all immunity is mucosal. Mucosal Immunol 2009; 2:464–466.

Kayamuro H, Abe Y, Yoshioka Y, Katayama K, et al. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 2009; 30:5869–5876.

Lavelle EC, Murphy C, O'Neill LAJ, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis [Review]. Mucosal Immunol 2010; 3:17–28.

Lee WJ. Bacterial-modulated host immunity and stem cell activation for gut homeostasis. Genes Dev 2009; 23:2260–2265.

• Martinez-Medina M, Aldeguer X, Lopez-Siles M, et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis 2009; 15:872–882.[30]

Mason KL, Huffnagle GB. Control of mucosal polymicrobial populations by innate immunity [Review]. Cell Microbiol 2009; 11:1297–1305.

Mestecky J, Moldoveanu Z, Smith PD, Hel Z, et al. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009; 83:196–200.

Niess JH, Adler G. Enteric Flora Expands Gut Lamina Propria CX(3)CR1(+) Dendritic Cells Supporting Inflammatory Immune Responses under Normal and Inflammatory Conditions. J Immunol 2010; 184:2026–2037.

• Nishikawa J, Kudo T, Sakata S, et al. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol 2009; 44:180–186.[18]

• Nones K, Knoch B, Dommels YE, et al. Multidrug resistance gene deficient (mdr1a−/−) mice have an altered caecal microbiota that precedes the onset of intestinal inflammation. J Appl Microbiol 2009; 107:557–566.[60]

Pabst O, Wahl B, Bernhardt G, Hammerschmidt S. Mesenteric lymph node stroma cells in the generation of intestinal immune responses [Review]. J Mol Med 2009; 87:945–951.

Pagnini C, Saeed R, Bamias G, Arseneau KO, et al. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA 2010; 107:454–459.

Paolillo R, Carratelli CR, Sorrentino S, Mazzola N, et al. Immunomodulatory effects of Lactobacillus plantarum on human colon cancer cells. Int Immunopharmacol 2009; 9:1265–1271.

Patsos G, Corfield A. Management of the human mucosal defensive barrier: evidence for glycan legislation [Review]. Biol Chem 2009; 390:581–590.

• Petersen AM, Nielsen EM, Litrup E, et al. A phylogenetic group of Escherichia coli associated with active left-sided inflammatory bowel disease. BMC Microbiol 2009; 9:171–177.[31]

• Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59–65.[09]

Raz E. Mucosal immunity: aliment and ailments. Mucosal Immunol 2010; 3:4–7.

•• Salzman NH, Hung K, Haribhai D, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2009; 11:76–83.[53]

Sanz Y, De Palma G. Gut Microbiota and Probiotics in Modulation of Epithelium and Gut-Associated Lymphoid Tissue Function [Review]. Int Rev Immunol 2009; 28:397–413.

Serino M, Luche E, Chabo C, Amar J, et al. Intestinal microflora and metabolic diseases [Review]. Diabetes Metab 2009; 35:262–272.

Shanahan F. Gut Microbes: From Bugs to Drugs [Review]. Am J Gastroenterol 2010; 105:275–279.

Sjogren YM, Tomicic S, Lundberg A, Bottcher MF, et al. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin Exp Allergy 2009; 39:1842–1851.

• Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15:1183–1189.[15]

Sonier B, Patrick C, Ajjikuttira P, Scott FW. Intestinal Immune Regulation as a Potential Diet-Modifiable Feature of Gut Inflammation and Autoimmunity [Review]. Int Rev Immunol 2009; 28:414–445.

Steinberg MW, Shui JW, Ware CF, Kronenberg M. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners [Review]. Semin Immunopathol 2009; 31:207–221.

Strober W. The Multifaceted Influence of the Mucosal Microflora on Mucosal Dendritic Cell Responses [Review]. Immunity 2009; 31:377–388.

Sugimoto M, Ohno T, Graham DY, Yamaoka Y. Gastric mucosal interleukin-17 and-18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Science 2009; 100:2152–2159.

Taniguchi Y, Yoshioka N, Nakata K, Nishizawa T, et al. Mechanism for Maintaining Homeostasis in the Immune System of the Intestine. Anticancer Res 2009; 29:4855–4860.

Ting JPY, Duncan JA, Lei Y. How the Noninflammasome NLRs Function in the Innate Immune System [Review]. Science 2010; 327:286–290.

•• Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457:480–484.[54]

•• Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328:228–231.[40]

• Wohlgemuth S, Haller D, Blaut M, Loh G. Reduced microbial diversity and high numbers of one single Escherichia coli strain in the intestine of colitic mice. Environ Microbiol 2009; 11:1562–1571.[07]

Zhao HY, Luo YY, Lu C, Lin N, et al. Enteric Mucosal Immune Response might Trigger the Immunomodulation Activity of Ganoderma lucidum Polysaccharide in Mice. Planta Med 2010; 76:223–227.

Back to Top | Article Outline

Regulation of NFkappaB and NOD signaling in innate immune regulation at mucosal surfaces

Amasheh S, Dullat S, Fromm M, Schulzke JD, et al. Inflamed pouch mucosa possesses altered tight junctions indicating recurrence of inflammatory bowel disease. Int J Colorectal Dis 2009; 24:1149–1156.

Angeletti S, Galluzzo S, Santini D, Ruzzo A, et al. NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. Hum Immunol 2009; 70:729–732.

Auvynet C, Rosenstein Y. Multifunctional host defense peptides: Antimicrobial peptides, the small yet big players in innate and adaptive immunity [Review]. FEBS J 2009; 276:6497–6508.

Barakat FM, McDonald V, Di Santo JP, Korbel DS. Roles for NK Cells and an NK Cell-Independent Source of Intestinal Gamma Interferon for Innate Immunity to Cryptosporidium parvum Infection. Infect Immun 2009; 77:5044–5049.

Bertrand MJM, Doiron K, Labbe K, Korneluk RG, et al. Cellular Inhibitors of Apoptosis cIAP1 and cIAP2 Are Required for Innate Immunity Signaling by the Pattern Recognition Receptors NOD1 and NOD2. Immunity 2009; 30:789–801.

Bishop NC, Gleeson M. Acute and chronic effects of exercise on markers of mucosal immunity [Review]. Front Biosci 2009:4444–4456.

Boulard O, Asquith MJ, Powrie F, Maloy KJ. TLR2-independent induction and regulation of chronic intestinal inflammation. Eur J Immunol 2010; 40:516–524.

Brandtzaeg P. The Mucosal Immune System and Its Integration with the Mammary Glands. J Pediatr 2010; 156:S8–S15.

Castellaneta A, Sumpter TL, Chen LP, Tokita D, et al. NOD2 Ligation Subverts IFN-alpha Production by Liver Plasmacytoid Dendritic Cells and Inhibits Their T Cell Allostimulatory Activity via B7-H1 Up-Regulation. J Immunol 2009; 183:6922–6932.

Clarke TB, Davis KM, Lysenko ES, Zhou AY, et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010; 16:228–NIL_137.

Cooney R, Baker J, Brain O, Danis B, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16:90–NIL_128.

Cui J, Le GW, Yang RL, Shi YH. Lipoic acid attenuates high fat diet-induced chronic oxidative stress and immunosuppression in mice jejunum: A microarray analysis. Cell Immunol 2009; 260:44–50.

Dai JY, De Frances MC, Zou CB, Johnson CJ, et al. The Met Protooncogene Is a Transcriptional Target of NFkappaB: Implications for Cell Survival. J Cell Biochem 2009; 107:1222–1236.

Dema B, Fernandez-Arquero M, Maluenda C, Polanco I, et al. Lack of association of NKX2-3, IRGM, and ATG16L1 inflammatory bowel disease susceptibility variants with celiac disease. Hum Immunol 2009; 70:946–949.

Deretic V, Levine B. Autophagy, Immunity, and Microbial Adaptations [Review]. Cell Host Microbe 2009; 5:527–549.

Dharmani P, Srivastava V, Kissoon-Singh V, Chadee K. Role of Intestinal Mucins in Innate Host Defense Mechanisms against Pathogens [Review]. J Innate Immun 2009; 1:123–135.

Fahlen-Yrlid L, Gustafsson T, Westlund J, Holmberg A, et al. CD11c(high) Dendritic Cells Are Essential for Activation of CD4(+) T Cells and Generation of Specific Antibodies following Mucosal Immunization. J Immunol 2009; 183:5032–5041.

Gao MH, Wang X, Wang DM, Xu F, et al. Regulation of Cell Death and Innate Immunity by Two Receptor-like Kinases in Arabidopsis. Cell Host Microbe 2009; 6:34–44.

Glenn GM, Francis DH, Danielsen EM. Toxin-Mediated Effects on the Innate Mucosal Defenses: Implications for Enteric Vaccines [Review]. Infect Immun 2009; 77:5206–5215.

Gonzalez-Navajas JM, Fine S, Law J, Datta SK, et al. TLR4 signaling in effector CD4(+) T cells regulates TCR activation and experimental colitis in mice. J Clin Invest 2010; 120:570–581.

Grewal RK, Mahmood A. A shift in microvillus membrane fucosylation to sialylation by ethanol ingestion in rat intestine. Mol Cell Biochem 2009; 331:19–25.

Hruz P, Zinkernagel AS, Jenikova G, Botwin GJ, et al. NOD2 contributes to cutaneous defense against Staphylococcus aureus through alpha-toxin-dependent innate immune activation. Proc Natl Acad Sci USA 2009; 106:12873–12878.

Ito J, Ito M, Nambu H, Fujikawa T, et al. Anatomical and histological profiling of orphan G-protein-coupled receptor expression in gastrointestinal tract of C57BL/6J mice. Cell Tissue Res 2009; 338:257–269.

Jakab C, Rusvai M, Galfi P, Szabo Z, et al. Expression of claudin-1,-3,-4,-5 and-7 proteins in low grade colorectal carcinoma of canines. Histol Histopathol 2010; 25:55–62.

Landfried K, Bataille F, Rogler G, Brenmoehl J, et al. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. Clin Exp Immunol 2010; 159:87–92.

Leung CH, Lam W, Ma DL, Gullen EA, et al. Butyrate mediates nucleotide-binding and oligomerisation domain (NOD) 2-dependent mucosal immune responses against peptidoglycan. Eur J Immunol 2009; 39:3529–3537.

Liu YJ, Mao EQ, Ouyang B, Chen J, et al. Effect of biliary tract external drainage on cytokine expression and histomorphology of intestine, liver, and lung in rats with hemorrhagic shock. Crit Care Med 2009; 37:2800–2806.

Long KZ, Rosado JL, Santos JI, Haas M, et al. Associations between Mucosal Innate and Adaptive Immune Responses and Resolution of Diarrheal Pathogen Infections. Infect Immun 2010; 78:1221–1228.

Mason KL, Huffnagle GB. Control of mucosal polymicrobial populations by innate immunity [Review]. Cell Microbiol 2009; 11:1297–1305.

Negroni A, Stronati L, Pierdomenico M, Tirindelli D, et al. Activation of NOD2-mediated Intestinal Pathway in a Pediatric Population with Crohn's Disease. Inflamm Bowel Dis 2009; 15:1145–1154.

Netea MG, Joosten LAB. A NOD for autophagy. Nat Med 2010; 16:28–30.

Pontell L, Castelucci P, Bagyanszki M, Jovic T, et al. Structural changes in the epithelium of the small intestine and immune cell infiltration of enteric ganglia following acute mucosal damage and local inflammation. Virchows Arch 2009; 455:55–65.

Schneider JD, Seibold I, Saxer-Sekulic N, Paredes BE, et al. Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis. Eur J Immunol 2009; 39:1743–1753.

Shang LM, Thirunarayanan N, Viejo-Borbolla A, Martin AP, et al. Expression of the Chemokine Binding Protein M3 Promotes Marked Changes in the Accumulation of Specific Leukocytes Subsets Within the Intestine. Gastroenterology 2009; 137:1006–1018.

Sharma R, Tepas JJ. Microecology, intestinal epithelial barrier and necrotizing enterocolitis [Review]. Pediatr Surg Int 2010; 26:11–21.

Shih DQ, Kwan LY, Chavez V, Cohavy O, et al. Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 2009; 39:3239–3250.

Skjoedt MO, Palarasah Y, Rasmussen K, Vitved L, et al. Two mannose-binding lectin homologues and an MBL-associated serine protease are expressed in the gut epithelia of the urochordate species Ciona intestinalis. Dev Comp Immunol 2010; 34:59–68.

Takahashi I, Nochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines [Review]. Curr Opin Immunol 2009; 21:352–358.

Turner JR. Intestinal mucosal barrier function in health and disease [Review]. Nat Rev Microbiol 2009; 9(11):799-809:799–809.

Wang TT, Dabbas B, Laperriere D, Bitton AJ, et al. Direct and Indirect Induction by 1,25-Dihydroxyvitamin D-3 of the NOD2/CARD15-Defensin beta 2 Innate Immune Pathway Defective in Crohn Disease. J Biol Chem 2010; 285:2237–2241.

Wells JM, Loonen LMP, Karczewski JM. The role of innate signaling in the homeostasis of tolerance and immunity in the intestine. Int J Med Microbiol 2010; 300:41–48.

Wullaert A. Role of NF-kappa B activation in intestinal immune homeostasis. Int J Med Microbiol 2010; 300:49–56.

Yamamoto S, Ma XJ. Role of Nod2 in the development of Crohn's disease [Review]. Microbes Infect 2009; 11:912–918.

Back to Top | Article Outline

Innate and adaptive immune connections in inflammatory bowel diseases

Review: (pp. 572–577)

Amasheh M, Grotjohann I, Amasheh S, Fromm A, et al. Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: A novel model for studying the pathomechanisms of inflammatory bowel disease cytokines. Scand J Gastroenterol 2009; 44:1226–1235.

Amasheh S, Dullat S, Fromm M, Schulzke JD, et al. Inflamed pouch mucosa possesses altered tight junctions indicating recurrence of inflammatory bowel disease. Int J Colorectal Dis 2009; 24:1149–1156.

Boulard O, Asquith MJ, Powrie F, Maloy KJ. TLR2-independent induction and regulation of chronic intestinal inflammation. Eur J Immunol 2010; 40:516–524.

Brost S, Koschny R, Sykora J, Stremmel W, et al. Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathol Res Pract 2010; 206.

•• Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010; 141:1135–1145.[43]

Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009; 206:1839–1843.

• Chow J, Mazmanian SK. A pathobiont of the microbiota balances host colonization and intestinal inflammation. Cell Host Microbe 2010; 7:265–276.[32]

Corinaldesi R, Stanghellini V, Cremon C, Gargano L, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30:245–252.

Cortot A, de Chambrun GP, Vernier-Massouille G, Vigneron B, et al. Inflammatory bowel disease: Genetic or environmental diseases? [French]. Gastroenterol Clin Biol 2009; 33:681–691.

da Silva APB, Ellen RP, Sorensen ES, Goldberg HA, et al. Osteopontin attenuation of dextran sulfate sodium-induced colitis in mice. Lab Invest 2009; 89:1169–1181.

De Stefano D, De Rosa G, Maiuri MC, Ungaro F, et al. Oligonucleotide decoy to NF-kappa B slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 2009; 60:33–40.

Frol'ova L, Smetana K, Borovska D, Kitanovicova A, et al. Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD? Inflamm Res 2009; 58:503–512.

Gao MH, Wang X, Wang DM, Xu F, et al. Regulation of Cell Death and Innate Immunity by Two Receptor-like Kinases in Arabidopsis. Cell Host Microbe 2009; 6:34–44.

Herrlinger K, Wittig B, Stange EF. Chronic inflammatory intestinal diseases. Pathophysiology and therapy [German]. Internist (Berl) 2009; 50:1229–1246.

Iglesias R, Citores L, Ferreras JM, Perez Y, et al. Sialic acid-binding dwarf elder four-chain lectin displays nucleic acid N-glycosidase activity. Biochimie 2010; 92:71–80.

Ishihara S, Aziz MM, Yuki T, Kazumori H, et al. Inflammatory bowel disease: review from the aspect of genetics [Review]. J Gastroenterology 2009; 44:1097–1108.

•• Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139:485–498.[35]

Joossens M, Van Steen K, Branche J, Sendid B, et al. Familial Aggregation and Antimicrobial Response Dose-Dependently Affect the Risk for Crohn's Disease. Inflamm Bowel Dis 2010; 16:58–67.

Jung C, Hugot JP. Inflammatory Bowel Diseases: the genetic revolution. Gastroenterol Clin Biol 2009; 33:S123–S130.

Kubler I, Koslowski MJ, Gersemann M, Fellermann K, et al. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease. Aliment Pharmacol Ther 2009; 30:621–633.

Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, et al. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Ther 2010; 17:72–82.

Lee G, Buchman AL. DNA-driven nutritional therapy of inflammatory bowel disease [Review]. Nutrition 2009; 25:885–891.

• Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009; 136:257–267.[12]

Liu ZJ, Yadav PK, Su JL, Wang JS, et al. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease [Review]. World J Gastroenterol 2009; 15:5784–5788.

Mackay IR. Clustering and commonalities among autoimmune diseases. J Autoimmun 2009; 33:170–177.

Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease [Review]. Annu Rev Immunol 2009:621–668.

•• Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010; 140:771–776.[01]

Meixlsperger S, Munz C. Morbus Crohn-a disease of failing macroautophagy in the immune system? [Review]. Int Immunol 2009; 21:1205–1211.

Mitsuyama K, Yamasaki H, Kuwaki K, Takedatsu H, et al. Recent Understanding of Leukocytapheresis (LCAP) for the Treatment of Inflammatory Bowel Disease [Review]. Curr Pharm Design 2009; 15:2110–2119.

Morbach H, Dick A, Beck C, Stenzel M, et al. Association of chronic non-bacterial osteomyelitis with Crohn's disease but not with CARD15 gene variants. Rheumatol Int 2010; 30:617–621.

Negroni A, Stronati L, Pierdomenico M, Tirindelli D, et al. Activation of NOD2-mediated Intestinal Pathway in a Pediatric Population with Crohn's Disease. Inflamm Bowel Dis 2009; 15:1145–1154.

Nemoto Y, Kanai T, Kameyama K, Shinohara T, et al. Long-Lived Colitogenic CD4(+) Memory T Cells Residing Outside the Intestine Participate in the Perpetuation of Chronic Colitis. J Immunol 2009; 183:5059–5068.

• O'Connor Jr W, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009; 10:603–609.[13]

Pena AS, Karimi O, Crusius JBA. A new avenue to investigate: the autophagic process. From crohn's disease to chlamydia. Drugs Today 2009; 45:113–117.

Perminow G, Beisner J, Koslowski M, Lyckander LG, et al. Defective Paneth Cell-Mediated Host Defense in Pediatric Ileal Crohn's Disease. Am J Gastroenterol 2010; 105:452–459.

Perminow G, Reikvam DH, Lyckander LG, Brandtzaeg P, et al. Increased Number and Activation of Colonic Macrophages in Pediatric Patients with Untreated Crohn's Disease. Inflamm Bowel Dis 2009; 15:1368–1378.

• Peterson DA, McNulty NP, Guruge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe 2007; 2:328–339.[38]

Rescigno M, Iliev ID. Interleukin-23: Linking Mesenteric Lymph Node Dendritic Cells With Th1 Immunity in Crohn's Disease. Gastroenterology 2009; 137:1566–1570.

Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map-Recent advances on the etiology of inflammatory bowel disease [Review]. Semin Immunol 2009; 21:334–345.

Sakuraba A, Sato T, Kamada N, Kitazume M, et al. Th1/Th17 Immune Response Is Induced by Mesenteric Lymph Node Dendritic Cells in Crohn's Disease. Gastroenterology 2009; 137:1736–1745.

Sato K, Shiota M, Fukuda S, Iwamoto E, et al. Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn's Disease in the Japanese Population. J Clin Immunol 2009; 29:815–825.

Savoye G. Is Preterm Delivery in Inflammatory Bowel Disease Women Part of the Burden of Innate Immunity Deficiency? Am J Gastroenterol 2010; 105:473–474.

Scrimgeour AG, Condlin ML. Zinc and micronutrient combinations to combat gastrointestinal inflammation. Curr Opin Clin Nutr Metab Care 2009; 12:653–660.

Shih DQ, Kwan LY, Chavez V, Cohavy O, et al. Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 2009; 39:3239–3250.

Stal P, Befrits R, Ronnblom A, Danielsson A, et al. Clinical trial: the safety and short-term efficacy of recombinant cholera toxin B subunit in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2010; 31:387–395.

• Tajima M, Wakita D, Noguchi D, et al. IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med 2008; 205:1019–1027.[11]

Valentine JF, Fedorak RN, Feagan B, Fredlund P, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut 2009; 58:1354–1362.

Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options? [Review]. Swiss Med Wkly 2009; 139:527–534.

Visekruna A, Slavova N, Dullat S, Grone J, et al. Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease. Int J Colorectal Dis 2009; 24:1133–1139.

Wallis RS. Infectious complications of tumor necrosis factor blockade [Review]. Curr Opin Infect Dis 2009; 22:403–409.

• Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008; 118:545–559.[19]

Wehkamp J, Stange EF, Fellermann K. Defensin-immunology in inflammatory bowel disease. Gastroenterol Clin Biol 2009; 33:S137–S144.

Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 2009; 16:1445–1459.

• Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15:1016–1022.[34]

Yamamoto S, Ma XJ. Role of Nod2 in the development of Crohn's disease [Review]. Microbes Infect 2009; 11:912–918.

• Yang Z, Fuss IJ, Watanabe T, et al. NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology 2007; 133:1510–1521.[29]

Back to Top | Article Outline

The role of the macrophage in sentinel responses in intestinal immunity

Review: (pp. 578–582)

Bluteau D, Lordier L, Di Stefano A, Chang Y, et al. Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 2009; 7:227–234.

• Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16:90–97.[13]

Deretic V, Levine B. Autophagy, Immunity, and Microbial Adaptations [Review]. Cell Host Microbe 2009; 5:527–549.

Fan J, Xie Y, Li XD, Guo GH, et al. The influence of Peyer's patch apoptosis on intestinal mucosal immunity in burned mice. Burns 2009; 35:687–694.

Galluzzi L, Kepp O, Zitvogel L, Kroemer G. Bacterial Invasion: Linking Autophagy and Innate Immunity. Curr Biol 2010; 20:R106–R108.

•• Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361:2033–2045.[39]

Hase K, Kawano K, Nochi T, Pontes GS, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009; 462:226–NIL_101.

Heath RJ, Xavier RJ. Autophagy, immunity and human disease. Curr Opin Gastroenterol 2009; 25:512–520.

Henry SC, Traver M, Daniell XJ, Indaram M, et al. Regulation of macrophage motility by Irgm1. J Leukoc Biol 2010; 87:333–343.

Jiang HQ, Patel PH, Kohlmaier A, Grenley MO, et al. Cytokine/Jak/Stat Signaling Mediates Regeneration and Homeostasis in the Drosophila Midgut. Cell 2009; 137:1343–1355.

Kamada N, Hisamatsu T, Honda H, Kobayashi T, et al. Human CD14(+) Macrophages in Intestinal Lamina Propria Exhibit Potent Antigen-Presenting Ability. J Immunol 2009; 183:1724–1731.

Kawakami K, Makino I, Kato I, Uchida K, et al. p-Cresol inhibits IL-12 production by murine macrophages stimulated with bacterial immunostimulant. Immunopharmacol Immunotoxicol 2009; 31:304–309.

Liang S, Domon H, Hosur KB, Wang M, et al. Age-related alterations in innate immune receptor expression and ability of macrophages to respond to pathogen challenge in vitro. Mech Ageing Dev 2009; 130:538–546.

Maheshwari A, Kurundkar AR, Shaik SS, Kelly DR, et al. Epithelial cells in fetal intestine produce chemerin to recruit macrophages. Am J Physiol-Gastroint Liver Physiol 2009; 297:G1–G10.

Mason KL, Huffnagle GB. Control of mucosal polymicrobial populations by innate immunity [Review]. Cell Microbiol 2009; 11:1297–1305.

• Murai M, Turovskaya O, Kim G, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009; 10:1178–1184.[37]

Plat-Sinnige MJT, Verkaik NJ, van Wamel WJB, de Groot N, et al. Induction of Staphylococcus aureus-specific IgA and agglutination potency in milk of cows by mucosal immunization. Vaccine 2009; 27:4001–4009.

Scillitani G, Liquori GE, Mastrodonato M, Ferri D. Histochemical and immunohistochemical characterization of exocrine cells in the foregut of the red-eared slider turtle, Trachemys scripta (Emydidae). Arch Histol Cytol 2008; 71:279–290.

• Sheikh SZ, Matsuoka K, Kobayashi T, et al. Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. J Immunol 2010; 184:4069–4073.[36]

• Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009; 206:1883–1897.[07]

Sugimoto M, Ohno T, Graham DY, Yamaoka Y. Gastric mucosal interleukin-17 and-18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Science 2009; 100:2152–2159.

Takenaka S, McCormick S, Safroneeva E, Xing Z, et al. Influence of the Tissue Microenvironment on Toll-Like Receptor Expression by CD11c(+) Antigen-Presenting Cells Isolated from Mucosal Tissues. Clin Vaccine Immunol 2009; 16:1615–1623, 2009 Nov.

Taniguchi Y, Yoshioka N, Nakata K, Nishizawa T, et al. Mechanism for Maintaining Homeostasis in the Immune System of the Intestine. Anticancer Res 2009; 29:4855–4860.

Xu T, Maloy S, McGuire KL. Macrophages influence Salmonella host-specificity in vivo. Microb Pathog 2009; 47:212–222.

Yoshioka N, Taniguchi Y, Yoshida A, Nakata K, et al. Intestinal Macrophages Involved in Intestine Have the Potential for the Homeostasis of the Responding to LPS. Anticancer Res 2009; 29:4861–4865.

Back to Top | Article Outline

Heads up! How the intestinal epithelium safeguards mucosal barrier immunity through the inflammasome and beyond

Review: (pp. 583–590)

• Allen IC, Tekippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207:1045–1056.[34]

Brink TC, Regenbrecht C, Demetrius L, Lehrach H, et al. Activation of the immune response is a key feature of aging in mice. Biogerontology 2009; 10:721–734.

• Brydges SD, Mueller JL, McGeough MD, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 2009; 30:875–887.[49]

Chen YB, Kim HT, McDonough S, Odze RD, et al. Up-Regulation of alpha 4 beta 7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2009; 15:1066–1076.

• Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16:90–97.[55]

•• Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol 2010; 40:599–606.[11]

• Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010; 32:367–378.[33]

• Ey B, Eyking A, Gerken G, et al. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J Biol Chem 2009; 284:22332–22343.[19]

• Franchi L, Eigenbrod T, Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009; 183:792–796.[47]

Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, et al. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia - art. no. 65. BMC Gastroenterology 2009:65.

• Hirota SA, Ng J, Khajah MA, et al. Loss of the NOD2-related molecule NLRP3 results in broad changes in the innate immune response and intestinal microbiota resulting in an increased susceptibility to intestinal inflammation. Gastroenterology 2010; 138:S94–S95. (abstract)[35]

• Iliev ID, Mileti E, Matteoli G, et al. Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. Mucosal Immunol 2009; 2:340–350.[21]

•• Jha S, Ting JP. Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases. J Immunol 2009; 183:7623–7629.[04]

Jia YX, Song T, Wei CW, Ni CF, et al. Negative Regulation of MAVS-Mediated Innate Immune Response by PSMA7. J Immunol 2009; 183:4241–4248.

• Lee SH, Hu LL, Gonzalez-Navajas J, et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med 2010; 16:665–670.[59]

• Meng G, Zhang F, Fuss I, et al. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009; 30:860–874.[48]

Mockelmann N, von Schonfels W, Buch S, von Kampen O, et al. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer - art. no. 79. BMC Gastroenterology 2009:79.

Nemoto Y, Kanai T, Kameyama K, Shinohara T, et al. Long-Lived Colitogenic CD4(+) Memory T Cells Residing Outside the Intestine Participate in the Perpetuation of Chronic Colitis. J Immunol 2009; 183:5059–5068.

Onyeagocha C, Hossain MS, Kumar A, Jones RM, et al. Latent Cytomegalovirus Infection Exacerbates Experimental Colitis. Am J Pathol 2009; 175:2034–2042.

• Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010; 107:8017–8022.[31]

• Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009; 137:209–220.[28]

•• Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821–832.[09]

Sidelnikov E, Bostick RM, Flanders WD, Long Q, et al. Colorectal Mucosal Expression of MSH2 as a Potential Biomarker of Risk for Colorectal Neoplasms. Cancer Epidemiol Biomarkers Prev 2009; 18.

• Sodhi CP, Shi XH, Richardson WM, et al. Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signalling in necrotizing enterocolitis. Gastroenterology 2010; 138:185–196.[25]

• Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009; 136:551–563.[18]

• Theiss AL, Vijay-Kumar M, Obertone TS, et al. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology 2009; 137:199–208. 208 e191–196[29]

Thevenon D, Engel E, Avet-Rochex A, Gottar M, et al. The Drosophila Ubiquitin-Specific Protease dUSP36/Scny Targets IMD to Prevent Constitutive Immune Signaling. Cell Host Microbe 2009; 6:309–320.

• Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11:55–62.[53]

• Uronis JM, Muhlbauer M, Herfarth HH, et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009; 4:e6026.[60]

• Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328:228–231.[02]

• Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009; 41:71–76.[46]

• Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32:379–391.[32]

Zhang JG, Zhao J, Xin Y. Significance and relationship between Cripto-1 and p-STAT3 expression in gastric cancer and precancerous lesions. World J Gastroenterol 2010; 16:571–577.

• Zheng L, Riehl TE, Stenson WF. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology 2009; 137:2041–2051.[24]

Back to Top | Article Outline

Vitamin D and mucosal immune function

Review: (pp. 591–595)

• Albert PJ, Proal AD, Marshall TG. Vitamin D: the alternative hypothesis. Autoimmun Rev 2009; 8:639–644.[10]

• Carlberg C, Seuter S. A genomic perspective on vitamin D signaling. Anticancer Res 2009; 29:3485–3493.[04]

Cross HS, Nittke T, Peterlik M. Modulation of Vitamin D Synthesis and Catabolism in Colorectal Mucosa: A New Target for Cancer Prevention. Anticancer Res 2009; 29:3705–3712.

• D'Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009; 136:1435–1443.[33]

• Gombart AF. The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol 2009; 4:1151–1165.[24]

• Hansdottir S, Monick MM, Lovan N, et al. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J Immunol 2010; 184:965–974.[35]

• Hewison M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol 2010; 321:103–111.[44]

• Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009; 3:5458–5467.[18]

Jonckheere N, Van Seuningen I. The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers [Review]. Biochimie 2010; 92:1–11.

•• Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene 2009; 28:3892–3902.[39]

• Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med 2010; 88:441–450.[09]

• Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology 2010; 151:2423–2432.[31]

• Montoya D, Cruz D, Teles RM, et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 2009; 6:343–353.[28]

•• Stambolsky P, Tabach Y, Fontemaggi G, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010; 17:273–285.[41]

Takahashi I, Nochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines [Review]. Curr Opin Immunol 2009; 21:352–358.

•• Von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11:344–349.[08]

• Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 2010; 285:2227–2231.[22]

• Wang Y, Becklund BR, De Luca HF. Identification of a highly specific and versatile vitamin D receptor antibody. Arch Biochem Biophys 2010; 494:166–177.[02]

• Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6:231–243.[26]

Yuki Y, Kiyono H. Mucosal vaccines: novel advances in technology and delivery [Review]. Expert Rev Vaccines 2009; 8:1083–1097.

Back to Top | Article Outline

Infection and immunity

Acevedo R, Callico A, del Campo J, Gonzalez E, et al. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 2009; 49:309–315.

Agrawal T, Vats V, Salhan S, Mittal A. The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women. J Reprod Immunol 2009; 83:173–178.

Ahlers JD, Belyakov IM. Strategies for optimizing targeting and delivery of mucosal HIV vaccines [Review]. Eur J Immunol 2009; 39:2657–2669.

Allaoui A, Botteaux A, Dumont JE, Hoste C, et al. Dual oxidases and hydrogen peroxide in a complex dialogue between host mucosae and bacteria [Review]. Trends Mol Med 2009; 15:571–579.

Auvynet C, Rosenstein Y. Multifunctional host defense peptides: Antimicrobial peptides, the small yet big players in innate and adaptive immunity [Review]. FEBS J 2009; 276:6497–6508.

Baba N, Samson S, Bourdet-Sicard R, Rubio M, et al. Selected commensal-related bacteria and Toll-like receptor 3 agonist combinatorial codes synergistically induce interleukin-12 production by dendritic cells to trigger a T helper type 1 polarizing programme. Immunology 2009; 128:e523–e531.

Barakat FM, McDonald V, Di Santo JP, Korbel DS. Roles for NK Cells and an NK Cell-Independent Source of Intestinal Gamma Interferon for Innate Immunity to Cryptosporidium parvum Infection. Infect Immun 2009; 77:5044–5049.

Barakat FM, McDonald V, Foster GR, Tovey MG, et al. Cryptosporidium parvum Infection Rapidly Induces a Protective Innate Immune Response Involving Type I Interferon. J Infect Dis 2009; 200:1548–1555.

Behjati S, Frank MH. The Effects of Tamoxifen on Immunity [Review]. Current Medicinal Chemistry 2009; 16:3076–3080.

Bishop NC, Gleeson M. Acute and chronic effects of exercise on markers of mucosal immunity [Review]. Front Biosci 2009:4444–4456.

Borges O, Lebre F, Bento D, Borchard G, et al. Mucosal Vaccines: Recent Progress in Understanding the Natural Barriers [Review]. Pharm Res 2010; 27:211–223.

Brandtzaeg P. Mucosal Immunity: Induction, Dissemination, and Effector Functions [Review]. Scand J Immunol 2009; 70:505–515.

Buchon N, Broderick NA, Chakrabarti S, Lemaitre B. Invasive and indigenous microbiota impact intestinal stem cell activity through multiple pathways in Drosophila. Genes Dev 2009; 23:2333–2344.

Caputo A, Castaldello A, Brocca-Cofano E, Voltan R, et al. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine 2009; 27:3605–3615.

Chakraborty K, Maity PC, Sil AK, Takeda Y, et al. cAMP Stringently Regulates Human Cathelicidin Antimicrobial Peptide Expression in the Mucosal Epithelial Cells by Activating cAMP-response Element-binding Protein, AP-1, and Inducible cAMP Early Repressor. J Biol Chem 2009; 284:21810–21827.

Chatterjee M, Ip YT. Pathogenic Stimulation of Intestinal Stem Cell response in Drosophila. J Cell Physiol 2009; 220:664–671.

Cherayil BJ. Indoleamine 2,3-Dioxygenase in Intestinal Immunity and Inflammation [Review]. Inflamm Bowel Dis 2009; 15:1391–1396.

Cooper PJ. Mucosal immunology of geohelminth infections in humans [Review]. Mucosal Immunol 2009; 2:288–299.

Corthesy B. Secretory immunoglobulin A: well beyond immune exclusion at mucosal surfaces [Review]. Immunopharmacol Immunotoxicol 2009; 31:174–179.

Courtney AN, Nehete PN, Nehete BR, Thapa P, et al. Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 2009; 27:3335–3341.

Cronin SJF, Nehme NT, Limmer S, Liegeois S, et al. Genome-Wide RNAi Screen Identifies Genes Involved in Intestinal Pathogenic Bacterial Infection. Science 2009; 325:340–343.

Cuthbert RJ, Wilson JM, Scott N, Coletta PL, et al. Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer 2009; 45:1654–1663.

de Leeuw E, Rajabi M, Zou GZ, Pazgier M, et al. Selective arginines are important for the antibacterial activity and host cell interaction of human alpha-defensin 5. FEBS Lett 2009; 583:2507–2512.

Dharmani P, Srivastava V, Kissoon-Singh V, Chadee K. Role of Intestinal Mucins in Innate Host Defense Mechanisms against Pathogens [Review]. J Innate Immun 2009; 1:123–135.

Dogi CA, Weill F, Perdigon G. Immune response of non-pathogenic Gram(+) and Gram(-) bacteria in inductive sites of the intestinal mucosa Study of the pathway of signaling involved. Immunobiology 2010; 215:60–69.

Erickson KL, Hubbard NE. Assessing mucosal immunity with new concepts and innovative, time-honored strategies [Review]. Nutr Rev 2009; 67:S172–S182.

Fournier B, Williams IR, Gewirtz AT, Neish AS. Toll-Like Receptor 5-Dependent Regulation of Inflammation in Systemic Salmonella enterica Serovar Typhimurium Infection. Infect Immun 2009; 77:4121–4129.

Fu YH, He JS, Zheng XX, Wang XB, et al. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. Biochem Biophys Res Commun 2010; 391:857–861.

Fujihashi K, Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases [Review]. Trends Immunol 2009; 30:334–343.

Galluzzi L, Kepp O, Zitvogel L, Kroemer G. Bacterial Invasion: Linking Autophagy and Innate Immunity. Curr Biol 2010; 20:R106–R108.

Georgousakis MM, McMillan DJ, Batzloff MR, Sriprakash KS. Moving forward: a mucosal vaccine against group A streptococcus [Review]. Expert Rev Vaccines 2009; 8:747–760.

Glenn GM, Francis DH, Danielsen EM. Toxin-Mediated Effects on the Innate Mucosal Defenses: Implications for Enteric Vaccines [Review]. Infect Immun 2009; 77:5206–5215.

Gonzalez-Navajas JM, Fine S, Law J, Datta SK, et al. TLR4 signaling in effector CD4(+) T cells regulates TCR activation and experimental colitis in mice. J Clin Invest 2010; 120:570–581.

Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58:929–939.

Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, et al. Antigen-Specific Memory B-Cell Responses to Vibrio cholerae O1 Infection in Bangladesh. Infect Immun 2009; 77:3850–3856.

Hase K, Kawano K, Nochi T, Pontes GS, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009; 462:226–NIL_101.

Hasselrot K. Genital and Oral Mucosal Immune Response Against HIV-1 in Exposed Uninfected Individuals. Crit Rev Immunol 2009; 29:369–377.

Heath RJ, Xavier RJ. Autophagy, immunity and human disease. Curr Opin Gastroenterol 2009; 25:512–520.

Herbert DR, Yang JQ, Hogan SP, Groschwitz K, et al. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med 2009; 206:2947–2957.

Hofer U, Speck RF. Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection [Review]. Semin Immunopathol 2009; 31:257–277.

Hu SJ, Xie Y. Helicobacter pylori vaccine: mucosal adjuvant & delivery systems [Review]. Indian J Med Res 2009; 130:115–124.

Ilan Y. Oral tolerance: Can we make it work? [Review]. Hum Immunol 2009; 70:768–776.

Ince MN, Elliott DE, Setiawan T, Metwali A, et al. Role of T cell TGF-beta signaling in intestinal cytokine responses and helminthic immune modulation. Eur J Immunol 2009; 39:1870–1878.

Isakov D, Dzutsev A, Belyakov IM, Berzofsky JA. Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCR alpha beta(+) CD8 alpha beta(+) T cells in the small intestinal mucosa. Mucosal Immunol 2009; 2:450–461.

Joossens M, Van Steen K, Branche J, Sendid B, et al. Familial Aggregation and Antimicrobial Response Dose-Dependently Affect the Risk for Crohn's Disease. Inflamm Bowel Dis 2010; 16:58–67.

Ju CH, Chockalingam A, Leifer CA. Early Response of Mucosal Epithelial Cells during Toxoplasma gondii Infection. J Immunol 2009; 183:7420–7427.

Kaetzel CS. ICMI 2009: all immunity is mucosal. Mucosal Immunol 2009; 2:464–466.

Kataoka K, Fujihashi K. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines [Review]. Expert Rev Vaccines 2009; 8:1183–1193.

Kaufman DR, Barouch DH. Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity [Review]. Clin Exp Immunol 2009; 157:165–173.

Kayamuro H, Abe Y, Yoshioka Y, Katayama K, et al. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 2009; 30:5869–5876.

Khare S, Nunes JS, Figueiredo JF, Lawhon SD, et al. Early Phase Morphological Lesions and Transcriptional Responses of Bovine Ileum Infected with Mycobacterium avium subsp paratuberculosis. Vet Pathol 2009; 46:717–728.

Kotarsky K, Sitnik KM, Stenstad H, Kotarsky H, et al. A novel role for constitutively expressed epithelial-derived chemokines as antibacterial peptides in the intestinal mucosa. Mucosal Immunol 2010; 3:40–48.

Kuenzel S, Till A, Winkler M, Hasler R, et al. The Nucleotide-Binding Oligomerization Domain-Like Receptor NLRC5 Is Involved in IFN-Dependent Antiviral Immune Responses. J Immunol 2010; 184:1990–2000.

Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, et al. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Ther 2010; 17:72–82.

Kwant-Mitchell A, Ashkar AA, Rosenthal KL. Mucosal Innate and Adaptive Immune Responses against Herpes Simplex Virus Type 2 in a Humanized Mouse Model. J Virol 2009; 83:10664–10676.

Lee WJ. Bacterial-modulated host immunity and stem cell activation for gut homeostasis. Genes Dev 2009; 23:2260–2265.

Long KZ, Rosado JL, Santos JI, Haas M, et al. Associations between Mucosal Innate and Adaptive Immune Responses and Resolution of Diarrheal Pathogen Infections. Infect Immun 2010; 78:1221–1228.

Luo Y, Caldwell KS, Wroblewski T, Wright ME, et al. Proteolysis of a Negative Regulator of Innate Immunity Is Dependent on Resistance Genes in Tomato and Nicotiana benthamiana and Induced by Multiple Bacterial Effectors. Plant Cell 2009; 21:2458–2472.

Malik B, Goyal AK, Mangal S, Zakir F, et al. Implication of Gut Immunology in the Design of Oral Vaccines [Review]. Current Molecular Medicine 2010; 10:47–70.

Marodi L, Casanova JL. Novel primary immunodeficiencies relevant to internal medicine: novel phenotypes. J Intern Med 2009; 266:502–506.

McBurney SP, Ross TM. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 2009; 27:4337–4349.

Menzies M, Reverter A, Andronicos N, Hunt P, et al. Nematode challenge induces differential expression of oxidant, antioxidant and mucous genes down the longitudinal axis of the sheep gut. Parasite Immunol 2010; 32:36–46.

Mestecky J, Moldoveanu Z, Smith PD, Hel Z, et al. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009; 83:196–200.

Michels CE, Scales HE, Saunders KA, McGowan S, et al. Neither interleukin-4 receptor alpha expression on CD4(+) T cells, or macrophages and neutrophils is required for protective immunity to Trichinella spiralis. Immunology 2009; 128:e385–e394.

Ng SC, Plamondon S, Al-Hassi HO, English N, et al. A novel population of human CD56+human leucocyte antigen D-related (HLA-DR plus ) colonic lamina propria cells is associated with inflammation in ulcerative colitis. Clin Exp Immunol 2009; 158:205–218.

Pala P, Gomez-Roman VR, Gilmour J, Kaleebu P. An African perspective on mucosal immunity and HIV-1 [Review]. Mucosal Immunol 2009; 2:300–314.

Paolillo R, Carratelli CR, Sorrentino S, Mazzola N, et al. Immunomodulatory effects of Lactobacillus plantarum on human colon cancer cells. Int Immunopharmacol 2009; 9:1265–1271.

Parthasarathy G, Mansfield LS. Recombinant interleukin-4 enhances Campylobacter jejuni invasion of intestinal pig epithelial cells (IPEC-1). Microb Pathog 2009; 47:38–46.

Pei SB, Xiong N, Zhang Y, Chen SY. Increasing M2 epitope density enhances systemic and mucosal immune responses to influenza A virus. Biotechnol Lett 2009; 31:1851–1856.

Peng T, Zhu J, Klock A, Phasouk K, et al. Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2. J Virol 2009; 83:12559–12568.

Plat-Sinnige MJT, Verkaik NJ, van Wamel WJB, de Groot N, et al. Induction of Staphylococcus aureus-specific IgA and agglutination potency in milk of cows by mucosal immunization. Vaccine 2009; 27:4001–4009.

Pregliasco F, Terracciano L, Marcassa S, Zava D, et al. Rationale for the clinical use of a ribosome-component immune modulator. Allergy Asthma Proc 2009; 30:S5–S12.

Qiao Y, Huang Y, Qiu C, Yue XY, et al. The use of PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses. Biomaterials 2010; 31:115–123.

Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease [Review]. J Clin Invest 2009; 119:2441–2450.

Salzman NH, Hung KC, Haribhai D, Chu HT, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11:76–NIL_1.

Satoh-Takayama N, Dumoutier L, Lesjean-Pottier S, Ribeiro VSG, et al. The Natural Cytotoxicity Receptor NKp46 Is Dispensable for IL-22-Mediated Innate Intestinal Immune Defense against Citrobacter rodentium. J Immunol 2009; 183:6579–6587.

Sayin B, Somavarapu S, Li XW, Sesardic D, et al. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci 2009; 38:362–369.

Schneider JD, Seibold I, Saxer-Sekulic N, Paredes BE, et al. Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis. Eur J Immunol 2009; 39:1743–1753.

Shanahan F. Gut Microbes: From Bugs to Drugs [Review]. Am J Gastroenterol 2010; 105:275–279.

Spehlmann ME, Dann SM, Hruz P, Hanson E, et al. CXCR2-Dependent Mucosal Neutrophil Influx Protects against Colitis-Associated Diarrhea Caused by an Attaching/Effacing Lesion-Forming Bacterial Pathogen. J Immunol 2009; 183:3332–3343.

Steinberg MW, Shui JW, Ware CF, Kronenberg M. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners [Review]. Semin Immunopathol 2009; 31:207–221.

Suhwold A, Hermosilla C, Seeger T, Zahner H, et al. T cell reactions of Eimeria bovis primary- and challenge-infected calves. Parasitol Res 2010; 106:595–605.

Takahashi I, Nochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines [Review]. Curr Opin Immunol 2009; 21:352–358.

Takenaka S, McCormick S, Safroneeva E, Xing Z, et al. Influence of the Tissue Microenvironment on Toll-Like Receptor Expression by CD11c(+) Antigen-Presenting Cells Isolated from Mucosal Tissues. Clin Vaccine Immunol 2009; 16:1615–1623, 2009 Nov.

Tessema TS, Schwamb B, Lochner M, Forster I, et al. Dynamics of gut mucosal and systemic Th1/Th2 cytokine responses in interferon-gamma and interleukin-12p40 knock out mice during primary and challenge Cryptosporidium parvum infection. Immunobiology 2009; 214:454–466.

Tokarev A, Skasko M, Fitzpatrick K, Guatelli J. Antiviral Activity of the Interferon-Induced Cellular Protein BST-2/Tetherin [Review]. AIDS Res Hum Retroviruses 2009; 25:1197–1210.

Uematsu S, Akira S. Immune responses of TLR5(+) lamina propria dendritic cells in enterobacterial infection [Review]. J Gastroenterology 2009; 44:803–811.

van Wijk F, Cheroutre H. Intestinal T cells: Facing the mucosal immune dilemma with synergy and diversity [Review]. Semin Immunol 2009; 21:130–138.

Wallis RS. Infectious complications of tumor necrosis factor blockade [Review]. Curr Opin Infect Dis 2009; 22:403–409.

Wang LS, Cheng C, Ko SY, Kong WP, et al. Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity. J Virol 2009; 83:7166–7175.

Wells JM, Loonen LMP, Karczewski JM. The role of innate signaling in the homeostasis of tolerance and immunity in the intestine. Int J Med Microbiol 2010; 300:41–48.

Xu GF, Wang SX, Zhuang L, Hackett A, et al. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera. Vaccine 2009; 27:3821–3830.

Xu T, Maloy S, McGuire KL. Macrophages influence Salmonella host-specificity in vivo. Microb Pathog 2009; 47:212–222.

Xu WF, Santini PA, Sullivan JS, He B, et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009; 10:1008–NIL_106.

Xue GH, Yu LH, Li ST, Shen XZ. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice. FEMS Immunol Med Microbiol 2010; 58:202–210.

Yuki Y, Kiyono H. Mucosal vaccines: novel advances in technology and delivery [Review]. Expert Rev Vaccines 2009; 8:1083–1097.

Zhao HY, Luo YY, Lu C, Lin N, et al. Enteric Mucosal Immune Response might Trigger the Immunomodulation Activity of Ganoderma lucidum Polysaccharide in Mice. Planta Med 2010; 76:223–227.

Zhao YO, Rohde C, Lilue JT, Konen-Waisman S, et al. Toxoplasma gondii and the immunity-related GTPase (IRG) resistance system in mice - A Review. Mem Inst Oswaldo Cruz 2009; 104:233–239.

Ziesche E, Scheiermann P, Bachmann M, Sadik CD, et al. Dexamethasone suppresses interleukin-22 associated with bacterial infection in vitro and in vivo. Clin Exp Immunol 2009; 157:370–376.

Back to Top | Article Outline

Effect of chemokines, cytokines and local GI hormones on the immunity

Allaoui A, Botteaux A, Dumont JE, Hoste C, et al. Dual oxidases and hydrogen peroxide in a complex dialogue between host mucosae and bacteria [Review]. Trends Mol Med 2009; 15:571–579.

Amasheh M, Grotjohann I, Amasheh S, Fromm A, et al. Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: A novel model for studying the pathomechanisms of inflammatory bowel disease cytokines. Scand J Gastroenterol 2009; 44:1226–1235.

Baba N, Samson S, Bourdet-Sicard R, Rubio M, et al. Selected commensal-related bacteria and Toll-like receptor 3 agonist combinatorial codes synergistically induce interleukin-12 production by dendritic cells to trigger a T helper type 1 polarizing programme. Immunology 2009; 128:e523–e531.

Barajon I, Serrao G, Arnaboldi F, Opizzi E, et al. Toll-like Receptors 3, 4, and 7 Are Expressed in the Enteric Nervous System and Dorsal Root Ganglia. J Histochem Cytochem 2009; 57:1013–1023.

Bertran E, Caja L, Navarro E, Sancho P, et al. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal 2009; 21:1595–1606.

Bogunovic M, Ginhoux F, Helft J, Shang LM, et al. Origin of the Lamina Propria Dendritic Cell Network. Immunity 2009; 31:513–525.

Boullier S, Tanguy M, Kadaoui KA, Caubet C, et al. Secretory IgA-Mediated Neutralization of Shigella flexneri Prevents Intestinal Tissue Destruction by Down-Regulating Inflammatory Circuits. J Immunol 2009; 183:5879–5885.

Carbone A, Vizio B, Novarino A, Mauri FA, et al. IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival. J Immunother 2009; 32:920–931.

Castellaneta A, Sumpter TL, Chen LP, Tokita D, et al. NOD2 Ligation Subverts IFN-alpha Production by Liver Plasmacytoid Dendritic Cells and Inhibits Their T Cell Allostimulatory Activity via B7-H1 Up-Regulation. J Immunol 2009; 183:6922–6932.

Colonna M. Interleukin-22-Producing Natural Killer Cells and Lymphoid Tissue Inducer-like Cells in Mucosal Immunity [Review]. Immunity 2009; 31:15–23.

Corinaldesi R, Stanghellini V, Cremon C, Gargano L, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30:245–252.

Dabrowska P, Freitak D, Vogel H, Heckel DG, et al. The phytohormone precursor OPDA is isomerized in the insect gut by a single, specific glutathione transferase. Proc Natl Acad Sci USA 2009; 106:16304–16309.

Daneman R, Rescigno M. The Gut Immune Barrier and the Blood-Brain Barrier: Are They So Different? [Review]. Immunity 2009; 31:722–735.

Dave SH, Tilstra JS, Matsuoka K, Li FL, et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009; 86:633–643.

Delgado MA, Deretic V. Toll-like receptors in control of immunological autophagy [Review]. Cell Death Differ 2009; 16:976–983.

Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity [Review]. J Leukoc Biol 2010; 87:79–92.

Eksteen B, Mora JR, Haughton EL, Henderson NC, et al. Gut Homing Receptors on CD8 T Cells Are Retinoic Acid Dependent and Not Maintained by Liver Dendritic or Stellate Cells. Gastroenterology 2009; 137:320–329.

Fahlen-Yrlid L, Gustafsson T, Westlund J, Holmberg A, et al. CD11c(high) Dendritic Cells Are Essential for Activation of CD4(+) T Cells and Generation of Specific Antibodies following Mucosal Immunization. J Immunol 2009; 183:5032–5041.

Fan J, Xie Y, Li XD, Guo GH, et al. The influence of Peyer's patch apoptosis on intestinal mucosal immunity in burned mice. Burns 2009; 35:687–694.

Fischer S, Schlosser E, Mueller M, Csaba N, et al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Targeting 2009; 17:652–661.

Fornai M, Antonioli L, Colucci R, Bernardini N, et al. Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions [Review]. Pharmacol Ther 2010; 125:62–78.

Fulcher JA, Chang MH, Wang S, Almazan T, et al. Galectin-1 Co-clusters CD43/CD45 on Dendritic Cells and Induces Cell Activation and Migration through Syk and Protein Kinase C Signaling. J Biol Chem 2009; 284:26860–26870.

Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58:929–939.

Gross K, Karagiannides I, Thomou T, Koon HW, et al. Substance P promotes expansion of human mesenteric preadipocytes through proliferative and antiapoptotic pathways. Am J Physiol-Gastroint Liver Physiol 2009; 296:G1012–G1019.

Hafez M, Hayes K, Goldrick M, Warhurst G, et al. The K5 Capsule of Escherichia coli Strain Nissle 1917 Is Important in Mediating Interactions with Intestinal Epithelial Cells and Chemokine Induction. Infect Immun 2009; 77:2995–3003.

Hasko G, Csoka B, Nemeth ZH, Vizi ES, et al. A(2B) adenosine receptors in immunity and inflammation [Review]. Trends Immunol 2009; 30:263–270.

Heilmann K, Hoffmann U, Witte E, Loddenkemper C, et al. Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 2009; 13:1162–1174.

Herbert DR, Yang JQ, Hogan SP, Groschwitz K, et al. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med 2009; 206:2947–2957.

Hu GK, Zhou R, Liu J, Gong AY, et al. MicroRNA-98 and let-7 Confer Cholangiocyte Expression of Cytokine-Inducible Src Homology 2-Containing Protein in Response to Microbial Challenge. J Immunol 2009; 183:1617–1624.

Huynh D, Dai XM, Nandi S, Lightowler S, et al. Colony Stimulating Factor-1 Dependence of Paneth Cell Development in the Mouse Small Intestine. Gastroenterology 2009; 137:136–144.

Isakov D, Dzutsev A, Belyakov IM, Berzofsky JA. Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCR alpha beta(+) CD8 alpha beta(+) T cells in the small intestinal mucosa. Mucosal Immunol 2009; 2:450–461.

Ito J, Ito M, Nambu H, Fujikawa T, et al. Anatomical and histological profiling of orphan G-protein-coupled receptor expression in gastrointestinal tract of C57BL/6J mice. Cell Tissue Res 2009; 338:257–269.

Kaetzel CS. ICMI 2009: all immunity is mucosal. Mucosal Immunol 2009; 2:464–466.

Kasakura K, Takahashi K, Aizawa T, Hosono A, et al. A TLR2 Ligand Suppresses Allergic Inflammatory Reactions by Acting Directly on Mast Cells. Int Arch Allergy Immunol 2009; 150:359–369.

Lavelle EC, Murphy C, O'Neill LAJ, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis [Review]. Mucosal Immunol 2010; 3:17–28.

Liu C, Li A, Weng YB, Duan ML, et al. Changes in intestinal mucosal immune barrier in rats with endotoxemia. World J Gastroenterol 2009; 15:5843–5850.

Liu WC, Ouyang XS, Yang JJ, Liu JG, et al. AP-1 Activated by Toll-like Receptors Regulates Expression of IL-23 p19. J Biol Chem 2009; 284:24006–24016.

Mizumori M, Ham M, Guth PH, Engel E, et al. Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum. J Physiol-London 2009; 587:3651–3663.

Monteleone G, Pallone F, Macdonald TT. Interleukin-21 as a new therapeutic target for immune-mediated diseases [Review]. Trends Pharmacol Sci 2009; 30:441–447.

Nakamura E, Hasumura M, San Gabriel A, Uneyama H, et al. New Frontiers in Gut Nutrient Sensor Research: Luminal Glutamate-Sensing Cells in Rat Gastric Mucosa [Review]. Journal of Pharmacological Sciences 2010; 112:13–18.

Narumiya S. Prostanoids and inflammation: a new concept arising from receptor knockout mice [Review]. J Mol Med 2009; 87:1015–1022.

Nijnik A, Madera L, Ma SH, Waldbrook M, et al. Synthetic Cationic Peptide IDR-1002 Provides Protection against Bacterial Infections through Chemokine Induction and Enhanced Leukocyte Recruitment. J Immunol 2010; 184:2539–2550.

Nijnik A, Pistolic J, Wyatt A, Tam S, et al. Human Cathelicidin Peptide LL-37 Modulates the Effects of IFN-gamma on APCs. J Immunol 2009; 183:5788–5798.

Oishi A, Gengyo-Ando K, Mitani S, Mohri-Shiomi A, et al. FLR-2, the glycoprotein hormone alpha subunit, is involved in the neural control of intestinal functions in Caenorhabditis elegans. Genes to Cells 2009; 14:1141–1154.

Pickert G, Neufert C, Leppkes M, Zheng Y, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206:1465–1472.

Pontell L, Castelucci P, Bagyanszki M, Jovic T, et al. Structural changes in the epithelium of the small intestine and immune cell infiltration of enteric ganglia following acute mucosal damage and local inflammation. Virchows Arch 2009; 455:55–65.

Radhakrishnan RS, Shah SK, Lance SH, Radhakrishnan HR, et al. Hypertonic saline alters hydraulic conductivity and up-regulates mucosal/submucosal aquaporin 4 in resuscitation-induced intestinal edema. Crit Care Med 2009; 37:2946–2952.

Raz E. Mucosal immunity: aliment and ailments. Mucosal Immunol 2010; 3:4–7.

Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease [Review]. J Clin Invest 2009; 119:2441–2450.

Rondanelli M, Opizzi A, Monteferrario F. THE BIOLOGICAL ACTIVITY OF BETA-GLUCANS [Italian]. Minerva Med 2009; 100:237–245.

Satoh-Takayama N, Dumoutier L, Lesjean-Pottier S, Ribeiro VSG, et al. The Natural Cytotoxicity Receptor NKp46 Is Dispensable for IL-22-Mediated Innate Intestinal Immune Defense against Citrobacter rodentium. J Immunol 2009; 183:6579–6587.

Sharma R, Tepas JJ. Microecology, intestinal epithelial barrier and necrotizing enterocolitis [Review]. Pediatr Surg Int 2010; 26:11–21.

Singh V, Aballay A. Regulation of DAF-16-mediated Innate Immunity in Caenorhabditis elegans. J Biol Chem 2009; 284:35580–35587.

Slattery ML, Fitzpatrick FA. Convergence of Hormones, Inflammation, and Energy-Related Factors: A Novel Pathway of Cancer Etiology [Review]. Cancer Prev Res 2009; 2:922–930.

Smalley SGR, Barrow PA, Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease [Review]. Clin Exp Immunol 2009; 157:225–234.

Sonier B, Patrick C, Ajjikuttira P, Scott FW. Intestinal Immune Regulation as a Potential Diet-Modifiable Feature of Gut Inflammation and Autoimmunity [Review]. Int Rev Immunol 2009; 28:414–445.

Steinberg MW, Shui JW, Ware CF, Kronenberg M. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners [Review]. Semin Immunopathol 2009; 31:207–221.

Su JM, Zhang TL, Tyson J, Li LW. The Interleukin-1 Receptor-Associated Kinase M Selectively Inhibits the Alternative, Instead of the Classical NF kappa B Pathway. J Innate Immun 2009; 1:164–174.

Taniguchi Y, Yoshioka N, Nakata K, Nishizawa T, et al. Mechanism for Maintaining Homeostasis in the Immune System of the Intestine. Anticancer Res 2009; 29:4855–4860.

Tessema TS, Schwamb B, Lochner M, Forster I, et al. Dynamics of gut mucosal and systemic Th1/Th2 cytokine responses in interferon-gamma and interleukin-12p40 knock out mice during primary and challenge Cryptosporidium parvum infection. Immunobiology 2009; 214:454–466.

Vavassori P, Mencarelli A, Renga B, Distrutti E, et al. The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity. J Immunol 2009; 183:6251–6261.

Watanabe T, Yamamoto T, Yoshida M, Fujiwara K, et al. The Traditional Herbal Medicine Saireito Exerts Its Inhibitory Effect on Murine Oxazolone-Induced Colitis via the Induction of Th1-Polarized Immune Responses in the Mucosal Immune System of the Colon. Int Arch Allergy Immunol 2010; 151:98–106.

Wells JM, Loonen LMP, Karczewski JM. The role of innate signaling in the homeostasis of tolerance and immunity in the intestine. Int J Med Microbiol 2010; 300:41–48.

Williams MA, Bauer S, Lu WJ, Guo J, et al. Deletion of the Mucin-Like Molecule Muc1 Enhances Dendritic Cell Activation in Response to Toll-Like Receptor Ligands. J Innate Immun 2010; 2:123–143.

Wu S, Zhang XF, Chen XM, Cao PS, et al. BmToll9, an Arthropod conservative Toll, is likely involved in the local gut immune response in the silkworm, Bombyx mori. Dev Comp Immunol 2010; 34:93–96.

Wullaert A. Role of NF-kappa B activation in intestinal immune homeostasis. Int J Med Microbiol 2010; 300:49–56.

Zhou C, Liu J, Wang HY, Tang CW. Decreased somatostatin is related to the hypersensitivity of intestinal epithelia to LPS via upregulated TLR4-TBK1 pathway in rats chronically exposed to ethanol. Alcohol 2009; 43:293–303.

Back to Top | Article Outline

Stomach and duodenum

Gastric secretion

Review: (pp. 598–603)

Abe K, Tani K, Nishizawa T, Fujiyoshi Y. A Novel Ratchet Mechanism of Gastric H+,K+-ATPase Revealed by Electron Crystallography of Two-dimensional Crystals [Review] [Japanese]. Yakugaku Zasshi-J Pharm Soc Jpn 2010; 130:205–210.

Alaynick WA, Way JM, Wilson SA, Benson WG, et al. ERR gamma Regulates Cardiac, Gastric, and Renal Potassium Homeostasis. Mol Endocrinol 2010; 24:299–309.

Ashrafian H, le Roux CW. Metabolic surgery and gut hormones - A review of bariatric entero-humoral modulation. Physiol Behav 2009; 97:620–631.

Baldwin CM, Keam SJ. Rabeprazole A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults [Review]. Drugs 2009; 69:1373–1401.

Bharathi DV, Hotha KK, Jagadeesh B, Chatki PK, et al. Simultaneous estimation of four proton pump inhibitors-lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. Biomed Chromatogr 2009; 23:732–739.

Breuer C, Rauh M, Zink S, Koch A, et al. Serum levels of gastric-acid-stimulating factors in children undergoing open heart surgery. Intensive Care Med 2009; 35:1619–1622.

Chan FKL. Immediate-release oral proton pump inhibitors: Panacea or a flash in the pan? J Gastroenterol Hepatol 2010; 25:6–7.

Clark K, Lam L, Currow D. Reducing gastric secretions-a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer 2009; 17:1463–1468.

Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials [Review]. Anaesthesia 2009; 64:652–657.

da Rocha JRM, Cecconello I, Ribeiro U, Baba ER, et al. Preoperative Gastric Acid Secretion and the Risk to Develop Barrett's Esophagus After Esophagectomy for Chagasic Achalasia. J Gastrointest Surg 2009; 13:1893–1898.

da Rocha JRM, Ribeiro U, Cecconello I, Sallum RAA, et al. Gastric secretory and hormonal patterns in end-stage chagasic achalasia. Dis Esophagus 2009; 22:606–610.

Dias LM. Pantoprazole A Proton Pump Inhibitor [Review]. Clin Drug Invest 2009; 29:3–12.

Edelsbrunner ME, Nakano M, Holzer P. Afferent signalling from the acid-challenged rat stomach is inhibited and gastric acid elimination is enhanced by lafutidine - art. no. 40. BMC Gastroenterology 2009:40.

• Ericson A, Mohammed Nur E, Petersson F, Kechagias S. The effects of capsaicin on gastrin secretion in isolated human antral glands: before and after ingestion of red chilli. Dig Dis Sci 2009; 54:491–498.[15]

•• Forte JG, Zhu LX. Apical recycling of the gastric parietal cell H,K-ATPase. Annu Rev Physiol 2010; 72:273–296.[38]

Franceschi M, Di Mario F, Leandro G, Maggi S, et al. Acid-related disorders in the elderly. Best Pract Res Clin Gastroent 2009; 23:839–848.

Goetze O, Treier R, Fox M, Steingoetter A, et al. The effect of gastric secretion on gastric physiology and emptying in the fasted and fed state assessed by magnetic resonance imaging. Neurogastroenterol Motil 2009; 21:725–E42.

Guilloteau P, Rome V, De laby L, Mendy F, et al. A new role of phosphopeptides as bioactive peptides released during milk casein digestion in the young mammal: Regulation of gastric secretion. Peptides 2009; 30:2221–2227.

Guilloteau P, Rome V, De laby L, Mendy F, et al. Is caseinomacropeptide from milk proteins, an inhibitor of gastric secretion? Regul Pept 2010; 159:129–136.

Guslandi M. Proton Pump Inhibitors and Mucus Secretion. Dig Dis Sci 2010; 55:217.

Hammadi M, Adi M, John R, Khoder GAK, et al. Dysregulation of gastric H,K-ATPase by cigarette smoke extract. World J Gastroenterol 2009; 15:4016–4022.

Haruma K, Kamada T, Manabe N, Kusunoki H, et al. Are Proton Pump Inhibitors Really Superior to Famotidine in Japanese Ulcer Patients? Hepato-Gastroenterol 2009; 56:1059–1063.

• Hass N, Schwarzenbacher K, Breer H. T1R3 is expressed in brush cells and ghrelin-producing cells of murine stomach. Cell Tissue Res 2010; 339:493–504.[29]

Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002 - art. no. 25. BMC Gastroenterology 2009:25.

Hirota K, Imai A, Kudo M, Hashimoto H, et al. Efficacy of a single 24-hour pre-anesthetic dose of proton pump inhibitors. J Gastroenterol Hepatol 2009; 24:1244–1247.

Hirschowitz BI, Fineberg N, Wilcox CM, Mohnen J, et al. Costs and Risks in the Management of Patients With Gastric Acid Hypersecretion. J Clin Gastroenterol 2010; 44:28–33.

Ho KY, Kuan A, Zano F, Goh KL, et al. Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. J Gastroenterology 2009; 44:697–707.

Iijima K, Ichikawa T, Okada S, Ogawa M, et al. Rebamipide, a Cytoprotective Drug, Increases Gastric Mucus Secretion in Human: Evaluations with Endoscopic Gastrin Test. Dig Dis Sci 2009; 54:1500–1507.

Iijima K, Koike T, Abe Y, Ara N, et al. Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication. J Gastroenterology 2009; 44:819–825.

Javid G, Zargar SA, Riyaz-u-Saif f, Khan BA, et al. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. J Gastroenterol Hepatol 2009; 24:1236–1243.

• Karam SM. A focus on parietal cells as a renewing cell population. World J Gastroenterol 2010; 16:538–546.[01]

Kidd M, Hauso O, Drozdov I, Gustafsson BI, et al. Delineation of the Chemomechanosensory Regulation of Gastrin Secretion Using Pure Rodent G Cells. Gastroenterology 2009; 137:231–241.

• Kopic S, Corradini S, Sidani S, et al. Ethanol inhibits gastric acid secretion in rats through increased AMP-kinase activity. Cell Physiol Biochem 2010; 25:195–202.[36]

Kopic S, Corradini S, Sidani S, Murek M, et al. Ethanol Inhibits Gastric Acid Secretion in Rats Through Increased AMP-Kinase Activity. Cell Physiol Biochem 2010; 25:195–202.

•• Kopic S, Murek M, Geibel JP. Revisiting the parietal cell. Am J Physiol Cell Physiol 2010; 298:C1–C10.[40]

Korner J, Inabet W, Fabres G, Conwell IM, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes 2009; 33:786–795.

Kuipers EJ. Barrett's oesophagus, proton pump inhibitors and gastrin: the fog is clearing. Gut 2010; 59:148–149.

Lai YC, Ho Y, Huang KH, Tsai LH. Effects of Serotonin on Acid Secretion in Isolated Rat Stomach: the Role of 5-HT3 Receptors. Chin J Physiol 2009; 52:395–405.

Lang R, Bardelmeier I, Weiss C, Rubach M, et al. Quantitation of N-beta-Alkanoyl-5-hydroxytryptamides in Coffee by Means of LC-MS/MS-SIDA and Assessment of Their Gastric Acid Secretion Potential Using the HGT-1 Cell Assay. J Agricultural Food Chem 2010; 58:1593–1602.

Lee ES, Kim N, Lee SH, Park YS, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther 2009; 30:154–164.

Lu Y, Owyang C. Secretin-induced gastric relaxation is mediated by vasoactive intestinal polypeptide and prostaglandin pathways. Neurogastroenterol Motil 2009; 21:754–E47.

Massignani JJ, Lemos M, Maistro EL, Schaphauser HP, et al. Antiulcerogenic Activity of the Essential Oil of Baccharis dracunculifolia on Different Experimental Models in Rats. Phythother Res 2009; 23:1355–1360.

Moraes TM, Kushima H, Moleiro FC, Santos RC, et al. Effects of limonene and essential oil from Citrus aurantium on gastric mucosa: Role of prostaglandins and gastric mucus secretion. Chem Biol Interact 2009; 180:499–505.

Morais TC, Pinto NB, Carvalho KMMB, Rios JB, et al. Protective effect of anacardic acids from cashew (Anacardium occidentale) on ethanol-induced gastric damage in mice. Chem Biol Interact 2010; 183:264–269.

• Murray L, Gabello M, Rudolph D, et al. Transmucosal gastric leak induced by proton pump inhibitors. Dig Dis Sci 2009; 54:1408–1417.[03]

Murray LJ, Gabello M, Rudolph DS, Farrell CP, et al. Transmucosal Gastric Leak Induced by Proton Pump Inhibitors. Dig Dis Sci 2009; 54:1408–1417.

Naik HB, Beshire M, Walsh BM, Liu JJ, et al. Secretory state regulates Zn2+ transport in gastric parietal cell of the rabbit. Am J Physiol-Cell Physiol 2009; 297:C979–C989.

Nichita C, Abdou AEW, Maerten P, Herranz M, et al. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers. Aliment Pharmacol Ther 2009; 30:1022–1029.

Pan Q, Ma J, Zhou QS, Li J, et al. KCNQ1 loss-of-function mutation impairs gastric acid secretion in mice. Mol Biol Rep 2010; 37:1329–1333.

Ramesh ST, Asad M, Dhamanigi SS, Prasad VS. Effect of central administration of ondansetron, a 5-hydroxytryptamine-3 receptor antagonist on gastric and duodenal ulcers. Fundam Clin Pharmacol 2009; 23:303–309.

•• Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137:80–87.[47]

Ribeiro U, Patti M, Demeester S. Preoperative Gastric Acid Secretion and the Risk to Develop Barrett's Esophagus After Esophagectomy for Chagasic Achalasia Discussion. J Gastrointest Surg 2009; 13:1898–1899.

Rieg T, Dominguez JA. Unravelling a role for KCNQ1 in K+ recycling and gastric acid secretion. J Physiol-London 2009; 587:4149–4150.

Rotte A, Mack AF, Bhandaru M, Kempe DS, et al. Pioglitazone Induced Gastric Acid Secretion. Cell Physiol Biochem 2009; 24:193–200.

Sasaki Y, Aihara E, Ohashi Y, Okuda S, et al. Stimulation by sparkling water of gastroduodenal HCO3- secretion in rats. Med Sci Monitor 2009; 15:BR349–BR356.

Schubert ML. Gastric exocrine and endocrine secretion. Curr Opin Gastroenterol 2009; 25:529–536.

Sidani S, Kopic S, Socrates T, Kirchhoff P, et al. AMP-activated protein kinase: a physiological off switch for murine gastric acid secretion. Pflugers Arch 2009; 459:39–46.

Song PH, Groos S, Riederer B, Feng Z, et al. KCNQ1 is the luminal K+ recycling channel during stimulation of gastric acid secretion. J Physiol-London 2009; 587:3955–3965.

Srikanta BM, Sathisha UV, Dharmesh SM. Alterations of matrix metalloproteinases, gastric mucin and prostaglandin E-2 levels by pectic polysaccharide of swallow root (Decalepis hamiltonii) during ulcer healing. Biochimie 2010; 92:194–203.

Stec-Michalska K, Malicki S, Michalski B, Peczek L, et al. Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients. World J Gastroenterol 2009; 15:5409–5417.

Tack J. Mandatory and optional function tests in gastroduodenal disorders. Best Pract Res Clin Gastroent 2009; 23:387–393.

Takaishi S, Tu SP, Dubeykovskaya ZA, Whary MT, et al. Gastrin Is an Essential Cofactor for Helicobacter-Associated Gastric Corpus Carcinogenesis in C57BL/6 Mice. Am J Pathol 2009; 175:365–375.

Tomita R. Relationship between Interdigestive Migrating Motor Complex and Gut Hormones in Human. Hepato-Gastroenterol 2009; 56:714–717.

Wada Y, Ito M, Takata S, Kitamura S, et al. Little Necessity of Acid Inhibition against Proton Pump Inhibitor Rebound Effects and Prior Helicobacter pylori Eradication Therapy in Gastric Ulcer Patients: A Randomized Prospective Study. Hepato-Gastroenterol 2009; 56:624–628.

•• Waldum HL, Qvigstad G, Fossmark R, et al. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2010; 45:389–394.[46]

Wang YP, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough - art. no. CD004275 [Review]. Cochrane Database of Systematic Reviews 2009:4275.

Weiss C, Rubach M, Lang R, Seebach E, et al. Measurement of the Intracellular pH in Human Stomach Cells: A Novel Approach To Evaluate the Gastric Acid Secretory Potential of Coffee Beverages. J Agricultural Food Chem 2010; 58:1976–1985.

Wozniak-Holecka J, Josko J, Tyrpien M, Kasperczyk J, et al. Influence of vascular endothelial growth factor (vegf) on gastroprotection in stress-induced gastric mucosal ulcers in rats. Methods Find Exp Clin Pharmacol 2009; 31:523–531.

Xu J, Song PH, Nakamura S, Miller M, et al. Deletion of the Chloride Transporter Slc26a7 Causes Distal Renal Tubular Acidosis and Impairs Gastric Acid Secretion. J Biol Chem 2009; 284:29470–29479.

Yin JD, Li XL, Li DF, Yue T, et al. Dietary supplementation with zinc oxide stimulates ghrelin secretion from the stomach of young pigs. J Nutr Biochem 2009; 20:783–790.

Zhao ZM, Sun YX, Hou N, Teng Y, et al. Capn8 Promoter Directs the Expression of Cre Recombinase in Gastric Pit Cells of Transgenic Mice. Genesis 2009; 47:674–679.

Zimmer V, Schilling MK, Buecker A, Lammert F, et al. Chronic Diarrhea Responding to Proton Pump Inhibitors: A Clinical Sign of Zollinger-Ellison Syndrome. Am J Med 2009; 122:E9–E10.

Back to Top | Article Outline

Gastroduodenal mucosal defense

Review: (pp. 604–610)

Abdullah M, Ohtsuka H, Rani AA, Sato T, et al. Helicobacter pylori infection and gastropathy: A comparison between Indonesian and Japanese patients. World J Gastroenterol 2009; 15:4928–4931.

• Akiba Y, Watanabe C, Mizumori M, Kaunitz JD. Luminal L-glutamate enhances duodenal mucosal defense mechanisms via multiple glutamate receptors in rats. Am J Physiol Gastrointest Liver Physiol 2009; 297:G781–G791.[15]

Al-Howiriny T, Alsheikh A, Alqasoumi S, Al-Yahya M, et al. Protective Effect of Origanum majorana L. ‘Marjoram’ on Various Models of Gastric Mucosal Injury in Rats. Am J Chin Med 2009; 37:531–545.

• Alam MS, Kurtz CC, Wilson JM, et al. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol 2009; 2:232–242.[40]

Arora G, Singh G, Triadafilopoulos G. Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice [Review]. Clin Gastroenterol Hepatol 2009; 7:725–735.

Bui XT, Vo TCM, Tanaka H, Le TL, et al. Diverse Characteristics of the cagA Gene of Helicobacter pylori Strains Collected from Patients from Southern Vietnam with Gastric Cancer and Peptic Ulcer. J Clin Microbiol 2009; 47:4021–4028.

Cozzarini E, Bellin M, Norberto L, Polese L, et al. CHIT1 and AMCase expression in human gastric mucosa: correlation with inflammation and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2009; 21:1119–1126.

Desai JC, Goo T, Fukata M, Sanyal S, et al. NSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression. Aliment Pharmacol Ther 2009; 30:71–81.

• Dial EJ, Tran DM, Romero JJ, et al. A direct role for secretory phospholipase A2 and lyso-phosphatidylcholine in the mediation of lipopolysaccharide-induced gastric injury. Shock 2009; 33:634–638.[20]

Du DS, Ma XB, Zhang JF, Zhang YM, et al. Cellular and molecular mechanisms of 17 beta-estradiol postconditioning protection against gastric mucosal injury induced by ischemia/reperfusion in rats. Life Sci 2010; 86:30–38.

Evangelista S. Role of Calcitonin Gene-Related Peptide in Gastric Mucosal Defence and Healing [Review]. Curr Pharm Design 2009; 15:3571–3576.

• Feng G, Xu X, Wang Q, et al. The protective effects of calcitonin gene-related peptide on gastric mucosa injury after cerebral ischemia reperfusion in rats. Regul Pept 2010; 160:121–128.[27]

Fujii T, Nakabayashi T, Hashimoto S, Kuwano H. Statin Use and Risk of Gastroduodenal Ulcer and Reflux Esophagitis. Hepato-Gastroenterol 2009; 56:641–644.

Futagami S, Hamamoto T, Shimpuku M, Nagoya H, et al. Celecoxib Inhibits CD133-Positive Cell Migration via Reduction of CCR2 in Helicobacter pylori-Infected Mongolian Gerbils. Digestion 2010; 81:193–203.

Gao L, Weck MN, Nieters A, Brenner H. Inverse association between a pro-inflammatory genetic profile and Helicobacter pylori seropositivity among patients with chronic atrophic gastritis: Enhanced elimination of the infection during disease progression? Eur J Cancer 2009; 45:2860–2866.

• Guha P, Dey A, Chatterjee A, et al. Pro-ulcer effects of resveratrol in mice with indomethacin-induced gastric ulcers are reversed by L-arginine. Br J Pharmacol 2010; 159:726–734.[17]

Guslandi M. Proton Pump Inhibitors and Mucus Secretion. Dig Dis Sci 2010; 55:217.

Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002 - art. no. 25. BMC Gastroenterology 2009:25.

• Hernandez C, Santamatilde E, McCreath KJ, et al. Induction of trefoil factor (TFF)1, TFF2 and TFF3 by hypoxia is mediated by hypoxia inducible factor-1: implications for gastric mucosal healing. Br J Pharmacol 2009; 156:262–272.[28]

• Hirata I, Naito Y, Handa O, et al. Heat-shock protein 70-overexpressing gastric epithelial cells are resistant to indomethacin-induced apoptosis. Digestion 2009; 79:243–250.[33]

Hokari R, Nagata N, Kurihara C, Watanabe C, et al. Increased expression and cellular localization of lipocalin-type prostaglandin D synthase in Helicobacter pylori-induced gastritis. J Pathol 2009; 219:417–426.

Iijima K, Ichikawa T, Okada S, Ogawa M, et al. Rebamipide, a Cytoprotective Drug, Increases Gastric Mucus Secretion in Human: Evaluations with Endoscopic Gastrin Test. Dig Dis Sci 2009; 54:1500–1507.

• Imatake K, Matsui T, Moriyama M. The effect and mechanism of action of capsaicin on gastric acid output. J Gastroenterol 2009; 44:396–404.[26]

Ishida K, Kojima R, Tsuboi M, Tsuda Y, et al. Effects of Artichoke Leaf Extract on Acute Gastric Mucosal Injury in Rats. Biological & Pharmaceutical Bulletin 2010; 33:223–229.

• Karakaya K, Hanci V, Bektas S, et al. Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor. World J Gastroenterol 2009; 15:5091–5096.[14]

Kato S, Kawahara R, Yasuda M, Amagase K, et al. Aggravation of Cold-Restraint Stress-Induced Gastric Lesions in Adjuvant Arthritic Rats: Pathogenic Role of Inducible and Endothelial Nitric Oxide. Journal of Pharmacological Sciences 2009; 111:244–252.

Katsurahara M, Kobayashi Y, Iwasa M, Ma N, et al. Reactive Nitrogen Species Mediate DNA Damage in Helicobacter pylori-Infected Gastric Mucosa. Helicobacter 2009; 14:552–558.

Kebapcilar L, Sari I, Renkal AH, Alacacioglu A, et al. The Influence of Helicobacter pylori Eradication on Leptin, Soluble CD40 Ligand, Oxidative Stress and Body Composition in Patients with Peptic Ulcer Disease. Intern Med 2009; 48:2055–2059.

Khamri W, Walker MM, Clark P, Atherton JC, et al. Helicobacter pylori Stimulates Dendritic Cells To Induce Interleukin-17 Expression from CD4(+) T Lymphocytes. Infect Immun 2010; 78:845–853.

Kopic S, Corradini S, Sidani S, Murek M, et al. Ethanol Inhibits Gastric Acid Secretion in Rats Through Increased AMP-Kinase Activity. Cell Physiol Biochem 2010; 25:195–202.

Kuipers EJ. Barrett's oesophagus, proton pump inhibitors and gastrin: the fog is clearing. Gut 2010; 59:148–149.

Lee ES, Yoon YS, Park CY, Kim HS, et al. Eradication of Helicobacter pylori Increases Ghrelin mRNA Expression in the Gastric Mucosa. J Korean Med Sci 2010; 25:265–271.

Lim JW, Kim KH, Kim H. alpha Pix interacts with Helicobacter pylori CagA to induce IL-8 expression in gastric epithelial cells. Scand J Gastroenterol 2009; 44:1166–1172.

• Machado AM, Figueiredo C, Seruca R, Rasmussen LJ. Helicobacter pylori infection generates genetic instability in gastric cells. Biochim Biophys Acta 2010; 1806:58–65.[35]

Magalhaes A, Marcos NT, Carvalho AS, David L, et al. Helicobacter pylori cag pathogenicity island-positive strains induce syndecan-4 expression in gastric epithelial cells. FEMS Immunol Med Microbiol 2009; 56:223–232.

Massignani JJ, Lemos M, Maistro EL, Schaphauser HP, et al. Antiulcerogenic Activity of the Essential Oil of Baccharis dracunculifolia on Different Experimental Models in Rats. Phythother Res 2009; 23:1355–1360.

Merai AH, Asad M, Prasad VS. Effect of Centrally Administered Losartan on Gastric and Duodenal Ulcers in Rats. Pharmacology 2009; 84:93–98.

Mir R, Singh N, Vikram G, Kumar RP, et al. The Structural Basis for the Prevention of Nonsteroidal Antiinflammatory Drug-Induced Gastrointestinal Tract Damage by the C-Lobe of Bovine Colostrum Lactoferrin. Biophys J 2009; 97:3178–3186.

• Mizumori M, Akiba Y, Kaunitz JD. Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci 2009; 54:2063–2069.[08]

• Mizumori M, Ham M, Guth PH, et al. Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum. J Physiol 2009; 587:3651–3663.[19]

Moraes TM, Kushima H, Moleiro FC, Santos RC, et al. Effects of limonene and essential oil from Citrus aurantium on gastric mucosa: Role of prostaglandins and gastric mucus secretion. Chem Biol Interact 2009; 180:499–505.

Morais TC, Pinto NB, Carvalho KMMB, Rios JB, et al. Protective effect of anacardic acids from cashew (Anacardium occidentale) on ethanol-induced gastric damage in mice. Chem Biol Interact 2010; 183:264–269.

Morsy M, Ashour O, Amin E, Rofaeil R. Gastroprotective effects of telmisartan on experimentally-induced gastric ulcers in rats. Pharmazie 2009; 64:590–594.

Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats. Clin Exp Pharmacol Physiol 2010; 37:173–177.

Murray LJ, Gabello M, Rudolph DS, Farrell CP, et al. Transmucosal Gastric Leak Induced by Proton Pump Inhibitors. Dig Dis Sci 2009; 54:1408–1417.

Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers [Review]. Aliment Pharmacol Ther 2009; 30:517–531.

• Nakagiri A, Murakami M. Roles of NADPH oxidase in occurrence of gastric damage and expression of cyclooxygenase-2 during ischemia/reperfusion in rat stomachs. J Pharmacol Sci 2009; 111:352–360.[24]

Nakajima T, Enomoto S, Yamashita S, Ando T, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterology 2010; 45:37–44.

Nakamura E, Hasumura M, San Gabriel A, Uneyama H, et al. New Frontiers in Gut Nutrient Sensor Research: Luminal Glutamate-Sensing Cells in Rat Gastric Mucosa [Review]. Journal of Pharmacological Sciences 2010; 112:13–18.

• Nakano T, Inoue I, Alpers DH, et al. Role of lysophosphatidylcholine in brush-border intestinal alkaline phosphatase release and restoration. Am J Physiol Gastrointest Liver Physiol 2009; 297:G207–G214.[23]

Nayeb-Hashemi H, Kaunitz JD. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2009; 25:537–543.

Ogiwara H, Sugimoto M, Ohno T, Vilaichone RK, et al. Role of Deletion Located between the Intermediate and Middle Regions of the Helicobacter pylori vacA Gene in Cases of Gastroduodenal Diseases. J Clin Microbiol 2009; 47:3493–3500.

Ortiz-Masia D, Hernandez C, Quintana E, Velazquez M, et al. iNOS-derived nitric oxide mediates the increase in TFF2 expression associated with gastric damage: role of HIF-1. FASEB J 2010; 24:136–145.

• Otaka M, Odashima M, Izumi Y, et al. Target molecules of molecular chaperone (HSP70 family) in injured gastric mucosa in vivo. Life Sci 2009; 84:664–667.[30]

• Peskar BM, Ehrlich K, Schuligoi R, Peskar BA. Role of lipoxygenases and the lipoxin A(4)/annexin 1 receptor in ischemia-reperfusion-induced gastric mucosal damage in rats. Pharmacol 2009; 84:294–299.[25]

Ramesh ST, Asad M, Dhamanigi SS, Prasad VS. Effect of central administration of ondansetron, a 5-hydroxytryptamine-3 receptor antagonist on gastric and duodenal ulcers. Fundam Clin Pharmacol 2009; 23:303–309.

Ramirez-Alcantara V, Lo Guidice A, Boelsterli UA. Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy. Am J Physiol-Gastroint Liver Physiol 2009; 297:G990–G998.

Rick JR, Goldman M, Semino-Mora C, Liu H, et al. In Situ Expression of cagA and Risk of Gastroduodenal Disease in Helicobacter pylori-infected Children. J Pediatr Gastroenterol Nutr 2010; 50:167–172.

Rodgers AD. SIRT - an uncommon cause of gastroduodenal ulceration. Histopathology 2009; 55:114.

Roesler BM, de Oliveira TB, Bonon SHA, Monici LT, et al. Restriction Fragment Length Polymorphism of Urease C and Urease B Genes of Helicobacter pylori Strains Isolated from Brazilian Patients with Peptic Ulcer and Chronic Gastritis. Dig Dis Sci 2009; 54:1487–1493.

Rotte A, Mack AF, Bhandaru M, Kempe DS, et al. Pioglitazone Induced Gastric Acid Secretion. Cell Physiol Biochem 2009; 24:193–200.

Seo JH, Lim JW, Yoon JH, Kim H. Proteinase-Activated Receptor-2 Mediates the Expression of Integrin alpha(5) and beta(1) in Helicobacter pylori-Infected Gastric Epithelial AGS Cells. Digestion 2009; 80:40–49.

Sheu BS, Yang HB, Yeh YC, Wu JJ. Helicobacter pylori colonization of the human gastric epithelium: A bug's first step is a novel target for us [Review]. J Gastroenterol Hepatol 2010; 25:26–32.

• Shibata W, Takaishi S, Muthupalani S, et al. Conditional deletion of IkB-kinase-b accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia. Gastroenterology 2010; 138:1022–1034.[39]

Shoman ME, Abdel-Aziz M, Aly OM, Farag HH, et al. Synthesis and investigation of anti-inflammatory activity and gastric ulcerogenicity of novel nitric oxide-donating pyrazoline derivatives. Eur J Med Chem 2009; 44:3068–3076.

Srikanta BM, Sathisha UV, Dharmesh SM. Alterations of matrix metalloproteinases, gastric mucin and prostaglandin E-2 levels by pectic polysaccharide of swallow root (Decalepis hamiltonii) during ulcer healing. Biochimie 2010; 92:194–203.

Suemasu S, Tanaka KI, Namba T, Ishihara T, et al. A Role for HSP70 in Protecting against Indomethacin-induced Gastric Lesions. J Biol Chem 2009; 284:19705–19715.

Sugimoto M, Furuta T, Yamaoka Y. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori [Review]. J Gastroenterol Hepatol 2009; 24:1725–1732.

Tahara T, Shibata T, Wang FY, Nakamura M, et al. Mannan-binding lectin B allele is associated with a risk of developing more severe gastric mucosal atrophy in Helicobacter pylori-infected Japanese patients. Eur J Gastroenterol Hepatol 2009; 21:781–786.

• Takeuchi K, Koyama M, Hayashi S, Aihara E. Prostaglandin EP receptor subtypes involved in regulating HCO3− secretion from gastroduodenal mucosa. Curr Pharm Des 2010; 16:1241–1251.[07]

• Tominaga M, Ohta M, Kai S, et al. Increased heat-shock protein 90 expression contributes to impaired adaptive cytoprotection in the gastric mucosa of portal hypertensive rats. J Gastroenterol Hepatol 2009; 24:1136–1141.[34]

Veijola LI, Oksanen AM, Sipponen PI, Rautelin HIK. Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection. World J Gastroenterol 2010; 16:83–88.

Waghray M, Zavros Y, Saqui-Salces M, El-Zaatari M, et al. Interleukin-1 beta Promotes Gastric Atrophy Through Suppression of Sonic Hedgehog. Gastroenterology 2010; 138:562–NIL_202.

• Wee JL, Chionh YT, Ng GZ, et al. Protease-activated receptor-1 down-regulates the murine inflammatory and humoral response to Helicobacter pylori. Gastroenterology 2010; 138:573–582.[38]

Wozniak-Holecka J, Josko J, Tyrpien M, Kasperczyk J, et al. Influence of vascular endothelial growth factor (vegf) on gastroprotection in stress-induced gastric mucosal ulcers in rats. Methods Find Exp Clin Pharmacol 2009; 31:523–531.

Yamamoto T, Isono A, Ebato T, Mishina Y, et al. Prevalence of gastroduodenal mucosal injury in asymptomatic patients taking antiplatelet agents in Japan. Int J Clin Pharmacol Ther 2009; 47:722–725.

Yan SL, Wu ST, Chen CH, Hung YH, et al. Mucosal patterns of Helicobacter pylori-related gastritis without atrophy in the gastric corpus using standard endoscopy. World J Gastroenterol 2010; 16:496–500.

Yokota S, Okabayashi T, Rehli M, Fujii N, et al. Helicobacter pylori Lipopolysaccharides Upregulate Toll-Like Receptor 4 Expression and Proliferation of Gastric Epithelial Cells via the MEK1/2-ERK1/2 Mitogen-Activated Protein Kinase Pathway. Infect Immun 2010; 78:468–476.

Zaidi SFH, Ahmed K, Yamamoto T, Kondo T, et al. Effect of Resveratrol on Helicobacter pylori-Induced Interleukin-8 Secretion, Reactive Oxygen Species Generation and Morphological Changes in Human Gastric Epithelial Cells. Biological & Pharmaceutical Bulletin 2009; 32:1931–1935.

Zalewska-Ziob M, Adamek B, Strzelczyk KJ, Gawron K, et al. TNF-alpha expression in gastric mucosa of individuals infected with different virulent Helicobacter pylori strains. Med Sci Monitor 2009; 15:BR166–BR171.

• Zhang Y, Chen H, Yang L. Toll-like receptor 4 participates in gastric mucosal protection through Cox-2 and PGE2. Dig Liver Dis 2009; 42:472–476.[11]

Zhao ZM, Sun YX, Hou N, Teng Y, et al. Capn8 Promoter Directs the Expression of Cre Recombinase in Gastric Pit Cells of Transgenic Mice. Genesis 2009; 47:674–679.

Back to Top | Article Outline

Helicobacter pylori infection and current clinical areas of contention

Review: (pp. 618–623)

Abbas Z, Yakoob J, Abid S, Jafri W, et al. Furazolidone, Co-amoxiclav, Colloidal Bismuth Subcitrate, and Esomeprazole for Patients Who Failed to Eradicate Helicobacter pylori with Triple Therapy. Dig Dis Sci 2009; 54:1953–1957.

Abdullah M, Ohtsuka H, Rani AA, Sato T, et al. Helicobacter pylori infection and gastropathy: A comparison between Indonesian and Japanese patients. World J Gastroenterol 2009; 15:4928–4931.

Alagozlu H, Simsek Z, Unal S, Cindoruk M, et al. Is there an association between Helicobacter pylori in the inlet patch and globus sensation? World J Gastroenterol 2010; 16:42–47.

Alvarez A, Moncayo JI, Santacruz JJ, Corredor LF, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Colombia [Spanish]. Rev Med Chil 2009; 137:1309–1314.

Arslan E, Atilgan H, Yavasoglu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Intern Med 2009; 20:695–697.

Asfeldt AM, Steigen SE, Lochen ML, Straume B, et al. The natural course of Helicobacter pylori infection on endoscopic findings in a population during 17 years of follow-up: the Sorreisa gastrointestinal disorder study. Eur J Epidemiol 2009; 24:649–658.

Ayada K, Yokota K, Hirai K, Fujimoto K, et al. Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis. Lupus 2009; 18:1154–1168.

Aydin A, Oruc N, Turan I, Ozutemiz O, et al. The Modified Sequential Treatment Regimen Containing Levofloxacin for Helicobacter pylori Eradication in Turkey. Helicobacter 2009; 14:520–524.

Baghaei K, Shokrzadeh L, Jafari F, Dabiri H, et al. Determination of Helicobacter pylori virulence by analysis of the cag pathogenicity island isolated from Iranian patients. Dig Liver Dis 2009; 41:634–638.

Bai HY, Li Q, Liu XL, Li YC. Characteristics and Interactions of Helicobacter pylori and H. pylori-Infected Human Gastroduodenal Epithelium in Peptic Ulcer: A Transmission Electron Microscopy Study. Dig Dis Sci 2010; 55:82–88.

Baumgaertner I, Copie-Bergman C, Levy M, Haioun C, et al. Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. World J Gastroenterol 2009; 15:5746–5750.

Bektas M, Soykan I, Altan M, Alkan M, et al. The effect of Helicobacter pylori eradication on dyspeptic symptoms, acid reflux and quality of life in patients with functional dyspepsia. Eur J Intern Med 2009; 20:419–423.

Belair C, Darfeuille F, Staedel C. Helicobacter pylori and gastric cancer: possible role of microRNAs in this intimate relationship [Review]. Clin Microbiol Infect 2009; 15:806–812.

Bommelaer G, Stef A. Gastroduodenal ulcer before and after Helicobacter pylori [French]. Gastroenterol Clin Biol 2009; 33:626–634.

Boukthir S, Mazigh SM, Kaach N, Bouyahya O, et al. The effect of non-steroidal anti-inflammatory drugs and Helicobacter pylori infection on the gastric mucosa in children with upper gastrointestinal bleeding. Pediatr Surg Int 2010; 26:227–230.

Boyanova L, Markovska R, Yordanov D, Marina M, et al. High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients. Diagn Microbiol Infect Dis 2009; 64:374–380.

Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents [Review]. Expert Rev Anti-Infect Ther 2010; 8:59–70.

Breckan RK, Paulssen EJ, Asfeldt AM, Mortensen L, et al. The impact of body mass index and Helicobacter pylori infection on gastro-oesophageal reflux symptoms: A population-based study in Northern Norway. Scand J Gastroenterol 2009; 44:1060–1066.

Broussard CS, Goodman KJ, Phillips CV, Smith MA, et al. Antibiotics taken for other illnesses and spontaneous clearance of Helicobacter pylori infection in children. Pharmacoepidemiology and Drug Safety 2009; 18:722–729.

Bui XT, Vo TCM, Tanaka H, Le TL, et al. Diverse Characteristics of the cagA Gene of Helicobacter pylori Strains Collected from Patients from Southern Vietnam with Gastric Cancer and Peptic Ulcer. J Clin Microbiol 2009; 47:4021–4028.

Cabral VLR, Patricio FRD, Gabbay MAL, Dib SA, et al. Intraepithelial lymphocytes in duodenum from Brazilian adolescents with type 1 diabetes. Influence of Helicobacter pylori. Pediatric Diabetes 2009; 10:316–320.

Cai WZ, Zhou LP, Ren W, Deng L, et al. Variables Influencing Outcome of Helicobacter pylori Eradication Therapy in South China. Helicobacter 2009; 14:91–96.

• Cambau E, Allerheiligen V, Coulon C, et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47:3600–3607.[54]

Carmack SW, Genta RM. Helicobacter pylori Seroprevalence in Symptomatic Veterans: A Study of 7310 Patients Over 11 Years. Helicobacter 2009; 14:298–302.

Cartagenes VD, Martins LC, Carneiro LM, Barile KAD, et al. Helicobacter pylori in children and association with CagA strains in mother-child transmission in the Brazilian Amazon region [Portuguese]. Revista da Sociedade Brasileira de Medicina Tropical 2009; 42:298–302.

Chang WL, Sheu BS, Cheng HC, Yang YJ, et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009; 24:1230–1235.

Chi H, Bair MJ, Wu MS, Chiu NC, et al. Prevalence of Helicobacter pylori Infection in High-school Students on Lanyu Island, Taiwan: Risk Factor Analysis and Effect on Growth. J Formos Med Assoc 2009; 108:929–936.

Chinniah A, Mohapatra S, Goswami S, Mahapatra A, et al. On the potential of Tephrosia purpurea as anti-Helicobacter pylori agent. J Ethnopharmacol 2009; 124:642–645.

Choi CY, Kim MS, Kim JM, Park SH, et al. Association between Helicobacter pylori infection and Posner-Schlossman syndrome. Eye 2010; 24:64–69.

Chomvarin C, Ottiwet O, Hahnvajanawong C, Intapan PM, et al. Seroreactivity to specific antigens of Helicobacter pylori infection is associated with an increased risk of the dyspeptic gastrointestinal diseases. Int J Infect Dis 2009; 13:647–654.

Con SA, Takeuchi H, Nishioka M, Morimoto N, et al. Clinical relevance of Helicobacter pylori babA2 and babA2/B in Costa Rica and Japan. World J Gastroenterol 2010; 16:474–478.

Cozzarini E, Bellin M, Norberto L, Polese L, et al. CHIT1 and AMCase expression in human gastric mucosa: correlation with inflammation and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2009; 21:1119–1126.

Cui Y, Wang CL, Liu XW, Wang XH, et al. Two stomach-originated lactobacillus strains improve Helicobacter pylori infected murine gastritis. World J Gastroenterol 2010; 16:445–452.

D'Elios MM, Andersen LP. Inflammation, Immunity, and Vaccines for Helicobacter pylori [Review]. Helicobacter 2009; 14:21–28.

Dabiri H, Maleknejad P, Yamaoka Y, Feizabadi MM, et al. Distribution of Helicobacter pylori cagA, cagE, oipA and vacA in different major ethnic groups in Tehran, Iran. J Gastroenterol Hepatol 2009; 24:1380–1386.

Dasanu CA, Rathmann J, Alexandrescu DT. H. pylori-Associated Gastric Cancer in a Husband-Wife Pair: A Veritable Family Affair. South Med J 2009; 102:1158–1160.

Deguchi R, Matsushima M, Suzuki T, Mine T, et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J Gastroenterology 2009; 44:713–716.

Dehghani SM, Erjaee A, Imanieh MH, Haghighat M. Efficacy of the Standard Quadruple Therapy Versus Triple Therapies Containing Proton Pump Inhibitor Plus Amoxicillin and Clarithromycin or Amoxicillin-Clavulanic Acid and Metronidazole for Helicobacter pylori Eradication in Children. Dig Dis Sci 2009; 54:1720–1724.

Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori [Review]. Expert Rev Vaccines 2009; 8:1037–1049.

Demir M, Gokturk HS, Ozturk NA, Arslan H, et al. Clarithromycin Resistance and Efficacy of Clarithromycin-Containing Triple Eradication Therapy for Helicobacter pylori Infection in Type 2 Diabetes Mellitus Patients. South Med J 2009; 102:1116–1120.

Demir M, Gokturk HS, Ozturk NA, Serin E, et al. Efficacy of Two Different Helicobacter pylori Eradication Regimens in Patients With Type 2 Diabetes and the Effect of Helicobacter pylori Eradication on Dyspeptic Symptoms in Patients With Diabetes: A Randomized Controlled Study. Am J Med Sci 2009; 338:459–464.

Dong J, Yu XF, Zou J. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: A meta-analysis. World J Gastroenterol 2009; 15:6102–6110.

Dong QJ, Wang Q, Xin YN, Li N, et al. Comparative genomics of Helicobacter pylori [Review]. World J Gastroenterol 2009; 15:3984–3991.

Emiroglu HH, Sokucu S, Suoglu OD, Gulluoglu M, et al. Is there a relationship between Helicobacter pylori infection and erosive reflux disease in children? Acta Paediatr 2010; 99:121–125.

Engstrand L. How will next-generation sequencing contribute to the knowledge concerning Helicobacter pylori? [Review]. Clin Microbiol Infect 2009; 15:823–828.

Eshraghian A, Hashemi SA, Jahromi AH, Eshraghian H, et al. Helicobacter pylori Infection as a Risk Factor for Insulin Resistance. Dig Dis Sci 2009; 54:1966–1970.

Eyigor M, Eyigor H, Gultekin B, Aydan N. Detection of Helicobacter pylori in adenotonsiller tissue specimens by rapid urease test and polymerase chain reaction. Eur Arch Otorhinolaryngol 2009; 266:1611–1613.

• Ferrara M, Capozzi L, Russo R. Effect of Helicobacter pylori eradication on platelet count in children with chronic idiopathic thrombocytopenic purpura. Hematology 2009; 14:282–285.[06]

Ferrasi AC, Pinheiro NA, Rabenhorst SHB, Caballero OL, et al. Helicobacter pylori and EBV in gastric carcinomas: Methylation status and microsatellite instability. World J Gastroenterol 2010; 16:312–319.

Ferreira JA, Pires C, Paulo M, Azevedo NF, et al. Bioaccumulation of Amylose-Like Glycans by Helicobacter pylori. Helicobacter 2009; 14:559–570.

Fischbach W. Helicobacter pylori [German]. Internist (Berl) 2009; 50:979–986.

Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, et al. S3-Guideline “Helicobacter pylori and gastroduodenal ulcer disease” of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e.V., German Society for Rheumatology, AWMF-Registration-no. 021/001 [Review]. Z Gastroenterol 2009; 47:1230–1263.

Fock KM, Katelaris P, Sugano K, Ang TL, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection [Review]. J Gastroenterol Hepatol 2009; 24:1587–1600.

Furuta T, Delchier JC. Helicobacter pylori and Non-malignant Diseases [Review]. Helicobacter 2009; 14:29–35.

Futagami S, Hamamoto T, Shimpuku M, Nagoya H, et al. Celecoxib Inhibits CD133-Positive Cell Migration via Reduction of CCR2 in Helicobacter pylori-Infected Mongolian Gerbils. Digestion 2010; 81:193–203.

Gao L, Weck MN, Nieters A, Brenner H. Inverse association between a pro-inflammatory genetic profile and Helicobacter pylori seropositivity among patients with chronic atrophic gastritis: Enhanced elimination of the infection during disease progression? Eur J Cancer 2009; 45:2860–2866.

Gonzalez CA, Lopez-Carrillo L. Helicobacter pylori, nutrition and smoking interactions: Their impact in gastric carcinogenesis [Review]. Scand J Gastroenterol 2010; 45:6–14.

Guarner J, Kalach N, Elitsur Y, Koletzko S. Helicobacter pylori diagnostic tests in children: review of the literature from 1999 to 2009 [Review]. Eur J Pediatr 2010; 169:15–25.

Gunji T, Matsuhashi N, Sato H, Fujibayashi K, et al. Helicobacter pylori Infection Significantly Increases Insulin Resistance in the Asymptomatic Japanese Population. Helicobacter 2009; 14:144–150.

Hernando-Harder AC, Booken N, Goerdt S, Singer MV, et al. Helicobacter pylori infection and dermatologic diseases [Review]. Eur J Dermatol 2009; 19:431–444.

Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma [Review]. Clin Microbiol Infect 2009; 15:971–976.

Hokari R, Nagata N, Kurihara C, Watanabe C, et al. Increased expression and cellular localization of lipocalin-type prostaglandin D synthase in Helicobacter pylori-induced gastritis. J Pathol 2009; 219:417–426.

Homan M, Luzar B, Kocjan BJ, Orel R, et al. Prevalence and Clinical Relevance of cagA, vacA, and iceA Genotypes of Helicobacter pylori Isolated From Slovenian Children. J Pediatr Gastroenterol Nutr 2009; 49:289–296.

Horiki N, Omata F, Uemura M, Suzuki S, et al. Annual Change of Primary Resistance to Clarithromycin among Helicobacter pylori Isolates from 1996 through 2008 in Japan. Helicobacter 2009; 14:86–90.

Hoshino C. Adult Onset Schonlein-Henoch Purpura Associated with Helicobacter pylori Infection. Intern Med 2009; 48:847–851.

Hung IFN, Chan P, Leung S, Chan FSY, et al. Clarithromycin-Amoxycillin-Containing Triple Therapy: A Valid Empirical First-Line Treatment for Helicobacter pylori Eradication in Hong Kong? Helicobacter 2009; 14:505–511.

Iijima K, Koike T, Abe Y, Ara N, et al. Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication. J Gastroenterology 2009; 44:819–825.

Inoue K, Shiota S, Yamada K, Gotoh K, et al. Evaluation of a New Tumor Necrosis Factor-alpha-Inducing Membrane Protein of Helicobacter pylori as a Prophylactic Vaccine Antigen. Helicobacter 2009; 14:135–143.

Iwai H, Nakamichi N, Nakae K, Konishi M, et al. Parotid Mucosa-Associated Lymphoid Tissue Lymphoma Regression After Helicobacter Pylori Eradication. Laryngoscope 2009; 119:1491–1494.

Jackson L, Britton J, Lewis SA, McKeever TM, et al. A Population-Based Epidemiologic Study of Helicobacter Pylori Infection and its Association with Systemic Inflammation. Helicobacter 2009; 14:108–113.

Jafarzadeh A, Hassanshahi GH, Nemati M. Serum Levels of High-Sensitivity C-Reactive Protein (hs-CRP) in Helicobacter pylori-Infected Peptic Ulcer Patients and Its Association with Bacterial CagA Virulence Factor. Dig Dis Sci 2009; 54:2612–2616.

Jafri W, Yakoob J, Abid S, Siddiqui S, et al. Helicobacter pylori infection in children: population-based age-specific prevalence and risk factors in a developing country. Acta Paediatr 2010; 99:279–282.

Jang JY, Yoon HJ, Yoon JY, Kim HS, et al. Crystal Structure of the TNF-alpha-Inducing Protein (Tip alpha) from Helicobacter pylori: Insights into Its DNA-Binding Activity. J Mol Biol 2009; 392:191–197.

Jia CL, Jiang GS, Li CH, Li CR. Effect of Dental Plaque Control on Infection of Helicobacter pylori in Gastric Mucosa. J Periodontol 2009; 80:1606–1609.

Jimenez-Soto LF, Kutter S, Sewald X, Ertl C, et al. Helicobacter pylori Type IV Secretion Apparatus Exploits beta 1 Integrin in a Novel RGD-Independent Manner - art. no. e1000684. PLoS Pathogens 2009; 5:684.

Kaboli SA, Zojaji H, Mirsattari D, Talaie R, et al. Effect of addition of vitamin C to clarithromycin-amoxicillin-omeprazol triple regimen on Helicobacter pylori eradication. Acta Gastroenterol Belg 2009; 72:222–224.

Kalach N, Papadopoulos S, Asmar E, Spyckerelle C, et al. In French Children, Primary Gastritis Is More Frequent Than Helicobacter pylori Gastritis. Dig Dis Sci 2009; 54:1958–1965.

Kanizaj TF, Katicic M, Presecki V, Gasparov S, et al. Serum Antibodies Positivity to 12 Helicobacter pylori Virulence Antigens in Patients with Benign or Malignant Gastroduodenal Diseases - Cross-sectional Study. Croatian Medical Journal 2009; 50:124–132.

Katsurahara M, Kobayashi Y, Iwasa M, Ma N, et al. Reactive Nitrogen Species Mediate DNA Damage in Helicobacter pylori-Infected Gastric Mucosa. Helicobacter 2009; 14:552–558.

Kaya T, Ozan H, Ozakin C. The presence of Helicobacter pylori in cervical preinvasive lesions. Clin Exp Obstet Gynecol 2009; 36:113–115.

Kebapcilar L, Sari I, Renkal AH, Alacacioglu A, et al. The Influence of Helicobacter pylori Eradication on Leptin, Soluble CD40 Ligand, Oxidative Stress and Body Composition in Patients with Peptic Ulcer Disease. Intern Med 2009; 48:2055–2059.

Khamri W, Walker MM, Clark P, Atherton JC, et al. Helicobacter pylori Stimulates Dendritic Cells To Induce Interleukin-17 Expression from CD4(+) T Lymphocytes. Infect Immun 2010; 78:845–853.

Kim KK, Kim HB. Protein interaction network related to Helicobacter pylori infection response. World J Gastroenterol 2009; 15:4518–4528.

Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis [Review]. J Physiol Pharmacol 2009; 60:3–21.

Lauwers GY, Fujita H, Nagata K, Shimizu M. Pathology of non-Helicobacter pylori gastritis: extending the histopathologic horizons [Review]. J Gastroenterology 2010; 45:131–145.

Lee BH, Kim N, Hwang TJ, Lee SH, et al. Bismuth-Containing Quadruple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea. Helicobacter 2010; 15:38–45.

Lee CW, Rickman B, Rogers AB, Muthupalani S, et al. Combination of Sulindac and Antimicrobial Eradication of Helicobacter pylori Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice. Cancer Res 2009; 69:8166–8174.

Lee ES, Yoon YS, Park CY, Kim HS, et al. Eradication of Helicobacter pylori Increases Ghrelin mRNA Expression in the Gastric Mucosa. J Korean Med Sci 2010; 25:265–271.

Lee GH, Jeong JY, Chung JW, Nam WH, et al. The Helicobacter pylori Mfd protein is important for antibiotic resistance and DNA repair. Diagn Microbiol Infect Dis 2009; 65:454–456.

Lee JS, Choe YH, Lee JH, Lee HJ, et al. Helicobacter pylori Urease Activity is Influenced by Ferric Uptake Regulator. Yonsei Medical Journal 2010; 51:39–44.

Lee JS, Kwon KA, Jung HS, Kim JH, et al. Korea Red Ginseng on Helicobacter pylori-Induced Halitosis: Newer Therapeutic Strategy and a Plausible Mechanism. Digestion 2009; 80:192–199.

Lembo AJ, Ganz RA, Sheth S, Cave D, et al. Treatment of Helicobacter pylori Infection With Intra-Gastric Violet Light Phototherapy: A Pilot Clinical Trial. Laser Surg Med 2009; 41:337–344.

Li W, Minohara M, Piao H, Matsushita T, et al. Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis 2009; 15:1411–1421.

Lienlaf M, Morales JP, Diaz MI, Diaz R, et al. Helicobacter pylori HopE and HopV porins present scarce expression among clinical isolates. World J Gastroenterol 2010; 16:320–329.

Lim JW, Kim KH, Kim H. alpha Pix interacts with Helicobacter pylori CagA to induce IL-8 expression in gastric epithelial cells. Scand J Gastroenterol 2009; 44:1166–1172.

Lin J, Huang WW. A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine. World J Gastroenterol 2009; 15:4715–4719.

•• Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010; 59:572–578.[53]

Mabe K, Takahashi M, Oizumi H, Tsukuma H, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol 2009; 15:4290–4297.

Magalhaes A, Marcos NT, Carvalho AS, David L, et al. Helicobacter pylori cag pathogenicity island-positive strains induce syndecan-4 expression in gastric epithelial cells. FEMS Immunol Med Microbiol 2009; 56:223–232.

Martini S, D'Addario C, Braconi D, Bernardini G, et al. Antibacterial Activity of Grape Extracts on cagA-Positive and -Negative Helicobacter pylori Clinical Isolates. J Chemother 2009; 21:507–513.

Mehmet S, Ozdal E, Kamil O, Besir K, et al. Eradication of Helicobacter pylori in Follicular and Nonfollicular Gastritis. Hepato-Gastroenterol 2009; 56:930–934.

Moon A, Solomon A, Beneck D, Cunningham-Rundles S. Positive Association Between Helicobacter pylori and Gastroesophageal. Reflux Disease in Children. J Pediatr Gastroenterol Nutr 2009; 49:283–288.

Nagiyev T, Yula E, Abayli B, Koksal F. Prevalence and Genotypes of Helicobacter pylori in Gastric Biopsy Specimens from Patients with Gastroduodenal Pathologies in the Cukurova Region of Turkey. J Clin Microbiol 2009; 47:4150–4153.

Nakagawa Y, Nagai T, Okawara H, Nakashima H, et al. Cap Polyposis (CP) Which Relapsed after Remission by Avoiding Straining at Defecation, and was Cured by Helicobacter pylori Eradication Therapy. Intern Med 2009; 48:2009–2013.

Nakajima T, Enomoto S, Yamashita S, Ando T, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterology 2010; 45:37–44.

Ogiwara H, Sugimoto M, Ohno T, Vilaichone RK, et al. Role of Deletion Located between the Intermediate and Middle Regions of the Helicobacter pylori vacA Gene in Cases of Gastroduodenal Diseases. J Clin Microbiol 2009; 47:3493–3500.

Ozcan C, Polat A, Otag F, Gorur K. Does Helicobacter pylori play a role in etiology of nasal polyposis? Auris Nasus Larynx 2009; 36.

Ozcan C, Vayisoglu Y, Otag F, Polat A, et al. Does Helicobacter pylori Have a Role in the Development of Chronic Otitis Media with Effusion? A Preliminary Study. J Otolaryngol-Head Neck Surg 2009; 38:526–531.

Papamichael KX, Papaioannou G, Karga H, Roussos A, et al. Helicobacter pylori infection and endocrine disorders: Is there a link? [Review]. World J Gastroenterol 2009; 15:2701–2707.

Park SY, Lee YD, Kim SK. Examination of Geographical, Clinical and Intrahost Variations in the 3 ' Repeat Region of CagA Gene in Helicobacter pylori. J Korean Med Sci 2010; 25:61–66.

Park SY, Yoo EJ, Cho NY, Kim N, et al. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J Pathol 2009; 219:410–416.

Pinto-Santini DM, Salama NR. Cag3 Is a Novel Essential Component of the Helicobacter pylori Cag Type IV Secretion System Outer Membrane Subcomplex. J Bacteriol 2009; 191:7343–7352.

Pirouz T, Zounubi L, Keivani H, Rakhshani N, et al. Detection of Helicobacter pylori in Paraffin-Embedded Specimens from Patients with Chronic Liver Diseases, Using the Amplification Method. Dig Dis Sci 2009; 54:1456–1459.

Raymond J, Lamarque D, Kalach N, Chaussade S, et al. High Level of Antimicrobial Resistance in French Helicobacter pylori Isolates. Helicobacter 2010; 15:21–27.

•• Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009; 58:636–642.[35]

Rick JR, Goldman M, Semino-Mora C, Liu H, et al. In Situ Expression of cagA and Risk of Gastroduodenal Disease in Helicobacter pylori-infected Children. J Pediatr Gastroenterol Nutr 2010; 50:167–172.

Roesler BM, de Oliveira TB, Bonon SHA, Monici LT, et al. Restriction Fragment Length Polymorphism of Urease C and Urease B Genes of Helicobacter pylori Strains Isolated from Brazilian Patients with Peptic Ulcer and Chronic Gastritis. Dig Dis Sci 2009; 54:1487–1493.

Rogha M, Pourmoghaddas Z, Rezaee M, Shirneshan K, et al. Azithromycin Effect on Helicobacter pylori Eradication: Double Blind Randomized Clinical Trial. Hepato-Gastroenterol 2009; 56:722–724.

Ryu KH, Yi SY, Na YJ, Baik SJ, et al. Reinfection rate and endoscopic changes after successful eradication of Helicobacter pylori. World J Gastroenterol 2010; 16:251–255.

Salehi Z, Abadi ASH, Ismail PBT, Kqueen CY, et al. Evaluation of Helicobacter pylori vacA Genotypes in Iranian Patients with Peptic Ulcer Disease. Dig Dis Sci 2009; 54:2399–2403.

Salomaa-Rasanen A, Kosunen TU, Aromaa ARJ, Knekt P, et al. A “Screen-and-Treat” Approach for Helicobacter pylori Infection: A Population-Based Study in Vammala, Finland. Helicobacter 2010; 15:28–37.

Santos IS, Boccio J, Davidsson L, Hernandez-Triana M, et al. Helicobacter pylori is not associated with anaemia in Latin America: results from Argentina, Brazil, Bolivia, Cuba, Mexico and Venezuela. Public Health Nutr 2009; 12:1862–1870.

Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment [Review]. Curr Opin Gastroenterol 2009; 25:549–556.

Seo JH, Lim JW, Yoon JH, Kim H. Proteinase-Activated Receptor-2 Mediates the Expression of Integrin alpha(5) and beta(1) in Helicobacter pylori-Infected Gastric Epithelial AGS Cells. Digestion 2009; 80:40–49.

Sheu BS, Yang HB, Yeh YC, Wu JJ. Helicobacter pylori colonization of the human gastric epithelium: A bug's first step is a novel target for us [Review]. J Gastroenterol Hepatol 2010; 25:26–32.

Shin CM, Kim N, Lee HS, Lee HE, et al. Validation of Diagnostic Tests for Helicobacter pylori with Regard to Grade of Atrophic Gastritis and/or Intestinal Metaplasia. Helicobacter 2009; 14:512–519.

Shin DW, Yun YH, Choi IJ, Koh E, et al. Cost-Effectiveness of Eradication of Helicobacter pylori in Gastric Cancer Survivors After Endoscopic Resection of Early Gastric Cancer. Helicobacter 2009; 14:536–544.

Shokrzadeh L, Baghaei K, Yamaoka Y, Dabiri H, et al. Analysis of 3′-end variable region of the cagA gene in Helicobacter pylori isolated from Iranian population. J Gastroenterol Hepatol 2010; 25:172–177.

Silva FM, Navarro-Rodriguez T, Barbuti RC, Mattar R, et al. Helicobacter pylori Reinfection in Brazilian Patients with Peptic Ulcer Disease: A 5-Year Follow-Up. Helicobacter 2010; 15:46–52.

So WY, Tong PC, Ko GT, Ma RC, et al. Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. Diabetes Res Clin Pract 2009; 86:89–95.

Songur Y, Senol A, Balkarli A, Basturk A, et al. Triple or Quadruple Tetracycline-Based Therapies Versus Standard Triple Treatment for Helicobacter pylori Treatment. Am J Med Sci 2009; 338:50–53.

Stec-Michalska K, Malicki S, Michalski B, Peczek L, et al. Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients. World J Gastroenterol 2009; 15:5409–5417.

Stec-Michalska K, Peczek L, Michalski B, Wisniewska-Jarosinska M, et al. Helicobacter pylori Infection and Family History of Gastric Cancer Decrease Expression of FHIT Tumor Suppressor Gene in Gastric Mucosa of Dyspeptic Patients. Helicobacter 2009; 14:126–134.

Stechova K, Pomahacova R, Hrabak J, Durilova M, et al. Reactivity to Helicobacter pylori Antigens in Patients Suffering from Thyroid Gland Autoimmunity. Exp Clin Endocrinol Diabetes 2009; 117:423–431.

Sugimoto M, Furuta T, Yamaoka Y. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori [Review]. J Gastroenterol Hepatol 2009; 24:1725–1732.

Sugimoto M, Yamaoka Y. The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. Clin Microbiol Infect 2009; 15:835–842.

Sugimoto M, Zali MR, Yamaoka Y. The association of vacA genotypes and Helicobacter pylori-related gastroduodenal diseases in the Middle East. Eur J Clin Microbiol Infect Dis 2009; 28:1227–1236.

•• Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15:233–238.[51]

Suto H, Yamazaki Y, Yoshida I, Yamakawa A, et al. The Effects of Helicobacter pylori Eradication on Body Mass Index and Dyspeptic Symptoms. Digestion 2009; 79:235–242.

Suzuki G, Cullings H, Fujiwara S, Matsuura S, et al. LTA 252GG and GA Genotypes are Associated with Diffuse-Type Noncardia Gastric Cancer Risk in the Japanese Population. Helicobacter 2009; 14:571–579.

Suzuki H, Iwasaki E, Hibi T. Helicobacter pylori and gastric cancer [Review]. In: Gastric Cancer 2009; 12:79–87.

Sykora J, Siala K, Varvarovska J, Pazdiora P, et al. Epidemiology of Helicobacter pylori Infection in Asymptomatic Children: A Prospective Population-Based Study from the Czech Republic. Application of a Monoclonal-Based Antigen-in-Stool Enzyme Immunoassay. Helicobacter 2009; 14:286–297.

Tahara T, Shibata T, Wang FY, Nakamura M, et al. Mannan-binding lectin B allele is associated with a risk of developing more severe gastric mucosal atrophy in Helicobacter pylori-infected Japanese patients. Eur J Gastroenterol Hepatol 2009; 21:781–786.

Takaishi S, Tu SP, Dubeykovskaya ZA, Whary MT, et al. Gastrin Is an Essential Cofactor for Helicobacter-Associated Gastric Corpus Carcinogenesis in C57BL/6 Mice. Am J Pathol 2009; 175:365–375.

Takeshima E, Tomimori K, Takamatsu R, Ishikawa C, et al. Helicobacter pylori VacA Activates NF-kappa B in T Cells via the Classical but not Alternative Pathway. Helicobacter 2009; 14:271–279.

Tanaka M, Kamata R, Yanagihara K, Sakai R. Suppression of gastric cancer dissemination by ephrin-B1-derived peptide. Cancer Science 2010; 101:87–93.

Tsumoto C, Tominaga K, Okazaki H, Tanigawa T, et al. Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol 2009; 88:789–793.

Vannella L, Gianni D, Lahner E, Amato A, et al. Pre-endoscopic screening for Helicobacter pylori and celiac disease in young anemic women. World J Gastroenterol 2009; 15:2748–2753.

Veijola LI, Oksanen AM, Sipponen PI, Rautelin HIK. Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection. World J Gastroenterol 2010; 16:83–88.

Wada Y, Ito M, Takata S, Kitamura S, et al. Little Necessity of Acid Inhibition against Proton Pump Inhibitor Rebound Effects and Prior Helicobacter pylori Eradication Therapy in Gastric Ulcer Patients: A Randomized Prospective Study. Hepato-Gastroenterol 2009; 56:624–628.

Wang GH, Yu DK, Tan W, Zhao D, et al. Genetic Polymorphism in Chemokine CCL22 and Susceptibility to Helicobacter pylori Infection-related Gastric Carcinoma. Cancer 2009; 115:2430–2437.

Wang XY, Yang J, Ho B, Yang Y, et al. Interaction of Helicobacter pylori with Genetic Variants in the MDM2 Promoter, is Associated with Gastric Cancer Susceptibility in Chinese Patients. Helicobacter 2009; 14:114–119.

Watari J, Moriichi K, Tanabe H, Sato R, et al. Differences in genetic instability and cellular phenotype among Barrett's, cardiac, and gastric intestinal metaplasia in a Japanese population with Helicobacter pylori. Histopathology 2009; 55:261–269.

Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. Curr Opin Clin Nutr Metab Care 2009; 12:522–525.

Wnuk M, Myszka A, Lewinska A, Tokarz I, et al. Helicobacter pylori cagA Gene Polymorphism Affects the Total Antioxidant Capacity of Human Saliva. Helicobacter 2010; 15:53–57.

Wu IC, Wu DC, Yu FJ, Wang JY, et al. Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol 2009; 15:5465–5471.

Yakoob J, Abid S, Abbas Z, Jafri W, et al. Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan - art. no. 87. BMC Gastroenterology 2009:87.

Yan SL, Wu ST, Chen CH, Hung YH, et al. Mucosal patterns of Helicobacter pylori-related gastritis without atrophy in the gastric corpus using standard endoscopy. World J Gastroenterol 2010; 16:496–500.

Yavasoglu I, Kucuk M, Cildag B, Arslan E, et al. A Novel Association Between Polycystic Ovary Syndrome and Helicobacter pylori. Am J Med Sci 2009; 338:174–177.

Yeh JM, Goldie SJ, Kuntz KM, Ezzati M. Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. Cancer Causes Control 2009; 20:2021–2029.

Yokota S, Okabayashi T, Rehli M, Fujii N, et al. Helicobacter pylori Lipopolysaccharides Upregulate Toll-Like Receptor 4 Expression and Proliferation of Gastric Epithelial Cells via the MEK1/2-ERK1/2 Mitogen-Activated Protein Kinase Pathway. Infect Immun 2010; 78:468–476.

• Yuan W, Li Y, Yang K, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45:665–676.[09]

Yuan WZ, Yang KH, Ma B, Li YM, et al. Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials. Intern Med 2009; 48:2069–2076.

Zaidi SFH, Ahmed K, Yamamoto T, Kondo T, et al. Effect of Resveratrol on Helicobacter pylori-Induced Interleukin-8 Secretion, Reactive Oxygen Species Generation and Morphological Changes in Human Gastric Epithelial Cells. Biological & Pharmaceutical Bulletin 2009; 32:1931–1935.

Zalewska-Ziob M, Adamek B, Strzelczyk KJ, Gawron K, et al. TNF-alpha expression in gastric mucosa of individuals infected with different virulent Helicobacter pylori strains. Med Sci Monitor 2009; 15:BR166–BR171.

Zhang DH, Zhou LY, Lin SR, Ding SG, et al. Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin Med J 2009; 122:1759–1763.

Zhang LJ, Wang SY, Huo XH, Zhu ZL, et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol 2009; 15:2731–2738.

Zheng ZL, Jia YB, Hou LF, Persson C, et al. Genetic Variation in a4GnT in Relation to Helicobacter pylori Serology and Gastric Cancer Risk. Helicobacter 2009; 14:120–125.

Back to Top | Article Outline

Endoscopic management in the bariatric surgical patient

Review: (pp. 632–639)

Abiles V, Rodriguez-Ruiz S, Abiles J, Mellado C, et al. Psychological Characteristics of Morbidly Obese Candidates for Bariatric Surgery. Obesity Surgery 2010; 20:161–167.

Adams TD, Hunt SC. Cancer and Obesity: Effect of Bariatric Surgery. World J Surg 2009; 33:2028–2033.

Ali MR, Tichansky DS, Kothari SN, McBride CL, et al. Validation that a 1-year fellowship in minimally invasive and bariatric surgery can eliminate the learning curve for laparoscopic gastric bypass. Surg Endosc 2010; 24:138–144.

Andersen JR, Aasprang A, Bergsholm P, Sletteskog N, et al. Predictors for health-related quality of life in patients accepted for bariatric surgery. Surg Obes Relat Dis 2009; 5:329–333.

Andreelli F, Amouyal C, Magnan C, Mithieux G. What can bariatric surgery teach us about the pathophysiology of type 2 diabetes? Diabetes Metab 2009; 35:499–507.

Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, et al. Adipokine Serum Levels Are Related to Liver Histology in Severely Obese Patients Undergoing Bariatric Surgery. Obesity Surgery 2009; 19:1313–1323.

Arterburn D, Livingston EH, Schifftner T, Kahwati LC, et al. Predictors of Long-term Mortality After Bariatric Surgery Performed in Veterans Affairs Medical Centers. Arch Surg 2009; 144:914–920.

Ashrafian H, le Roux CW. Metabolic surgery and gut hormones - A review of bariatric entero-humoral modulation. Physiol Behav 2009; 97:620–631.

Balduf LM, Kohn GP, Galanko JA, Farrell TM. The Impact of Socioeconomic Factors on Patient Preparation for Bariatric Surgery. Obesity Surgery 2009; 19:1089–1095.

Bao JJ, Desai V, Christoffel KK, Smith-Ray P, et al. Prevalence of Obesity Among Children and/or Grandchildren of Adult Bariatric Surgery Patients. Obesity Surgery 2009; 19:833–839.

Batsis JA, Clark MM, Grothe K, Lopez-Jimenez F, et al. Self-efficacy after bariatric surgery for obesity. A population-based cohort study. Appetite 2009; 52:637–645.

Batsis JA, Lopez-Jimenez F, Collazo-Clavell ML, Clark MM, et al. Quality of Life after Bariatric Surgery: A Population-based Cohort Study - art. no. 1055.e1. Am J Med 2009; 122:E1.

Bays HE, Laferrere B, Dixon J, Aronne L, et al. Adiposopathy and bariatric surgery: is ‘sick fat’ a surgical disease? [Review]. Int J Clin Practice 2009; 63:1285–1300.

Benedix F, Scheidbach H, Arend J, Lippert H, et al. Revision after Failed Bariatric Surgery - Review of Complications and Current Therapeutic Options [German]. Zentbl Chir 2008; 134:214–224.

Boehm R, Stroh C, Blueher S, Till H, et al. Bariatric Surgery in Children and Adolescents [Review] [German]. Zentbl Chir 2009; 134:532–536.

Bond DS, Raynor HA, Vithiananthan S, Sax HC, et al. Differences in Salivary Habituation to a Taste Stimulus in Bariatric Surgery Candidates and Normal-Weight Controls. Obesity Surgery 2009; 19:873–878.

Breznikar B, Dinevski D. Bariatric Surgery for Morbid Obesity: Pre-operative Assessment, Surgical Techniques and Post-operative Monitoring. J Int Med Res 2009; 37:1632–1645.

Browne AF, Inge T. How young for bariatric surgery in children? Semin Pediatr Surg 2009; 18:176–185.

Bruno C, Fulford AD, Potts JR, McClintock R, et al. Serum Markers of Bone Turnover Are Increased at Six and 18 Months after Roux-En-Y Bariatric Surgery: Correlation with the Reduction in Leptin. J Clin Endocrinol Metab 2010; 95:159–166.

Buchwald H, Oien DM. Metabolic/Bariatric Surgery Worldwide 2008. Obesity Surgery 2009; 19:1605–1611.

Bueter M, le Roux CW. Sir David Cuthbertson Medal Lecture Bariatric surgery as a model to study appetite control. Proc Nutr Soc 2009; 68:227–233.

Campos GM, Rabl C, Peeva S, Ciovica R, et al. Improvement in Peripheral Glucose Uptake After Gastric Bypass Surgery Is Observed Only After Substantial Weight Loss Has Occurred and Correlates with the Magnitude of Weight Lost. J Gastrointest Surg 2010; 14:15–22.

Caniano DA. Ethical issues in pediatric bariatric surgery. Semin Pediatr Surg 2009; 18:186–192.

Chavaez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients - art. no. CD007340 [Review]. Cochrane Database of Systematic Reviews 2010:7340.

Christou NV. Impact of Obesity and Bariatric Surgery on Survival. World J Surg 2009; 33:2022–2027.

Ciangura C, Basdevant A. Bariatric surgery in young massively obese diabetic patients. Diabetes Metab 2009; 35:532–536.

•• Cote GA, Edmundowicz SA. Emerging technology: endoluminal treatment of obesity. Gastrointest Endosc 2009; 70:991–999.[37]

• Csendes A, Burgos AM, Altuve J, Bonacic S. Incidence of marginal ulcer 1 month and 1 to 2 years after gastric bypass: a prospective consecutive endoscopic evaluation of 442 patients with morbid obesity. Obes Surg 2009; 19:135–138.[29]

Dar M, Pories WJ. Bariatric surgery: What is the effect on type 2 diabetes? [Review]. Curr Opin Investig Drugs 2009; 10:1078–1084.

Dargent J. Lap Banding as a Redo Surgery: “Restriction over Restriction” May Be a Relevant Bariatric Strategy. Obesity Surgery 2009; 19:1243–1249.

de Kerviler S, Husler R, Banic A, Constantinescu MA. Body Contouring Surgery Following Bariatric Surgery and Dietetically Induced Massive Weight Reduction: A Risk Analysis. Obesity Surgery 2009; 19:553–559.

de Oliveira LD, Diniz MTC, Diniz MDHS, Savassi-Rocha AL, et al. Rhabdomyolysis After Bariatric Surgery by Roux-en-Y Gastric Bypass: A Prospective Study. Obesity Surgery 2009; 19:1102–1107.

de Souza SAF, Faintuch J, Fabris SM, Nampo FK, et al. Six-minute walk test: functional capacity of severely obese before and after bariatric surgery. Surg Obes Relat Dis 2009; 5:540–543.

Dixon JB. Obesity and Diabetes: The Impact of Bariatric Surgery on Type-2 Diabetes. World J Surg 2009; 33:2014–2021.

Dolce CJ, Russo M, Keller JE, Buckingham J, et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg Obes Relat Dis 2009; 5:323–328.

Dufour F, Champault G. Is bariatric surgery in adolescents appropriate? [French]. J Chir (Paris) 2009; 146:24–29.

Eerdekens A, Debeer A, Van Hoey G, De Borger C, et al. Maternal bariatric surgery: adverse outcomes in neonates. Eur J Pediatr 2010; 169:191–196.

Faria SL, Kelly ED, Lins RD, Faria OP. Nutritional Management of Weight Regain After Bariatric Surgery. Obesity Surgery 2010; 20:135–139.

• Fernandez-Esparrach G, Lautz DB, Thompson CC. Endoscopic repair of gastrogastric fistula after Roux-en-Y gastric bypass: a less-invasive approach. Surg Obes Relat Dis 2010; 6:282–288.[27]

Flum DR, Belle SH, King WC, Wahed AS, et al. Perioperative Safety in the Longitudinal Assessment of Bariatric Surgery. N Engl J Med 2009; 361:445–454.

Gagne DJ, Papasavas PK, Dovec EA, Urbandt JE, et al. Effect of immunosuppression on patients undergoing bariatric surgery. Surg Obes Relat Dis 2009; 5:339–345.

Garb J, Welch G, Zagarins S, Kuhn J, et al. Bariatric Surgery for the Treatment of Morbid Obesity: A Meta-analysis of Weight Loss Outcomes for Laparoscopic Adjustable Gastric Banding and Laparoscopic Gastric Bypass [Review]. Obesity Surgery 2009; 19:1447–1455.

Goldfine AB, Shoelson SE, Aguirre V. Expansion and contraction Treating diabetes with bariatric surgery. Nat Med 2009; 15:616–617.

Granado-Lorencio F, Herrero-Barbudo C, Olmedilla-Alonso B, Blanco-Navarro I, et al. Hypocarotenemia After Bariatric Surgery: A Preliminary Study. Obesity Surgery 2009; 19:879–882.

•• Huang CS. The role of the endoscopist in a multidisciplinary obesity center. Gastrointest Endosc 2009; 70:763–767.[07]

Hunt HR, Gross AM. Prediction of Exercise in Patients Across Various Stages of Bariatric Surgery: A Comparison of the Merits of the Theory of Reasoned Action Versus the Theory of Planned Behavior. Behav Modif 2009; 33:795–817.

Hwang KO, Childs JH, Goodrick GK, Aboughali WA, et al. Explanations for Unsuccessful Weight Loss Among Bariatric Surgery Candidates. Obesity Surgery 2009; 19:1377–1383.

Imberti D, Legnani C, Baldini E, Cini M, et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: A prospective, randomised study comparing two doses of parnaparin (BAFLUX STUDY). Thromb Res 2009; 124:667–671.

Kelles SMB, Barreto SM, Guerra HL. Mortality and Hospital Stay After Bariatric Surgery in 2,167 Patients: Influence of the Surgeon Expertise. Obesity Surgery 2009; 19:1228–1235.

Khoueir P, Black MH, Crookes PF, Kaufman HS, et al. Prospective assessment of axial back pain symptoms before and after bariatric weight reduction surgery. Spine Journal 2009; 9:454–463, 2009 Jun.

Korner J, Inabet W, Fabres G, Conwell IM, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes 2009; 33:786–795.

Laferrere B. Effect of gastric bypass surgery on the incretins. Diabetes Metab 2009; 35:513–517.

Laville M, Disse E. Bariatric surgery for diabetes treatment: why should we go rapidly to surgery. Diabetes Metab 2009; 35:562–563.

Lee YC, Lee WJ, Lin YC, Liew PL, et al. Obesity and the Decision Tree: Predictors of Sustained Weight loss after Bariatric Surgery. Hepato-Gastroenterol 2009; 56:1745–1749.

Lim CSH, Liew V, Talbot ML, Jorgensen JO, et al. Revisional Bariatric Surgery. Obesity Surgery 2009; 19:827–832.

Lin E, Davis SS, Srinivasan J, Sweeney JF, et al. Dual Mechanism for Type-2 Diabetes Resolution after Roux-en-Y Gastric Bypass. Am Surg 2009; 75:498–502.

•• Lopes TL, Wilcox CM. Endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anatomy. Gastroenterol Clin North Am 2010; 39:99–107.[31]

Mathurin P, Hollebecque A, Arnalsteen L, Buob D, et al. Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. Gastroenterology 2009; 137:532–540.

Merhi ZO. Impact of bariatric surgery on female reproduction [Review]. Fertil Steril 2009; 92:1501–1508.

Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement resolution of type 2 diabetes after bariatric surgery. Diabetes Metab 2009; 35:518–523.

Mingrone G, Castagneto M. Bariatric surgery: unstressing or boosting the beta-cell? Diabetes Obes Metab 2009; 11.

Mistry SB, Omana JJ, Kini S. Rat Models for Bariatric Surgery and Surgery for Type 2 Diabetes Mellitus [Review]. Obesity Surgery 2009; 19:655–660.

Monkhouse SJW, Morgan JDT, Norton SA. Complications of bariatric surgery: presentation and emergency management - a review [Review]. Ann R Coll Surg Engl 2009; 91:280–286.

Moschen AR, Molnar C, Wolf AM, Weiss H, et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009; 51:765–777.

• Munoz R, Ibanez L, Salinas J, et al. Importance of routine preoperative upper GI endoscopy: why all patients should be evaluated? Obes Surg 2009; 19:427–431.[06]

Nadler EP, Brotman LM, Miyoshi T, Fryer GE, et al. Morbidity in obese adolescents who meet the adult National Institutes of Health criteria for bariatric surgery. J Pediatr Surg 2009; 44:1869–1876.

• Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39:1–7.[02]

•• Obstein KL, Thompson CC. Endoscopy after bariatric surgery (with videos). Gastrointest Endosc 2009; 70:1161–1166.[15]

Ojo P, Valin E. Cost-Effective Restrictive Bariatric Surgery: Laparoscopic Vertical Banded Gastroplasty Versus Laparoscopic Adjustable Gastric Band. Obesity Surgery 2009; 19:1536–1541.

Overby DW, Kohn GP, Cahan MA, Galanko JA, et al. Prevalence of Thrombophilias in Patients Presenting for Bariatric Surgery. Obesity Surgery 2009; 19:1278–1285.

Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications [Review]. Obesity Rev 2010; 11:41–50.

Peterli R, Wolnerhanssen B, Peters T, Devaux N, et al. Improvement in Glucose Metabolism After Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy A Prospective Randomized Trial. Ann Surg 2009; 250:234–241.

Pillai AA, Rinella ME. Non-Alcoholic Fatty Liver Disease: Is Bariatric Surgery the Answer? [Review]. Clin Liver Dis 2009; 13:689–.

Pongchairerks P. Slow Progress of Bariatric Surgery in Thailand: Surgeons' Opinions. Asian Journal of Surgery 2009; 32:205–215.

Pournaras DJ, le Roux CW. Obesity, Gut Hormones, and Bariatric Surgery. World J Surg 2009; 33:1983–1988.

Pournaras DJ, Le Roux CW. The effect of bariatric surgery on gut hormones that alter appetite. Diabetes Metab 2009; 35:508–512.

Ramirez J, Carpio D, Mezzano S, Mukdsi J, et al. Bariatric surgery in patients with focal segmental glomerulosclerosis secondary to obesity [Spanish]. Nefrologia 2009; 29:266–269.

Renard E. Bariatric surgery in patients with late-stage type 2 diabetes: expected beneficial effects on risk ratio and outcomes. Diabetes Metab 2009; 35:564–568.

Rottembourg D, O'Gorman CS, Urbach S, Garneau PY, et al. Outcome after Bariatric Surgery in Two Adolescents with Hypothalamic Obesity Following Treatment of Craniopharyngioma. J Pediatr Endocrinol Metab 2009; 22:867–872.

Salgado W, Cunha FD, dos Santos JS, Nonino-Borges CB, et al. Early Identification of Infectious Complications in Bariatric Surgery by the Determination of Peritoneal and Systemic Cytokines. Obesity Surgery 2009; 19:867–872.

Sarkar S, Smith D, Scott MH. A Rare Complication of Abdominoplasty After Bariatric Surgery. Ann Plast Surg 2010; 64:7–8.

Savastano S, Angrisani L, Di Somma C, Rota F, et al. Relationship Between Growth Hormone/Insulin-Like Growth Factor-1 Axis Integrity and Voluntary Weight Loss After Gastric Banding Surgery for Severe Obesity. Obesity Surgery 2010; 20:211–220.

Scheen AJ, De Flines J, De Roover A, Paquot N. Bariatric surgery in patients with Type 2 diabetes: benefits, risks, indications and perspectives. Diabetes Metab 2009; 35:537–543.

Schlienger JL, Pradignac A, Luca F, Meyer L, et al. Medical management of diabetes after bariatric surgery. Diabetes Metab 2009; 35:558–561.

•• Schreiner MA, Fennerty MB. Endoscopy in the obese patient. Gastroenterol Clin North Am 2010; 39:87–97.[08]

Schweiger C, Weiss R, Berry E, Keidar A. Nutritional Deficiencies in Bariatric Surgery Candidates. Obesity Surgery 2010; 20:193–197.

Segal JB, Clark JM, Shore AD, Dominici F, et al. Prompt Reduction in Use of Medications for Comorbid Conditions After Bariatric Surgery. Obesity Surgery 2009; 19:1646–1656.

Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009; 10:653–662.

Sledzinski T, Sledzinski M, Smolenski RT, Swierczynski J. Increased Serum Nitric Oxide Concentration After Bariatric Surgery-A Potential Mechanism for Cardiovascular Benefit. Obesity Surgery 2010; 20:204–210.

Snyder B, Nguyen A, Scarbourough T, Yu S, et al. Comparison of those who succeed in losing significant excessive weight after bariatric surgery and those who fail. Surg Endosc 2009; 23:2302–2306.

Stroh C, Birk D, Flade-Kuthe R, Frenken M, et al. Evidence of Thromboembolism Prophylaxis in Bariatric Surgery-Results of a Quality Assurance Trial in Bariatric Surgery in Germany from 2005 to 2007 and Review of the Literature. Obesity Surgery 2009; 19:928–936.

Stroh C, Birk D, Flade-Kuthe R, Frenken M, et al. Results of Sleeve Gastrectomy-Data from a Nationwide Survey on Bariatric Surgery in Germany. Obesity Surgery 2009; 19:632–640.

Stroh C, Meyer F, Lippert H, Manger T. “Rhabdomyolysis after Bariatric Surgery by Roux-en-Y Gastric Bypass: A Prospective Study”. Obesity Surgery 2010; 20:261–262.

Sturm W, Tschoner A, Engl J, Kaser S, et al. Effect of bariatric surgery on both functional and structural measures of premature atherosclerosis. Eur Heart J 2009; 30:2038–2043.

Sundbom M, Karlson BM. Low Mortality in Bariatric Surgery 1995 Through 2005 in Sweden, in Spite of a Shift to More Complex Procedures. Obesity Surgery 2009; 19:1697–1701.

Swierczynski J, Sledzinski T, Slominska E, Smolenski R, et al. Serum Phenylalanine Concentration as a Marker of Liver Function in Obese Patients Before and After Bariatric Surgery. Obesity Surgery 2009; 19:883–889.

Teixeira ARF, Bellodi-Privato M, Carvalheira JB, Pilla VF, et al. The Incapacity of the Surgeon to Identify NASH in Bariatric Surgery Makes Biopsy Mandatory. Obesity Surgery 2009; 19:1678–1684.

van den Broek RJC, Buise MP, van Dielen FM, Bindels AJGH, et al. Characteristics and Outcome of Patients Admitted to the ICU Following Bariatric Surgery. Obesity Surgery 2009; 19:560–564.

van der Beek ESJ, te Riele W, Specken TF, Boerma D, et al. The Impact of Reconstructive Procedures Following Bariatric Surgery on Patient Well-being and Quality of Life. Obesity Surgery 2010; 20:36–41.

Vaziri K, Bhanot P, Hungness ES, Morasch MD, et al. Retrievable inferior vena cava filters in high-risk patients undergoing bariatric surgery. Surg Endosc 2009; 23:2203–2207.

von Drygalski A, Andris DA. Anemia After Bariatric Surgery: More Than Just Iron Deficiency [Review]. Nutrition in Clinical Practice 2009; 24:217–226.

Wee CC. A 52-Year-Old Woman With Obesity Review of Bariatric Surgery. JAMA 2009; 302:1097–1104.

White MA, Kalarchian MA, Masheb RM, Marcus MD, et al. Loss of Control Over Eating Predicts Outcomes in Bariatric Surgery Patients: A Prospective, 24-Month Follow-Up Study. J Clin Psychiatry 2010; 71:175–184.

Xanthakos SA. Nutritional Deficiencies in Obesity and After Bariatric Surgery. Pediatr Clin North Am 2009; 56:1105.

Yuan X, Hawver LRM, Ojo P, Wolfe LA, et al. Bariatric surgery in Medicare patients: greater risks but substantial benefits. Surg Obes Relat Dis 2009; 5:299–304.

Yurcisin BM, Gaddor MM, De Maria EJ. Obesity and Bariatric Surgery [Review]. Clin Chest Med 2009; 30:539–.

Zaldivar SS, Horcajadas FA, Martinez JJG, Romero SS. Evolution of psychopathologycal alterations in patients with morbid obesity after bariatric surgery [Spanish]. Med Clin (Barc) 2009; 133:206–212.

Ziegler O, Sirveaux MA, Brunaud L, Reibel N, et al. Medical follow up after bariatric surgery: nutritional and drug issues General recommendations for the prevention and treatment of nutritional deficiencies. Diabetes Metab 2009; 35:544–557.

Back to Top | Article Outline

Multidisciplinary management of gastric cancer

Review: (pp. 640–646)

•• Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28:1547–1553.[22]

Al-Refaie WB, Gay G, Virnig BA, Tseng JF, et al. Variations in Gastric Cancer Care. Cancer 2010; 116:465–475.

Alakus H, Monig SP, Warnecke-Eberz U, Alakus G, et al. Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer. World J Gastroenterol 2009; 15:6061–6067.

Antonio L, Guzman P, Villaseca M, Araya J, et al. Concomitant presence of a gastric adenocarcinoma and gastrointestinal stromal tumor. Report of one case [Spanish]. Rev Med Chil 2009; 137:531–536.

Anzidei M, Napoli A, Zaccagna F, Di Paolo P, et al. Diagnostic performance of 64-MDCT and 1.5-T MRI with high-resolution sequences in the T staging of gastric cancer: a comparative analysis with histopathology. Radiol Med (Torino) 2009; 114:1065–1079.

Bartchewsky W, Martini MR, Squassoni AC, Alvarez MC, et al. Effects of Helicobacter pylori Infection on the Expressions of Bax and Bcl-2 in Patients with Chronic Gastritis and Gastric Cancer. Dig Dis Sci 2010; 55:111–116.

Baumgaertner I, Copie-Bergman C, Levy M, Haioun C, et al. Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. World J Gastroenterol 2009; 15:5746–5750.

Belair C, Darfeuille F, Staedel C. Helicobacter pylori and gastric cancer: possible role of microRNAs in this intimate relationship [Review]. Clin Microbiol Infect 2009; 15:806–812.

Bertuccio P, Edefonti V, Bravi F, Ferraroni M, et al. Nutrient Dietary Patterns and Gastric Cancer Risk in Italy. Cancer Epidemiol Biomarkers Prev 2009; 18.

Bi J, Lau SH, Lv ZL, Xie D, et al. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 2009; 40:1790–1797.

Bi R, Sheng WQ, Wang J. Collision tumor of the stomach: Gastric adenocarcinoma intermixed with gastrointestinal stromal tumor. Pathol Int 2009; 59:880–883.

Binici DN, Koca T, Dursun H. Dietary Habits, Demographical, and Socio-economical Risk Factors of the Newly Diagnosed Gastric Cancers in the Eastern Anatolia Region of Turkey: An Endemic Upper Gastrointestinal Cancer Region. Dig Dis Sci 2009; 54:2629–2633.

Boda-Heggemann J, Hofheinz RD, Weiss C, Mennemeyer P, et al. Combined adjuvant radiochemotherapy with imrt/xelox improves outcome with low renal toxicity in gastric cancer. Int J Radiat Oncol Biol Phys 2009; 75.

Boku N, Yamamoto S, Fukuda H, Shirao K, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10:1063–1069.

Buckland G, Agudo A, Lujan L, Jakszyn P, et al. Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr 2010; 91:381–390.

Bui XT, Vo TCM, Tanaka H, Le TL, et al. Diverse Characteristics of the cagA Gene of Helicobacter pylori Strains Collected from Patients from Southern Vietnam with Gastric Cancer and Peptic Ulcer. J Clin Microbiol 2009; 47:4021–4028.

Capelle LG, de Vries AC, Haringsma J, Steyerberg EW, et al. Serum Levels of Leptin As Marker For Patients At High Risk of Gastric Cancer. Helicobacter 2009; 14:596–604.

Capelle LG, Van Grieken NCT, Lingsma HF, Steyerberg EW, et al. Risk and Epidemiological Time Trends of Gastric Cancer in Lynch Syndrome Carriers in The Netherlands. Gastroenterology 2010; 138:487–492.

Chang H, Rha SY, Jeung HC, Im CK, et al. Association of the ABCB1 3435C > T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep 2010; 23:271–278.

Chang HM, Lee SW, Nomura E, Tanigawa N. Laparoscopic Versus Open Gastrectomy for Gastric Cancer Patients With COPD. J Surg Oncol 2009; 100:456–458.

Chen JS, Chan DC, Chung MJ, Chang LC, et al. Altered fibrinolytic activities in gastric cancer and uremic patients after intervention. Clin Nephrol 2009; 72:468–472.

Chiaravalli AM, Klersy C, Tava F, Manca R, et al. Lower- and higher-grade subtypes of diffuse gastric cancer. Hum Pathol 2009; 40:1591–.

Cho YK, Kim SW, Hur WH, Nam KW, et al. Clinical Outcomes of Self-Expandable Metal Stent and Prognostic Factors for Stent Patency in Gastric Outlet Obstruction Caused by Gastric Cancer. Dig Dis Sci 2010; 55:668–674.

Chung HW, Noh SH, Lim JB. Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol 2010; 16:256–263.

Cianni R, Urigo C, Notarianni E, Saltarelli A, et al. Selective Internal Radiation Therapy with SIR-Spheres for the Treatment of Unresectable Colorectal Hepatic Metastases. Cardiovasc Intervent Radiol 2009; 32:1179–1186.

Clark K, Lam L, Currow D. Reducing gastric secretions-a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer 2009; 17:1463–1468.

Dasanu CA, Rathmann J, Alexandrescu DT. H. pylori-Associated Gastric Cancer in a Husband-Wife Pair: A Veritable Family Affair. South Med J 2009; 102:1158–1160.

de la Pena S, Sampieri CL, Leon-Cordoba K. Matrix metalloproteases as molecular markers in gastric cancer [Review] [Spanish]. Med Clin (Barc) 2010; 134:123–126.

Deandrea S, Foschi R, Galeone C, La Vecchia C, et al. Is temperature an effect modifier of the association between green tea intake and gastric cancer risk? Eur J Cancer Prev 2010; 19:18–22.

Dong NN, Jiang WR, Li HQ, Liu ZF, et al. Triweekly Oxaliplatin Plus Oral Capecitabine as First-Line Chemotherapy in Elderly Patients With Advanced Gastric Cancer. Am J Clin Oncol-Cancer Clin Trials 2009; 32:559–563, 2009 Dec.

Dragan R, Nebojsa M, Dejan S, Ivan P, et al. Clinical Application of Sentinel Lymph Node Biopsy for Staging, Treatment and Prognosis of Colon and Gastric Cancer. Hepato-Gastroenterol 2009; 56:1606–1611.

Eussen SJPM, Vollset SE, Hustad S, Midttun O, et al. Vitamins B2 and B6 and Genetic Polymorphisms Related to One-Carbon Metabolism as Risk Factors for Gastric Adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2010; 19.

Ferrasi AC, Pinheiro NA, Rabenhorst SHB, Caballero OL, et al. Helicobacter pylori and EBV in gastric carcinomas: Methylation status and microsatellite instability. World J Gastroenterol 2010; 16:312–319.

Firat O, Yazici P, Makay O, Aydin A, et al. Co-existence of Gastrointestinal Stromal Tumors with Malign Epithelial Tumors: a Report of Two Cases. Acta Chir Belg 2009; 109:629–632.

Gaidos JKJ, Draganov PV. Treatment of malignant gastric outlet obstruction with endoscopically placed self-expandable metal stents. World J Gastroenterol 2009; 15:4365–4371.

Gao CP, Zhang ZY, Liu WZ, Xiao SD, et al. Reduced MicroRNA-218 Expression Is Associated With High Nuclear Factor kappa B Activation in Gastric Cancer. Cancer 2010; 116:41–49.

Garcia-Esquinas E, Perez-Gomez B, Pollan M, Boldo E, et al. Gastric cancer mortality trends in Spain, 1976-2005, differences by autonomous region and sex - art. no. 346. BMC Cancer 2009:346.

Gonzalez CA, Lopez-Carrillo L. Helicobacter pylori, nutrition and smoking interactions: Their impact in gastric carcinogenesis [Review]. Scand J Gastroenterol 2010; 45:6–14.

Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod [Review]. J Gastroenterology 2010; 45:1–8.

Griniatsos J, Gakiopoulou H, Yiannakopoulou E, Dimitriou N, et al. Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer. World J Gastroenterol 2009; 15:5568–5572.

Guan XX, Zhao H, Niu JG, Tang DF, et al. The VEGF-634G > C promoter polymorphism is associated with risk of gastric cancer - art. no. 77. BMC Gastroenterology 2009:77.

He RB, Chen JQ. Pre-operative Chemotherapy for Gastric Cancer [Review]. J Int Med Res 2009; 37:1259–1266.

Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma [Review]. Clin Microbiol Infect 2009; 15:971–976.

Hinojosa MW, Mailey BA, Smith BR, Reavis KM, et al. Minimally invasive Ivor-Lewis esophagogastrectomy for gastric cardia cancer. Surg Endosc 2009; 23:2656.

Hiraki M, Kitajima Y, Sato S, Nakamura J, et al. Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World J Gastroenterol 2010; 16:330–338.

Hirasawa T, Gotoda T, Miyata S, Kato Y, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. In: Gastric Cancer 2009; 12:148–152.

Hong WS, Chung DJ, Lee JM, Byun JH, et al. Metastatic Gastric Linitis Plastica from Bladder Cancer Mimicking a Primary Gastric Carcinoma: a Case Report. Korean J Radiol 2009; 10:645–648.

Hou LF, Savage SA, Blaser MJ, Perez-Perez G, et al. Telomere Length in Peripheral Leukocyte DNA and Gastric Cancer Risk. Cancer Epidemiol Biomarkers Prev 2009; 18.

Hu X, Tian DY, Cao L, Yi Y. Progression and Prognosis of Gastric Stump Cancer. J Surg Oncol 2009; 100:472–476.

Hur H, Song KY, Park CH, Jeon HM. Follow-Up Strategy After Curative Resection of Gastric Cancer: A Nationwide Survey in Korea. Ann Surg Oncol 2010; 17:54–64.

Im CK, Rha SY, Jeung HC, Ahn JB, et al. A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. Am J Clin Oncol-Cancer Clin Trials 2010; 33:56–60, 2010 Feb 10.

Im CK, Rha SY, Jeung HC, Jeong J, et al. A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status. Oncology (Williston Park) 2009:349–357.

Im JP, Kim SG, Kim JS, Jung HC, et al. Time-dependent morphologic change in depressed-type early gastric cancer. Surg Endosc 2009; 23:2509–2514.

Imamura Y, Ishikawa S, Sato N, Karashima R, et al. Adenoviral Oncolytic Suicide Gene Therapy for a Peritoneal Dissemination Model of Gastric Cancer in Mice. Ann Surg Oncol 2010; 17:643–652.

Imazawa M, Kojima T, Boku N, Onozawa Y, et al. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. In: Gastric Cancer 2009; 12:153–157.

Inoue K, Nakane Y, Michiura T, Yamaki S, et al. Feasibility and accuracy of second-look laparoscopy after gastrectomy for gastric cancer. Surg Endosc 2009; 23:2307–2313.

Ishigami H, Kitayama J, Kaisaki S, Hidemura A, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010; 21:67–70.

Jeon TY, Han ME, Lee YW, Lee YS, et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010; 102:710–718.

Jeung HC, Rha SY, Shin SJ, Ahn JB, et al. Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m(2) bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. Jpn J Clin Oncol 2010; 40:29–35.

Kameda C, Nakamura M, Tanaka H, Yamasaki A, et al. Oestrogen receptor-alpha contributes to the regulation of the hedgehog signalling pathway in ER alpha-positive gastric cancer. Br J Cancer 2010; 102:738–747.

Kang HY, Kim SG, Kim JS, Jung HC, et al. Clinical outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Surg Endosc 2010; 24:509–516.

Kanizaj TF, Katicic M, Presecki V, Gasparov S, et al. Serum Antibodies Positivity to 12 Helicobacter pylori Virulence Antigens in Patients with Benign or Malignant Gastroduodenal Diseases - Cross-sectional Study. Croatian Medical Journal 2009; 50:124–132.

Kato M, Uedo N, Ishihara R, Kizu T, et al. Analysis of the color patterns of early gastric cancer using an autofluorescence imaging video endoscopy system. In: Gastric Cancer 2009; 12:219–224.

Kawasaki H, Kitayama J, Ishigami H, Hidemura A, et al. Solitary splenic metastasis from early gastric cancer: Report of a case. Surg Today 2010; 40:60–63.

Khalique SC, Cheng-Lai A. Drug Interaction Between Clopidogrel and Proton Pump Inhibitors. Cardiology in Review 2009; 17:198–200.

Kim HJ, Park JY, Bang S, Park SW, et al. Self-Expandable Metal Stents for Recurrent Malignant Obstruction after Gastric Surgery. Hepato-Gastroenterol 2009; 56:914–917.

Kim JW, Hwang I, Kim MJ, Jang SJ. Clinicopathological Characteristics and Predictive Markers of Early Gastric Cancer with Recurrence. J Korean Med Sci 2009; 24:1158–1164.

Kim MC, Heo GU, Jung GJ. Robotic gastrectomy for gastric cancer: surgical techniques and clinical merits. Surg Endosc 2010; 24:610–615.

Kim N, Cho SI, Lee HS, Park JH, et al. The Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Korea. Dig Dis Sci 2010; 55:101–110.

Kim T, Chung H, Yu W, Kim JY, et al. Localization of Gastric Cancer by CT Gastrography: A Prospective Study. Hepato-Gastroenterol 2009; 56:1580–1584.

Kiriyama S, Oda I, Nishimoto F, Mashimo Y, et al. Pilot study to assess the safety of local lidocaine injections during endoscopic submucosal dissection for early gastric cancer. In: Gastric Cancer 2009; 12:142–147.

Kochi M, Fujii M, Kanamori N, Kaiga T, et al. Irinotecan Plus S-1 for Liver Metastases of Gastric Cancer. Hepato-Gastroenterol 2009; 56:1755–1759.

Kodera Y, Ito S, Mochizuki Y, Kondo K, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol 2009; 35:1158–1163.

Koizumi W, Akiya T, Sato A, Yamaguchi K, et al. Second-line Chemotherapy with Biweekly Paclitaxel after Failure of Fluoropyrimidine-based Treatment in Patients with Advanced or Recurrent Gastric Cancer: a Report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial. Jpn J Clin Oncol 2009; 39:713–719.

Konturek PC, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis [Review]. J Physiol Pharmacol 2009; 60:3–21.

Kurishima K, Satoh H, Kagohashi K, Homma S, et al. Patients With Lung Cancer With Metachronous or Synchronous Gastric Cancer. Clin Lung Cancer 2009; 10:422–425.

Lee CW, Rickman B, Rogers AB, Muthupalani S, et al. Combination of Sulindac and Antimicrobial Eradication of Helicobacter pylori Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice. Cancer Res 2009; 69:8166–8174.

Lee HJ, Kim HH, Kim MC, Ryu SY, et al. The impact of a high body mass index on laparoscopy assisted gastrectomy for gastric cancer. Surg Endosc 2009; 23:2473–2479.

Lee HY, Park EC, Jun JK, Choi KS, et al. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol 2010; 16:245–250.

Lee JH, Ryu KW, Lee SE, Cho SJ, et al. Learning Curve for Identification of Sentinel Lymph Node Based on a Cumulative Sum Analysis in Gastric Cancer. Dig Surg 2009; 26:465–470.

Lee KM, Choi SJ, Shin SJ, Hwang JC, et al. Palliative treatment of malignant gastroduodenal obstruction with metallic stent: prospective comparison of covered and uncovered stents. Scand J Gastroenterol 2009; 44:846–852.

Lee KW, Bang SM, Kim S, Lee HJ, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 2010; 8:540–547.

Li C, Yan M, Chen J, Xiang M, et al. Survival Benefit of Non-curative Gastrectomy for Gastric Cancer Patients with Synchronous Distant Metastasis. J Gastrointest Surg 2010; 14:282–288.

Li GQ, Xie J, Lei XY, Zhang L. Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway. World J Gastroenterol 2009; 15:5541–5548.

Li MQ, Zhang JX, Wang DY, Zhong BL, et al. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer. Anticancer Drug 2009; 20:941–945.

Liu CG, Lu Y, Jun Z, Zhang RS, et al. Impact of total retrieved lymph nodes on staging and survival of patients with gastric cancer invading the subserosa. Surg Oncol-Oxf 2009; 18:379–384.

Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010; 102:500–505.

Lu Y, Lu P, Zhu Z, Xu HM, et al. Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer - art. no. 125. J Exp Clin Cancer Res 2009:125.

Ma Y, Xue YW, Li YF, Lan XW, et al. Subclassification of Stage IV Gastric Cancer (IVa, IVb, and IVc) and Prognostic Significance of Substages. J Gastrointest Surg 2010; 14:484–492.

Mabe K, Takahashi M, Oizumi H, Tsukuma H, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol 2009; 15:4290–4297.

Meng CF, Zhu XJ, Peng G, Dai DQ. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells. Oncol Rep 2009; 22:1221–1227.

Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009; 9:1543–1551.

Mikami K, Maekawa T, Shinohara T, Hoshino S, et al. Predictive Factors of Early Recurrent Death After a Curative Resection of Gastric Cancer. Int Surg 2009; 94:144–148.

Mizuno S, Kobayashi M, Tomita S, Miki I, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. In: Gastric Cancer 2009; 12:158–163.

Mohri Y, Omori Y, Hiro J, Yokoe T, et al. Clinicopathological. Features and Prognosis of Gastric Cancer Patients ≥ 75 Years of Age After Laparotomy. Int Surg 2009; 94:38–42.

Mohri Y, Tanaka K, Ohi M, Yokoe T, et al. Prognostic Significance of Host- and Tumor-Related Factors in Patients with Gastric Cancer. World J Surg 2010; 34:285–290.

Moon YW, Rha SY, Zhang X, Jeung HC, et al. Increments of alpha-Dystroglycan Expression in Liver Metastasis Correlate With Poor Survival in Gastric Cancer. J Surg Oncol 2009; 100:459–465.

Morgagni P, Marfisi C, Gardini A, Marrelli D, et al. Subtotal Gastrectomy as Treatment for Distal Multifocal Early Gastric Cancer. J Gastrointest Surg 2009; 13:2239–2244.

Namikawa T, Kitagawa H, Iwabu J, Okabayashi T, et al. Clinicopathological Properties of the Superficial Spreading Type Early Gastric Cancer. J Gastrointest Surg 2010; 14:52–57.

Nieminen A, Kokkola A, Yla-Liedenpohja J, Louhimo J, et al. Early Gastric Cancer: Clinical Characteristics and Results of Surgery. Dig Surg 2009; 26:378–383.

Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer [Review]. In: Gastric Cancer 2009; 12:132–141.

Noyan T, Guducuoglu H, Ilhan M. A Study of Oxidative Stress Parameters in Anti-Helicobacter Pylorus Immunoglobulin G Positive and Negative Gastric Cancer Patients. Yonsei Medical Journal 2009; 50:677–682.

Ogata K, Mochiki E, Yanai M, Toyomasu Y, et al. Factors Correlated with Early and Late Recurrence after Curative Gastrectomy for Gastric Cancer. Hepato-Gastroenterol 2009; 56:1760–1764.

Oh SJ, Hyung WJ, Song J, Kang W, et al. A Simple Method for Trimming of the Lesser and Greater Curvature using “Bovie” in Gastric Cancer Surgery. Hepato-Gastroenterol 2009; 56:1765–1767.

Ohnita K, Isomoto H, Yamaguchi N, Fukuda E, et al. Factors related to the curability of early gastric cancer with endoscopic submucosal dissection. Surg Endosc 2009; 23:2713–2719.

Ohtsuka T, Kitajima Y, Takahashi T, Sato S, et al. Infectious Complications after Gastric Cancer Surgery Accelerate a Rapid Hepatic Recurrence. Hepato-Gastroenterol 2009; 56:1277–1280.

Oldani A, Cormont M, Hofman V, Chiozzi V, et al. Helicobacter pylori Counteracts the Apoptotic Action of Its VacA Toxin by Injecting the CagA Protein into Gastric Epithelial Cells - art. no. e1000603. PLoS Pathogens 2009; 5:603.

Otani A, Amano Y, Koshino K, Takahashi Y, et al. Is Autofluorescence Imaging Endoscopy Useful for Determining the Depth of Invasion in Gastric Cancer? Digestion 2010; 81:96–103.

Ott K, Lordick F. Neoadjuvant therapy in the upper gastro-intestinal tract Gastric cancer from a surgical viewpoint [German]. Chirurg 2009; 80:1028–1034.

Ou XL, Chen HJ, Sun WH, Hang C, et al. Effects of angiopoietin-1 on attachment and metastasis of human gastric cancer cell line BGC-823. World J Gastroenterol 2009; 15:5432–5441.

Palser TR, Cromwell DA, Hardwick RH, Riley SA, et al. Re-organisation of oesophago-gastric cancer care in England: progress and remaining challenges - art. no. 204. BMC Health Services Research 2009:204.

Pan ZL, Zhang H, Yan C, Du LJ, et al. Determining gastric cancer resectability by dynamic MDCT. Eur Radiol 2010; 20:613–620.

Park DI, Park SH, Yoo TW, Kim HS, et al. The Prevalence of Colorectal Neoplasia in Patients With Gastric Cancer A Korean Association for the Study of Intestinal Disease (KASID) Study. J Clin Gastroenterol 2010; 44:102–105.

Park I, Lee JL, Ryu MH, Chang HM, et al. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2010; 65:473–480.

Park SR, Kook MC, Choi IJ, Kim CG, et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2010; 65:579–587.

Park SY, Yoo EJ, Cho NY, Kim N, et al. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J Pathol 2009; 219:410–416.

Pinheiro C, Longatto A, Simoes K, Jacob CE, et al. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 2009; 45:2418–2424.

Qiu FM, Yu JK, Chen YD, Jin QF, et al. Mining novel biomarkers for prognosis of gastric cancer with serum proteomics - art. no. 126. J Exp Clin Cancer Res 2009:126.

Rhoads MG, Kandarian SC, Pacelli F, Doglietto GB, et al. Expression of NF-kappa B and I kappa B proteins in skeletal muscle of gastric cancer patients. Eur J Cancer 2010; 46:191–197.

•• Rivera F, Galan M, Tabernero J, et al. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys 2009; 75:1430–1436.[34]

Ryu MH, Kang YK. ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer [Review]. Expert Rev Anticancer Ther 2009; 9:1745–1751.

Sah BK, Chen MM, Yan M, Zhu ZG. Reoperation for early postoperative complications after gastric cancer surgery in a Chinese hospital. World J Gastroenterol 2010; 16:98–103.

Sakuramoto S, Kikuchi S, Futawatari N, Katada N, et al. Laparoscopy-assisted pancreas- and spleen-preserving total gastrectomy for gastric cancer as compared with open total gastrectomy. Surg Endosc 2009; 23:2416–2423.

Santiago JR, Osorio J, Gutierrez I, Perez N, et al. Prognostic Usefulness of Lymph Node Ratio in Understaged Gastric Cancer. Hepato-Gastroenterol 2009; 56:1557–1561.

Seidl C, Port M, Apostolidis C, Bruchertseifer F, et al. Differential gene expression triggered by highly cytotoxic alpha-Emitter-immunoconjugates in gastric cancer cells. Invest New Drugs 2010; 28:49–60.

Shimizu H, Imamura H, Ohta K, Miyazaki Y, et al. Usefulness of staging laparoscopy for advanced gastric cancer. Surg Today 2010; 40:119–124.

Shimoyama R, Yasui H, Boku N, Onozawa Y, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. In: Gastric Cancer 2009; 12:206–211.

Shin DW, Yun YH, Choi IJ, Koh E, et al. Cost-Effectiveness of Eradication of Helicobacter pylori in Gastric Cancer Survivors After Endoscopic Resection of Early Gastric Cancer. Helicobacter 2009; 14:536–544.

Sitarz R, Leguit RJ, de Leng WWJ, Morsink FHM, et al. Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines. Cellular Oncology 2009; 31:475–485.

Skipworth RJE, Deans DAC, Tan BHL, Sangster K, et al. Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br J Cancer 2010; 102:665–672.

Songun I, van de Velde CJH. Optimal surgery for advanced gastric cancer [Review]. Expert Rev Anticancer Ther 2009; 9:1849–1858.

•• Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27:851–856.[36]

Stec-Michalska K, Peczek L, Michalski B, Wisniewska-Jarosinska M, et al. Helicobacter pylori Infection and Family History of Gastric Cancer Decrease Expression of FHIT Tumor Suppressor Gene in Gastric Mucosa of Dyspeptic Patients. Helicobacter 2009; 14:126–134.

Su LY, Xu GH, Shen J, Tuo Y, et al. Anticancer bioactive peptide suppresses human gastric cancer growth through modulation of apoptosis and the cell cycle. Oncol Rep 2010; 23:3–9.

Suda A, Saito N, Seshimo A, Kameoka S, et al. Examination of Transforming Growth Factor beta(1) Expression in the Serum and Tumor Tissue of Gastric Cancer. Int Surg 2009; 94:182–188.

Sun Q, Hang M, Xu W, Mao WD, et al. Irinotecan Plus Capecitabine as a Second-line Treatment after Failure of 5-Fluorouracil and Platinum in Patients with Advanced Gastric Cancer. Jpn J Clin Oncol 2009; 39:791–796.

Suzuki G, Cullings H, Fujiwara S, Matsuura S, et al. LTA 252GG and GA Genotypes are Associated with Diffuse-Type Noncardia Gastric Cancer Risk in the Japanese Population. Helicobacter 2009; 14:571–579.

Suzuki H, Iwasaki E, Hibi T. Helicobacter pylori and gastric cancer [Review]. In: Gastric Cancer 2009; 12:79–87.

Tanai C, Hamaguchi T, Watanabe S, Katai H, et al. A Case of Long-term Survival after Surgical Resection of Solitary Pulmonary Metastasis from Gastric Cancer. Jpn J Clin Oncol 2010; 40:85–89.

Tanaka M, Kamata R, Yanagihara K, Sakai R. Suppression of gastric cancer dissemination by ephrin-B1-derived peptide. Cancer Science 2010; 101:87–93.

Tinoco RC, Tinoco ACA, El-Kadre LJ, Sueth DM, et al. Laparoscopic Gastrectomy for Gastric Cancer. Surg Laparosc Endosc Pct Tech 2009; 19.

Tomita R, Fujisak S, Park YJ. Mini-laparotomy with Abdominal Wall Lifting for Partial Gastrectomy in Patients with Early Gastric Mucosal Cancer at Lesser Curvature of the Middle Stomach. Hepato-Gastroenterol 2009; 56:1768–1772.

Tomiyama N, Hidaka M, Hidaka H, Kawano Y, et al. Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer. Cancer Chemother Pharmacol 2010; 65:807–809.

Tzanakis NE, Peros G, Karakitsos P, Giannopoulos GA, et al. Prognostic Significance of p53 and Ki67 Proteins Expression in Greek Gastric Cancer Patients. Acta Chir Belg 2009; 109:606–611.

Wang GH, Yu DK, Tan W, Zhao D, et al. Genetic Polymorphism in Chemokine CCL22 and Susceptibility to Helicobacter pylori Infection-related Gastric Carcinoma. Cancer 2009; 115:2430–2437.

Wang XY, Yang J, Ho B, Yang Y, et al. Interaction of Helicobacter pylori with Genetic Variants in the MDM2 Promoter, is Associated with Gastric Cancer Susceptibility in Chinese Patients. Helicobacter 2009; 14:114–119.

Wen SC, Moss SF. Helicobacter pylori virulence factors in gastric carcinogenesis [Review]. Cancer Lett 2009; 282:1–8.

Wong J, Schulman A, Kelly K, Zamarin D, et al. Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Cancer-Specific Newcastle Disease Virus. J Gastrointest Surg 2010; 14:7–12.

Wu IC, Wu DC, Yu FJ, Wang JY, et al. Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol 2009; 15:5465–5471.

Xia HHX, Yang Y, Chu KM, Gu Q, et al. Serum Macrophage Migration-Inhibitory Factor as a Diagnostic and Prognostic Biomarker for Gastric Cancer. Cancer 2009; 115:5441–5449.

Xing CG, Zhu BS, Fan XQ, Liu HH, et al. Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J Gastroenterol 2009; 15:5044–5052.

Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer [Review]. Br J Cancer 2010; 102:237–242.

Yakoub D, Athanasiou T, Tekkis P, Hanna GB. Laparoscopic assisted distal gastrectomy for early gastric cancer: Is it an alternative to the open approach? [Review]. Surg Oncol-Oxf 2009; 18:322–333.

Yamaguchi N, Isomoto H, Fukuda E, Ikeda K, et al. Clinical Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer by Indication Criteria. Digestion 2009; 80:173–181.

Yang P, Zhou Y, Chen B, Wan HW, et al. Overweight, obesity and gastric cancer risk: Results from a meta-analysis of cohort studies. Eur J Cancer 2009; 45:2867–2873.

Ye YW, Fu H, Zhou Y, Du CY, et al. Study on the Different Expression of Molecular Markers between Cardiac Cancer and Distal Gastric Cancer and Their Correlations with Clinicopathological Features. Dig Surg 2009; 26:384–391.

Yeh JM, Goldie SJ, Kuntz KM, Ezzati M. Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. Cancer Causes Control 2009; 20:2021–2029.

Yoo CH, Kim HO, Hwang SI, Son BH, et al. Short-term outcomes of laparoscopic-assisted distal gastrectomy for gastric cancer during a surgeon's learning curve period. Surg Endosc 2009; 23:2250–2257.

Yoshikawa T, Tsuburaya A, Shimada K, Sato A, et al. A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer. In: Gastric Cancer 2009; 12:212–218.

Yuan WJ, Chen ZK, Wu SB, Ge J, et al. Expression of EphA2 and E-cadherin in Gastric Cancer: Correlated with Tumor Progression and Lymphogenous Metastasis. Pathol Oncol Res 2009; 15:473–478.

Zhang DH, Zhou LY, Lin SR, Ding SG, et al. Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin Med J 2009; 122:1759–1763.

Zhang JG, Zhao J, Xin Y. Significance and relationship between Cripto-1 and p-STAT3 expression in gastric cancer and precancerous lesions. World J Gastroenterol 2010; 16:571–577.

Zhang LJ, Wang SY, Huo XH, Zhu ZL, et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol 2009; 15:2731–2738.

Zheng LD, Jiang GS, Pu JR, Mei H, et al. Stable knockdown of heparanase expression in gastric cancer cells in vitro. World J Gastroenterol 2009; 15:5442–5448.

Zheng ZL, Jia YB, Hou LF, Persson C, et al. Genetic Variation in a4GnT in Relation to Helicobacter pylori Serology and Gastric Cancer Risk. Helicobacter 2009; 14:120–125.

Back to Top | Article Outline

Adverse effects of proton pump inhibitor drugs: clues and conclusions

Review: (pp. 624–631)

Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, et al. Do Proton Pump Inhibitors Attenuate the Effect of Aspirin on Platelet Aggregation? A Randomized Crossover Study. J Cardiovasc Pharmacol 2009; 54:163–168.

• Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122:896–903.[02]

Ali T, Roberts DN, Tierney WM. Long-term Safety Concerns with Proton Pump Inhibitors [Review]. Am J Med 2009; 122:896–903.

Andriulli A, Marmo R. Proton Pump Inhibitors After Endoscopy in Peptic Ulcer Bleeding Response. Am J Gastroenterol 2009; 104:1595–1596.

Baldwin CM, Keam SJ. Rabeprazole A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults [Review]. Drugs 2009; 69:1373–1401.

Bhala N, Banerjee A. Combination therapy with clopidogrel and proton-pump inhibitors. Lancet 2010; 375:28.

Broeren MAC, Geerdink EAM, Vader HL, Bake AWLV. Hypomagnesemia Induced by Several Proton-Pump Inhibitors. Ann Intern Med 2009; 151:755–756.

Chae YK, Kim J. Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel. JAMA 2009; 302:29.

Chua D, Lo A, Day J, Drummond I, et al. Comment: Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors. Ann Pharmacother 2010; 44:225–226.

•• Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and Histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139:93–101.[12]

Cuisset T, Frere C, Quilici J, Poyet R, et al. Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study. J Am Coll Cardiol 2009; 54:1149–1153.

Dakik HA, Barada K. Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel. JAMA 2009; 302:30.

•• Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 104(S2); 2009:S10–S16.[14]

Dias LM. Pantoprazole A Proton Pump Inhibitor [Review]. Clin Drug Invest 2009; 29:3–12.

Duh MS, Gosselin A, Luo R, Lohoues H, et al. Impact of Compliance With Proton Pump Inhibitors on NSAID Treatment. Am J Managed Care 2009; 15:681–688.

Famularo G, Gasbarrone L, De Simone C. Proton Pump Inhibitors and the Risk for Clostridium difficile Infection. JAMA 2009; 302:31–32.

Fernandez-Fernandez FJ, Pia G, Sesma P. Risks of proton-pump inhibitors: what every doctor should know. Med J Aust 2009; 190:652–653.

Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures [Review]. Maturitas 2009; 64:9–13.

Fricker J. Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines. Eur Heart J 2009; 30:2820.

Gau JT, Heh V, Acharya U, Yang YX, et al. Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiology and Drug Safety 2009; 18:865–871.

Gill SK, Brien LO, Einarson TR, Koren G. The Safety of Proton Pump Inhibitors (PPIs) in Pregnancy: A Meta-Analysis [Review]. Am J Gastroenterol 2009; 104:1541–1545.

Godman B, Schwabe U, Selke G, Wettermark B. Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs. Pharmacoeconomics 2009; 27:435–438.

Granger CB. Concomitant use of proton-pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI Commentary. Ann Intern Med 2009; 151:NIL_216.

Hart J, Hawkey CJ, Lanas A, Naesdal J, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther 2009; 31:143–149.

Ho PM, Rumsfeld JS, Wang L. Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel Reply. JAMA 2009; 302:31.

Howard PA, Vacek JL. Potential Interaction between Clopidogrel and Proton Pump Inhibitors. Am J Cardiovasc Drugs 2009; 9:353–359.

Hsiao FY, Tsai YW, Huang WF, Wen YW, et al. A Comparison of Aspirin and Clopidogrel With or Without Proton Pump Inhibitors for the Secondary Prevention of Cardiovascular Events in Patients at High Risk for Gastrointestinal Bleeding. Clin Ther 2009; 31:2038–2047.

Jakob AH. Medication interaction between proton pump inhibitors and clopidogrel Observation study [German]. Med Klin 2009; 104:659.

Juurlink D. Concomitant use of proton-pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI - art. no. JC2-13. Ann Intern Med 2009; 151:13.

Juurlink DN. Proton Pump Inhibitors and Clopidogrel Putting the Interaction in Perspective. Circulation 2009; 120:2310–2312.

Kapoor JR. Impact of Combining Proton Pump Inhibitors and Clopidogrel. Am J Cardiol 2009; 103:1624.

Kelly CP. Proton Pump Inhibitors and the Risk for Clostridium difficile Infection Reply. JAMA 2009; 302:32.

Khara HS, Pitchumoni CS. Proton Pump Inhibitors: A Better Prescription is Needed. J Clin Gastroenterol 2009; 43:597–598.

• Klotz U. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Euro J Clin Pharmacol 2009; 65:1–2.[38]

Klotz U. Proton Pump Inhibitors - Their Pharmacological Impact on the Clinical Management of Acid-Related Disorders [Review]. Arzneimittelforschung 2009; 59:271–282.

Kofler S, Shvets N, Bigdeli AK, Konig MA, et al. Proton Pump Inhibitors Reduce Mycophenolate Exposure in Heart Transplant Recipients-A Prospective Case-Controlled Study. Am J Transplant 2009; 9:1650–1656.

Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors - a review [Review]. Neth J Med 2009; 67:169–172.

Labenz J, Meyners W, Petersen KU. Clopidogrel and proton pump inhibitors - boon or bane? [German]. Dtsch Med Wochenschr 2010; 135:203–206.

Last EJ, Sheehan AH. Review of recent evidence: Potential interaction between clopidogrel and proton pump inhibitors. Am J Health-Syst Pharm 2009; 66:2117–2122.

Lee ES, Kim N, Lee SH, Park YS, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther 2009; 30:154–164.

Lin HJ. Proton Pump Inhibitors After Endoscopy in Peptic Ulcer Bleeding. Am J Gastroenterol 2009; 104:1595.

• Lodato F, Azzaroli F, Turco L, Mazella N, et al. Adverse effects of proton pump inhibitors. Best Prac Res Clin Gastroenterol 2010; 24:193–201.[03]

• Mega JL, Close SL, Wiviott SD, Shen L, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354–362.[36]

Morton AP. Risks of proton-pump inhibitors: what every doctor should know. Med J Aust 2009; 190:653.

Muldowney JAS, Benge CD. Combination therapy with clopidogrel and proton-pump inhibitors. Lancet 2010; 375:27–28.

Mullin JM, Gabello M, Murray LJ, Farrell CP, et al. Proton pump inhibitors: actions and reactions [Review]. Drug Discov Today 2009; 14:647–660.

Nerandzic MM, Pultz MJ, Donskey CJ. Examination of Potential Mechanisms To Explain the Association between Proton Pump Inhibitors and Clostridium difficile Infection. Antimicrob Agents Chemother 2009; 53:4133–4137.

Norgard NB, Mathews KD, Wall GC. Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors. Ann Pharmacother 2009; 43:1266–1274.

Norgard NB, Wall GC. Comment: Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors REPLY. Ann Pharmacother 2010; 44:226–227.

O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, et al. Combination therapy with clopidogrel and proton-pump inhibitors reply. Lancet 2010; 375:28–29.

Ramamoorthy SL, Lee JK, Mintz Y, Cullen J, et al. The impact of proton-pump inhibitors on intraperitoneal sepsis: a word of caution for transgastric NOTES procedures. Surg Endosc 2010; 24:16–20.

Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome. Circulation 2009; 120:2322–NIL_34.

Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients. Aliment Pharmacol Ther 2009; 30:725–732.

•• Reimer C, Sondergard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137:80–87.[25]

• Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci 2010; 55:2431–2440.[26]

Schinke T, Schilling AF, Baranowsky A, Seitz S, et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 2009; 15:674–NIL_111.

Talley NJ, Dimoska A, Gan K. Risks of proton-pump inhibitors: what every doctor should know REPLY. Med J Aust 2009; 190:653.

Targownik LE. Another bad break for proton-pump inhibitors? Nat Rev Rheumatol 2009; 5:478–480.

• Targownik LE, Lix LM, Leung S, Leslie WD. Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138:896–904.[09]

• Thompson ABR, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16:2323–2330.[04]

van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MPP, et al. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiology and Drug Safety 2009; 18:880–890.

Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, et al. Gastric and Esophagus Events Before and During Treatment of Osteoporosis. Calcif Tissue Int 2010; 86:110–115.

•• Waldum HL, Qvigstad G, Fossmark R, et al. Rebound hypersecretion of acid from a physiological, pathophysiological and clinical point of view. Scand J Gastroenterol 2010; 45:389–394.[24]

Wang SSW, Tsai SS, Hsu PC, Yang CY, et al. Concomitant Use of Clopidogrel and Proton Pump Inhibitors or Cimetidine After Acute Myocardial Infarction Would Increase the Risk of Re-Infarction. Am J Gastroenterol 2009; 104:3116–3117.

Wang ZM, Chen KM, Gong J, Zheng YF, et al. Combined Arterial Infusion and Stent Implantation Compared with Metal Stent Alone in Treatment of Malignant Gastroduodenal Obstruction. Cardiovasc Intervent Radiol 2009; 32:1011–1018.

Weiss J. Is it possible to combine clopidogrel with proton pump inhibitors? [German]. Dtsch Med Wochenschr 2009; 134:2266.

Back to Top | Article Outline

Gastrointestinal stromal tumor

Adenis A, Penel N, Blay JY. Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter? [Review]. Oncology (Williston Park) 2009:157–161.

Aliberti S, Grignani G, Allione P, Fizzotti M, et al. An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient. Am J Clin Oncol-Cancer Clin Trials 2009; 32:640–641, 2009 Dec.

Antonio L, Guzman P, Villaseca M, Araya J, et al. Concomitant presence of a gastric adenocarcinoma and gastrointestinal stromal tumor. Report of one case [Spanish]. Rev Med Chil 2009; 137:531–536.

Aoyagi K, Kouhuji K, Yano S, Miyagi M, et al. Malignant Potential of Gastrointestinal Stromal Tumor of the Stomach. Int Surg 2009; 94:1–9.

Ardeleanu C, Arsene D, Hinescu M, Andrei F, et al. Pancreatic Expression of DOG1 A Novel Gastrointestinal Stromal Tumor (GIST) Biomarker. Appl Immunohistochem Mol Morphol 2009; 17:413–418.

Bar-Sela G, Kedem E, Hadad S, Pollack S, et al. Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Sunitinib in a Patient with a Gastrointestinal Stromal Tumor. Jpn J Clin Oncol 2010; 40:163–165.

Battochio A, Mohammed S, Winthrop D, Lefresne S, et al. Detection of c-KIT and PDGFRA Gene Mutations in Gastrointestinal Stromal Tumors Comparison of DHPLC and DNA Sequencing Methods Using a Single Population-Based Cohort. Am J Clin Pathol 2010; 133:149–155.

Beddy P, McGrath A, Reynolds JV, Ryan JMF. Primary Embolization of a Symptomatic Gastrointestinal Stromal Tumor. J Vasc Interv Radiol 2009; 20:1099–1101.

Beltran MA, Barria C, Contreras MA, Wilson CS, et al. Gastrointestinal stromal tumor (GIST) in a patient with neurofibromatosis type 1. Report of one case [Spanish]. Rev Med Chil 2009; 137:1197–1200.

Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, et al. Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment. Semin Oncol 2009; 36:302–311.

Bi R, Sheng WQ, Wang J. Collision tumor of the stomach: Gastric adenocarcinoma intermixed with gastrointestinal stromal tumor. Pathol Int 2009; 59:880–883.

Blay JY, Reichardt P. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations [Review]. Expert Rev Anticancer Ther 2009; 9:831–838.

Brabec P, Sufliarsky J, Linke Z, Plank L, et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma 2009; 56:459–464.

Brown TH, Menon VS, Richards DG, Griffiths AP. Gastrointestinal bleeding in a pregnant woman: mucinous cystic neoplasm of pancreas mimicking gastrointestinal stromal tumor of stomach. J Hepato-Biliary-Pancreatic Surg 2009; 16:681–683.

Campbell T, Felsten L, Moore J. Disappearance of Lentigines in a Patient Receiving Imatinib Treatment for Familial Gastrointestinal Stromal Tumor Syndrome. Arch Dermatol 2009; 145:1313–1316.

Carter RR, Mundluru SN, Margolin DJ. Small Bowel Gastrointestinal Stromal Tumor: An Unusual Cause of Massive Lower Gastrointestinal Bleeding. Am Surg 2010; 76:229–231.

Chetty R, Vajpeyi R. Vasculopathic Changes, a Somatostatin-Producing Neuroendocrine Carcinoma and a Jejunal Gastrointestinal Stromal Tumor in a Patient with Type 1 Neurofibromatosis. Endocr Pathol 2009; 20:177–181.

Cheung MC, Zhuge Y, Yang R, Koniaris LG. Disappearance of Racial Disparities in Gastrointestinal Stromal Tumor Outcomes. J Am Coll Surg 2009; 209:7–16.

Choi D, Yoo EY, Kim KM, Sohn TS, et al. Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment. AJR Am J Roentgenol 2009; 193:W100–W105.

D'Adamo D. Advances in the Treatment of Gastrointestinal Stromal Tumor [Review]. Adv Ther 2009; 26:826–837.

Daum O, Ferdova E, Kural T, Grossmann P, et al. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells masquerading as (extra)gastrointestinal stromal tumor: Potential diagnostic pitfall. Pathol Int 2010; 60:59–61.

De Primo SE, Huang X, Blackstein ME, Garrett CR, et al. Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure. Clin Cancer Res 2009; 15:5869–5877.

Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, et al. Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. Clin Cancer Res 2009; 15:5902–5909.

Dudeja V, Armstrong LH, Gupta P, Ansel H, et al. Emergence of Imatinib Resistance Associated with Downregulation of C-Kit Expression in Recurrent Gastrointestinal Stromal Tumor (GIST): Optimal Timing of Resection. J Gastrointest Surg 2010; 14:557–561.

Dupart JJ, Trent JC, Lee HY, Hess KR, et al. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro - art. no. 99. Mol Cancer 2009:99.

Egorin MJ, Shah DD, Christner SM, Yerk MA, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009; 68:370–374.

Elshenawy YM, Ganote CE, Al-Abbadi MA. Fatal abdominal sarcomatosis secondary to gastrointestinal stromal tumor with bland histology. Saudi Med J 2009; 30:1469–1472.

Firat O, Yazici P, Makay O, Aydin A, et al. Co-existence of Gastrointestinal Stromal Tumors with Malign Epithelial Tumors: a Report of Two Cases. Acta Chir Belg 2009; 109:629–632.

Garcia AB, Feria MR, Cuadrado MG, Sousa CN, et al. Gastrointestinal bleeding secondary to gastrointestinal stromal tumor in two patients with neuroribromatosis [Spanish]. Rev Esp Enferm Dig 2009; 101:591–592.

Gong L, Li YH, Zhao HD, Zhao JY, et al. The clinicopathologic observation, c-KIT gene mutation and clonal status of gastrointestinal stromal tumor in the sacrum - art. no. 43. BMC Gastroenterology 2009:43.

Gunaratnam M, Swank S, Haider SM, Galesa K, et al. Targeting Human Gastrointestinal Stromal Tumor Cells with a Quadruplex-Binding Small Molecule. J Med Chem 2009; 52:3774–3783.

Hirashima K, Takamori H, Hirota M, Tanaka H, et al. Multiple gastrointestinal stromal tumors in neurofibromatosis type 1: Report of a case. Surg Today 2009; 39:979–983.

Hou YY, Grabellus F, Weber F, Zhou Y, et al. Impact of KIT and PDGFRA Gene Mutations on Prognosis of Patients with Gastrointestinal Stromal Tumors After Complete Primary Tumor Resection. J Gastrointest Surg 2009; 13:1583–1592.

Kaneta T, Takahashi S, Fukuda H, Arisaka Y, et al. Clinical significance of performing F-18-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med 2009; 23:459–464.

Kang GH, Kim KM, Noh JH, Sohn TS, et al. WT-1 expression in gastrointestinal stromal tumours. Pathology 2010; 42:54–57.

Karagulle E, Gokturk HS, Turk E, Kiyici H, et al. Giant small intestine gastrointestinal stromal tumor with gastrointestinal bleeding. Acta Gastroenterol Belg 2009; 72:458–461.

Kikuta K, Gotoh M, Kanda T, Tochigi N, et al. Pfetin as a Prognostic Biomarker in Gastrointestinal Stromal Tumor: Novel Monoclonal Antibody and External Validation Study in Multiple Clinical Facilities. Jpn J Clin Oncol 2010; 40:60–72.

Kim JY, Lee JM, Kim KW, Park HS, et al. Ectopic Pancreas: CT Findings with Emphasis on Differentiation from Small Gastrointestinal Stromal Tumor and Leiomyoma. Radiology 2009; 252:92–100.

Kobayashi K, Szklaruk J, Trent JC, Ensor J, et al. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. Am J Clin Oncol-Cancer Clin Trials 2009; 32:574–581, 2009 Dec.

Kurtz LE, Greenberg RE. Pyogenic Liver Abscess Associated With a Gastrointestinal Stromal Tumor of the Stomach. Am J Gastroenterol 2010; 105:232–233.

Kwon MJ, Nam ES, Cho SJ, Park HR, et al. Comparison of tissue microarray and full section in immunohistochemistry of gastrointestinal stromal tumors. Pathol Int 2009; 59:851–856.

Kwon Y, Dang NDT, Elmunzer BJ. Gastrointestinal stromal tumor complicated by Streptococcus milleri bacteremia and liver abscess. Eur J Gastroenterol Hepatol 2009; 21:824–826.

Lamparter S, Goecke W, Koehler HH. Hepatic Portal Venous Gas after Upper Endoscopy in a Patient with a Gastrointestinal Stromal Tumor. J Clin Ultrasound 2009; 37:401–402.

Lao XM, Ye ZY, Guo RP, Guo ZX, et al. A gastrointestinal stromal tumor of the jejunum associated with intrahepatic cholangiocarcinoma and pulmonary hamartoma: A case report. Acta Oncol 2009; 48:934–937.

Ledo-Rodriguez A, Ulla-Rocha JL, Baltar-Arias R, Vazquez-Rodriguez S, et al. Endoscopic resection of rectal gastrointestinal stromal tumor (GIST) using band ligation. Rev Esp Enferm Dig 2009; 101:870–871.

Luo XL, Liu D, Yang JJ, Zheng MW, et al. Primary gastrointestinal stromal tumor of the liver: A case report. World J Gastroenterol 2009; 15:3704–3707.

Manouras A, Pappas A, Katergiannakis V, Filis K, et al. Gastrointestinal stromal tumors of the rectum: report of five cases. Acta Gastroenterol Belg 2009; 72:257–261.

McCarthy CJ, O'Brien GC, Cummins RJ, Kay EW, et al. GIST with a Twist-Upregulation of PDGF-B Resulting in Metachronous Gastrointestinal Stromal Tumor and Dermatofibrosarcoma Protuberans. J Gastrointest Surg 2010; 14:398–403.

Miettinen M, Sobin LH, Lasota J. Gastrointestinal Stromal Tumors Presenting as Omental Masses-A Clinicopathologic Analysis of 95 Cases. Am J Surg Pathol 2009; 33:1267–1275.

Miettinen M, Wang ZF, Lasota J. DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors A Study of 1840 Cases. Am J Surg Pathol 2009; 33:1401–1408.

Miyata K, Igaki H. A Case of Gastrointestinal Stromal Tumor of the Esophagus. Jpn J Clin Oncol 2009; 39:695.

Molina I, Seamon LG, Copeland LJ, Suarez A. Reclassification of Leiomyosarcoma as an Extra-gastrointestinal Stromal Tumor of the Gynecologic Tract. Int J Gynecol Pathol 2009; 28:458–463.

Nishida T, Takahashi T, Miyazaki Y. Gastrointestinal stromal tumor: a bridge between bench and bedside [Review]. In: Gastric Cancer 2009; 12:175–188.

Ochiai T, Sonoyama T, Kikuchi S, Ikoma H, et al. Primary large gastrointestinal stromal tumor of the liver: Report of a case. Surg Today 2009; 39:633–636.

Ponti G, Luppi G, Martorana D, Rossi G, et al. Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep 2010; 23:437–444.

Pulcini G, Villanacci V, Rossi E, Gheza F, et al. Gastrointestinal Stromal Tumor with Chondroid Differentiation. Anticancer Res 2009; 29:2761–2765.

Raut CP, Wang Q, Manola J, Morgan JA, et al. Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate. Ann Surg Oncol 2010; 17:407–415.

Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor [Review]. Expert Rev Anticancer Ther 2010; 10:221–232.

Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 2009; 8:2172–2182.

Rubin BP, Blanke CD, Demetri GD, De Matteo RP, et al. Protocol for the Examination of Specimens From Patients With Gastrointestinal Stromal Tumor. Arch Pathol Lab Med 2010; 134:165–170.

Sakai M, Kato H, Saito K, Tanaka N, et al. Clinical Applications of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastrointestinal Stromal Tumor of the Esophagus. Int Surg 2009; 93:209–213.

Sawaki A, Yamada Y, Komatsu Y, Kanda T, et al. Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemother Pharmacol 2010; 65:961–967.

Shen ZL, Wang S, Ye YJ, Wang YL, et al. Carcinosarcoma of pancreas with liver metastasis combined with gastrointestinal stromal tumour of the stomach: is there a good prognosis with the complete resection? Eur J Cancer Care 2010; 19:118–123.

Stamatakos M, Douzinas E, Stefanaki C, Safioleas P, et al. Gastrointestinal stromal tumor - art. no. 61 [Review]. World J Surg Oncol 2009:61.

Theodoropoulos GE, Linardoutsos D, Tsamis D, Stamopoulos P, et al. Gastrointestinal stromal tumor causing small bowel intussusception in a patient with Crohn's disease. World J Gastroenterol 2009; 15:5224–5227.

Trent JC, Patel SS, Zhang JH, Araujo DM, et al. Rare Incidence of Congestive Heart Failure in Gastrointestinal Stromal Tumor and Other Sarcoma Patients Receiving Imatinib Mesylate. Cancer 2010; 116:184–192.

Turkoz HK, Alkan I, Sisman S, Ozcan D. Cyclooxygenase-2 expression and connection with tumor recurrence and histopathologic parameters in gastrointestinal stromal tumors. APMIS 2009; 117:825–830.

Vital C, Bonnin A, Dumas P, Vital A. Acute sarcoid neuropathy developed 4 months after the occurrence of a gastrointestinal stromal tumor (gist). Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:69–72.

Wronski M, Cebulski W, Slodkowski M, Krasnodebski IW. Gastrointestinal Stromal Tumors Ultrasonographic Spectrum of the Disease. J Ultrasound Med 2009; 28:941–948.

Yang WL, Yu JR, Wu YJ, Zhu KK, et al. Duodenal Gastrointestinal Stromal Tumor: Clinical, Pathologic, Immunohistochemical Characteristics, and Surgical Prognosis. J Surg Oncol 2009; 100:606–610.

Yoshida S, Yamashita K, Yokozawa M, Kida M, et al. Diagnostic findings of ultrasound-guided fine-needle aspiration cytology for gastrointestinal stromal tumors: Proposal of a combined cytology with newly defined features and histology diagnosis. Pathol Int 2009; 59:712–719.

Zappacosta R, Caraceni D, Stura S, Zappacosta B, et al. Thin-Layer Cytopathology of a Gastrointestinal Stromal Tumor (GIST) in Effusion: Diagnostic Dilemmas. Ann Clin Lab Sci 2009; 39:367–371.

Zhang LZ, Smyrk TC, Young WF, Stratakis CA, et al. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases. Am J Surg Pathol 2010; 34:53–64.

Back to Top | Article Outline

NSAID-induced gastrointestinal and cardiovascular injury

Review: (pp. 611–617)

Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, et al. Do Proton Pump Inhibitors Attenuate the Effect of Aspirin on Platelet Aggregation? A Randomized Crossover Study. J Cardiovasc Pharmacol 2009; 54:163–168.

Arora G, Singh G, Triadafilopoulos G. Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice [Review]. Clin Gastroenterol Hepatol 2009; 7:725–735.

Asano T, Tanaka KI, Yamakawa N, Adachi H, et al. HSP70 Confers Protection against Indomethacin-Induced Lesions of the Small Intestine. J Pharmacol Exp Ther 2009; 330:458–467.

• Bhatt DL, Cryer B, Contant CF. COGENT: a Prospective, Randomised, Placebo-Controlled Trial of Omeprazole in patients receiving aspirin and clopidogrel. Transvascular Cardiovascular Therapeutics Annual Meeting; 2009.[51]

Boukthir S, Mazigh SM, Kaach N, Bouyahya O, et al. The effect of non-steroidal anti-inflammatory drugs and Helicobacter pylori infection on the gastric mucosa in children with upper gastrointestinal bleeding. Pediatr Surg Int 2010; 26:227–230.

•• Chan FK, Scheiman JM, Lanas A, et al. Celecoxib versus diclofenac and omeprazole: a randomised controlled trial comparing a composite outcome across the entire GI tract (The Condor Trial). Lancet 2010; 376:173–179.[29]

Chan FKL, Cryer B, Goldstein JL, Lanas A, et al. A Novel Composite Endpoint to Evaluate the Gastrointestinal (GI) Effects of Nonsteroidal Antiinflammatory Drugs Through the Entire GI Tract. J Rheumatol 2010; 37:167–174.

• Cheung R, Cheng TT, Dong Y, et al. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis 2010; 13:151–157.[30]

Chiou SK, Hoa N. Up-regulation of GADD45 alpha expression by NSAIDs leads to apoptotic and necrotic colon cancer cell deaths. Apoptosis 2009; 14:1341–1351.

Desai JC, Goo T, Fukata M, Sanyal S, et al. NSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression. Aliment Pharmacol Ther 2009; 30:71–81.

Duh MS, Gosselin A, Luo R, Lohoues H, et al. Impact of Compliance With Proton Pump Inhibitors on NSAID Treatment. Am J Managed Care 2009; 15:681–688.

Fujii T, Nakabayashi T, Hashimoto S, Kuwano H. Correlation between Serum Triglycerides and Gastro-Duodenal Ulcer Associated with Low-Dose Aspirin. Hepato-Gastroenterol 2009; 56:1241–1244.

Fujimori S, Seo T, Gudis K, Ehara A, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 2009; 69:1339–1346.

Fujisawa M, Murata T, Hori M, Ozaki H. The 5-HT4 receptor agonist mosapride attenuates NSAID-induced gastric mucosal damage. J Gastroenterology 2010; 45:179–186.

Futagami S, Hamamoto T, Shimpuku M, Nagoya H, et al. Celecoxib Inhibits CD133-Positive Cell Migration via Reduction of CCR2 in Helicobacter pylori-Infected Mongolian Gerbils. Digestion 2010; 81:193–203.

Ganguly K, Swarnakar S. Induction of matrix metalloproteinase-9 and-3 in nonsteroidal anti-inflammatory drug-induced acute gastric ulcers in mice: regulation by melatonin. J Pineal Res 2009; 47:43–55.

Higuchi K, Umegaki E, Watanabe T, Yoda Y, et al. Present status and strategy of NSAIDs-induced small bowel injury [Review]. J Gastroenterology 2009; 44:879–888.

Howard PA, Vacek JL. Potential Interaction between Clopidogrel and Proton Pump Inhibitors. Am J Cardiovasc Drugs 2009; 9:353–359.

Hsiao FY, Tsai YW, Huang WF, Wen YW, et al. A Comparison of Aspirin and Clopidogrel With or Without Proton Pump Inhibitors for the Secondary Prevention of Cardiovascular Events in Patients at High Risk for Gastrointestinal Bleeding. Clin Ther 2009; 31:2038–2047.

Huang WJ, Hung CR, Chen MC, Wang JR, et al. Involvement of cyclooxygenase 2 and prostaglandin e-2 in the effects of insulin on gastric emptying in male rats. J Physiol Pharmacol 2009; 60:109–118.

Hunt RH, Lanas A, Stichtenoth DO, Scarpignato C. Myths and facts in the use of anti-inflammatory drugs [Review]. Ann Med 2009; 41:423–437.

Kakimoto K, Takai S, Murano M, Ishida K, et al. Significance of Chymase-Dependent Matrix Metalloproteinase-9 Activation on Indomethacin-Induced Small Intestinal Damages in Rats. J Pharmacol Exp Ther 2010; 332:684–689.

Kapoor JR. Impact of Combining Proton Pump Inhibitors and Clopidogrel. Am J Cardiol 2009; 103:1624.

Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? [Review]. Eur J Clin Pharmacol 2009; 65:963–970.

Lai LH, Chan FKL. Nonsteroid anti-inflammatory drug-induced gastroduodenal injury. Curr Opin Gastroenterol 2009; 25:544–548.

Lanas A, Esplugues JV, Zapardiel J, Sobreviela E. Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications. World J Gastroenterol 2009; 15:5953–5959.

• Lanas A, Osenenko K, Medin J, et al. A systematic review of the risk of upper gastrointestinal complications among patients on low-dose aspirin with additional risk factors. Gastroenterology 138(Suppl 1) 2010:T1146.[18]

Lanas A, Sopena F. Nonsteroidal Anti-Inflammatory Drugs and Lower Gastrointestinal Complications. Gastroenterol Clin North Am 2009; 38:333.

Latimer N, Lord J, Grant RL, O'Mahony R, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis - art. no. b2538. BMJ 2009:B2538.

Lim YJ, Lee JS, Ku YS, Hahm KB. Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage. J Gastroenterol Hepatol 2009; 24:1169–1178.

Mandery K, Bujok K, Schmidt I, Wex T, et al. Influence of Cyclooxygenase Inhibitors on the Function of the Prostaglandin Transporter Organic Anion-Transporting Polypeptide 2A1 Expressed in Human Gastroduodenal Mucosa. J Pharmacol Exp Ther 2010; 332:345–351.

• Masso Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62:1592–1601.[10]

Mehrabani D, Rezaee A, Azarpira N, Fattahi MR, et al. The healing effects of Teucrium polium in the repair of indomethacin-induced gastric ulcer in rats. Saudi Med J 2009; 30:494–499.

Mir R, Singh N, Vikram G, Kumar RP, et al. The Structural Basis for the Prevention of Nonsteroidal Antiinflammatory Drug-Induced Gastrointestinal Tract Damage by the C-Lobe of Bovine Colostrum Lactoferrin. Biophys J 2009; 97:3178–3186.

Mizokami Y. Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan. World J Gastroenterol 2009; 15:5097–5102.

Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats. Clin Exp Pharmacol Physiol 2010; 37:173–177.

Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers [Review]. Aliment Pharmacol Ther 2009; 30:517–531.

Nemmani KVS, Mali SV, Borhade N, Pathan AR, et al. NO-NSAIDs: Gastric-sparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs. Bioorg Med Chem Lett 2009; 19:5297–5301.

•• Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138:82–88.[34]

Niwa Y, Nakamura M, Miyahara R, Ohmiya N, et al. Geranylgeranylacetone Protects against Diclofenac-Induced Gastric and Small Intestinal Mucosal Injuries in Healthy Subjects: A Prospective Randomized Placebo-Controlled Double-Blind Cross-Over Study. Digestion 2009; 80:260–266.

Ramirez-Alcantara V, Lo Guidice A, Boelsterli UA. Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy. Am J Physiol-Gastroint Liver Physiol 2009; 297:G990–G998.

•• Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152:337–345.[52]

• Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29:481–496.[03]

Satoh H, Shiotani S, Otsuka N, Hatao K, et al. Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats. Gut 2009; 58:1590–1596.

Sivalingam N, Basivireddy J, Pulimood AB, Balasubramanian KA, et al. Activation of phospholipase A(2) is involved in indomethacin-induced damage in Caco-2 cells. Toxicol In Vitro 2009; 23:887–896.

Suemasu S, Tanaka KI, Namba T, Ishihara T, et al. A Role for HSP70 in Protecting against Indomethacin-induced Gastric Lesions. J Biol Chem 2009; 284:19705–19715.

• Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1–9.[36]

•• Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:119–125.[32]

Van Boxel OS, Hagenaars MP, Smout AJPM, Siersema PD. Sociodemographic Factors Influence Use of Proton Pump Inhibitors Among Users of Nonsteroidal Anti-Inflammatory Drugs. Clin Gastroenterol Hepatol 2009; 7:855–861.

van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MPP, et al. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiology and Drug Safety 2009; 18:880–890.

Yeomans ND, Hawkey CJ, Brailsford W, Naesdal J. Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs [Review]. Curr Med Res Opin 2009; 25:2785–2793.

Zhang LJ, Wang SY, Huo XH, Zhu ZL, et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol 2009; 15:2731–2738.

• Zhou Y, Lichtenberger LM. Nonsteroidal anti-inflammatory drugs alter lateral distribution within epithelial cell plasma membrane. Gastroenterology 138(Suppl 1); 2010:T1136.[13]

Back to Top | Article Outline

Gastroduodenal motility

Review: (pp. 647–655)

Alagozlu H, Simsek Z, Unal S, Cindoruk M, et al. Is there an association between Helicobacter pylori in the inlet patch and globus sensation? World J Gastroenterol 2010; 16:42–47.

• Ameloot K, Janssen P, Scarpellini E, et al. Endocannabinoid control of gastric sensorimotor function in man. Aliment Pharmacol Ther 2010; 31:1123–1131.[10]

• Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology 2009; 137:94–100.[06]

Babygirija R, Zheng J, Ludwig K, Takahashi T. Central oxytocin is involved in restoring impaired gastric motility following chronic repeated stress in mice. Am J Physiol-Regul Integr Comp Physiol 2010; 298:R157–R165.

Banihashemi L, Rinaman L. Repeated brief postnatal maternal separation enhances hypothalamic gastric autonomic circuits in juvenile rats. Neuroscience 2010; 165:265–277.

Deane AM, Nguyen NQ, Stevens JE, Fraser RJL, et al. Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia. J Clin Endocrinol Metab 2010; 95:215–221.

• Ejskjaer N, Vestergaard ET, Hellström PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009; 29:1179–1187.[59]

Fruehauf H, Steingoetter A, Fox MR, Kwiatek MA, et al. Characterization of gastric volume responses and liquid emptying in functional dyspepsia and health by MRI or barostat and simultaneous C-13-acetate breath test. Neurogastroenterol Motil 2009; 21:697–E37.

Goetze O, Treier R, Fox M, Steingoetter A, et al. The effect of gastric secretion on gastric physiology and emptying in the fasted and fed state assessed by magnetic resonance imaging. Neurogastroenterol Motil 2009; 21:725–E42.

Hammadi M, Adi M, John R, Khoder GAK, et al. Dysregulation of gastric H,K-ATPase by cigarette smoke extract. World J Gastroenterol 2009; 15:4016–4022.

Huang WJ, Hung CR, Chen MC, Wang JR, et al. Involvement of cyclooxygenase 2 and prostaglandin e-2 in the effects of insulin on gastric emptying in male rats. J Physiol Pharmacol 2009; 60:109–118.

Keller J, Beglinger C, Holst JJ, Andresen V, et al. Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. Am J Physiol-Gastroint Liver Physiol 2009; 297:G861–G868.

Kidd M, Hauso O, Drozdov I, Gustafsson BI, et al. Delineation of the Chemomechanosensory Regulation of Gastrin Secretion Using Pure Rodent G Cells. Gastroenterology 2009; 137:231–241.

Kusano M, Zai H, Hosaka H, Shimoyama Y, et al. New Frontiers in Gut Nutrient Sensor Research: Monosodium L-Glutamate Added to a High-Energy, High-Protein Liquid Diet Promotes Gastric Emptying: a Possible Therapy for Patients With Functional Dyspepsia [Review]. Journal of Pharmacological Sciences 2010; 112:33–36.

Kwiatek MA, Fox MR, Steingoetter A, Menne D, et al. Effects of clonidine and sumatriptan on postprandial gastric volume response, antral contraction waves and emptying: an MRI study. Neurogastroenterol Motil 2009; 21:NIL_19–NIL_28.

Lu Y, Owyang C. Secretin-induced gastric relaxation is mediated by vasoactive intestinal polypeptide and prostaglandin pathways. Neurogastroenterol Motil 2009; 21:754–E47.

Ma J, Bellon M, Wishart JM, Young RL, et al. Effects of cefaclor on gastric emptying and cholecystokinin release in healthy humans. Regul Pept 2010; 159:156–159.

Ma J, Stevens JE, Cukier K, Maddox AF, et al. Effects of a Protein Preload on Gastric Emptying, Glycemia, and Gut Hormones After a Carbohydrate Meal in Diet-Controlled Type 2 Diabetes. Diabetes Care 2009; 32:1600–1602.

• Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010; 22:618-e173.[54]

• McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010. [Epub ahead of print][69]

• Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009; 104:2779–2787.[64]

Severini C, La Corte G, Improta G, Broccardo M, et al. In vitro and in vivo pharmacological role of TLQP-21, a VGF-derived peptide, in the regulation of rat gastric motor functions. Br J Pharmacol 2009; 157:984–993.

Stec-Michalska K, Malicki S, Michalski B, Peczek L, et al. Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients. World J Gastroenterol 2009; 15:5409–5417.

Stevens JE, Doran S, Russo A, O'Donovan D, et al. Effects of intravenous fructose on gastric emptying and antropyloroduodenal motility in healthy subjects. Am J Physiol-Gastroint Liver Physiol 2009; 297:G1274–G1280.

Stricker EM, Bykowski MR, Hossler CAS, Curtis KS, et al. Gastric emptying and intestinal absorption of ingested water and saline by hypovolemic rats. Physiol Behav 2009; 98:570–578.

Tanaka R, Inui A, Asakawa A, Atsuchi K, et al. New method of manometric measurement of gastroduodenal motility in conscious mice: effects of ghrelin and Y2 depletion. Am J Physiol-Gastroint Liver Physiol 2009; 297:G1028–G1034.

Uneyama H, Niijima A, Kitamura A, Torii K. Existence of NO-triggered vagal afferent activation in the rat gastric mucosa. Life Sci 2009; 85:782–787.

• Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29:765–773.[34]

Witte AB, Gryback P, Holst JJ, Hilsted L, et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009; 158:57–62.

• Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology 2010; 138:1302–1311.[07]

Back to Top | Article Outline

Miscellaneous

Burris JM, Lin PH, Johnston WF, Huynh TT, et al. Emergent embolization of the gastroduodenal artery in the treatment of upper gastrointestinal bleeding, The experience from a surgeon-initiated interventional program. Am J Surg 2009; 198:59–63.

Cha JM, Lee JI, Joo KR, Shin HP. Eosinophilic Gastroenteritis with Eosinophilic Dermatitis. Yonsei Medical Journal 2010; 51:145–147.

Cordero-Fernandez C, Garzon-Benavides M, Pizarro-Moreno A, Garcia-Lozano R, et al. Gastroduodenal involvement in patients with familial adenomatous polyposis. Prospective study of the nature and evolution of polyps: evaluation of the treatment and surveillance methods applied. Eur J Gastroenterol Hepatol 2009; 21:1161–1167.

Hillenbrand A, Waidner U, Henne-Bruns D, Wolf AM, et al. After 3 Years of Starvation: Duodenum Swallowed Remaining Stomach. Obesity Surgery 2009; 19:664–666.

Hoover JG, Schumaker AL, Franklin KJ. Use of Intravenous Proton-Pump Inhibitors in a Teaching Hospital Practice. Dig Dis Sci 2009; 54:1947–1952.

Huang C, Wang XB. Increased use of proton pump inhibitors in patients with diabetes and neuropathy. Endocrine Practice 2009; 15:653–654.

Jimenez-Rodriguez RM, Martinez JMA, Artacho GS, Bellido CB, et al. Liver graft necrosis caused by a gastroduodenal arterial steal syndrome [Spanish]. Rev Esp Enferm Dig 2009; 101:446–447.

Kedika RR, Souza RF, Spechler SJ. Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical Implications [Review]. Dig Dis Sci 2009; 54:2312–2317.

Kim H, Lim DH, Paik SW, Yoo BC, et al. Predictive factors of gastroduodenal toxicity in cirrhotic patients after three-dimensional conformal radiotherapy for hepatocellular carcinoma. Radiother Oncol 2009; 93:302–306.

Leong RW. Differences in Peptic Ulcer Between the East and the West. Gastroenterol Clin North Am 2009; 38:363–.

Leontiadis GI, Howden CW. The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Bleeding. Gastroenterol Clin North Am 2009; 38:199–.

Loffroy R, Guiu B. Role of transcatheter arterial embolization for massive bleeding from gastroduodenal ulcers. World J Gastroenterol 2009; 15:5889–5897.

Mandalari G, Adel-Patient K, Barkholt V, Baro C, et al. In vitro digestibility of beta-casein and beta-lactoglobulin under simulated human gastric and duodenal conditions: A multi-laboratory evaluation. Regul Toxicol Pharmacol 2009; 55:372–381.

Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes. Med Hypotheses 2009; 73:29–32.

Missaghi S, Young C, Fegely K, Rajabi-Siahboomi AR. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies. Drug Dev Ind Pharm 2010; 36:180–189.

Oida T, Mimatsu K, Kawasaki A, Kano H, et al. Modified Devine Exclusion with Vertical Stomach Reconstruction for Gastric Outlet Obstruction: A Novel Technique. J Gastrointest Surg 2009; 13:1226–1232.

Savic S, Stevanovic R, Alempijevic D, Petkovic S, et al. Medicolegal Aspects of Post-traumatic Gastroduodenal Ulcers: A Retrospective Study. J Forensic Sci 2009; 54:1423–1428.

Smith HS, Dhingra R, Ryckewaert L, Bonner D. Proton Pump Inhibitors and Pain. Pain Physician 2009; 12:1013–1023.

Tan VPY, Wong BCY. Management of acute peptic ulcers: How ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation. J Gastroenterol Hepatol 2009; 24:1157–1158.

Vila S, Garcia C, Piscoya A, de los Rios R, et al. Giant Gastroduodenal Trichobezoar: Rapunzel Syndrome. Am J Gastroenterol 2009; 104:2864–2865.

© 2010 Lippincott Williams & Wilkins, Inc.